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Abstract 
Planar heterocycles such as benzoxazoles are biologically active and often used as a scaffold 
for drug discovery. However, due to some toxicities associated with this group of compounds, 
analogues of benzoxazoles such as benzothiazoles, benzimidazoles and more recently, the 
oxazolopyridines have been developed in medicinal chemistry programs. The oxazolopyridine 
is an easy and versatile scaffold to synthesise as it is stable and has many sites for the addition 
of functional groups. The oxazolopyridine scaffold is also highly polar, contributing to 
improved target interaction in biological systems. This results in the anti-bacterial, anti-fungal, 
anti-parasitic and anti-inflammatory activities, and in sirtuin modulation of the 
oxazolopyridines. In fact, oxazolopyridines are shown to be non-toxic in vitro and in vivo in 
some studies, making it a very suitable scaffold for drug candidates. However, the full toxicity 
profile of the oxazolopyridine compounds, which include mutagenicity, is unknown and needs 
to be investigated to determine any unwanted effects. The oxazolopyridines and 
imidazopyridines are structurally similar and have some similar biological activities, but more 
concerningly, the carcinogen, 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP)  46 
also belongs to the imidazopyridine family. In the current study, 2-(3-
aminophenyl)oxazolopyridine, 60 was chosen as the lead compound given its structural 
similarities to PhIP 46. It was therefore hypothesised that compound 60 may be genotoxic 
(DNA damaging) and mutagenic, where its mode of action is similar to PhIP 46 via the amino 
group attached. Toxicology screens were conducted on compound 60 in vitro. Consistent with 
previous studies, compound 60 was found to be non-cytotoxic in the colony forming assay. 
However, compound 60 was genotoxic in cells in the γH2AX assay. The non-cytotoxic but 
genotoxic nature of compound 60 was found to be attributed by the ability of the cells to repair 
the DNA damage to maintain survival after 24 hours. Compound 60 was later found to be 
mutagenic in the Ames test indicating that the cellular repair of the DNA damage is error-
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prone. In fact, compound 60 is a pro-mutagen which is dependent on oxidation and enzymatic 
bio-activation by liver enzymes for activity. More importantly, compound 60 was also found 
to transform cells in the soft agar invasion assay.   
Further studies were carried out to determine the genotoxic and mutagenic mode of action of 
compound 60. Through quantitative structural-activity relationship (QSAR) determination, the 
amino group of compound 60 was not the factor for activity. This was supported by the 
generated Hammett plot using analogues of 2-aryloxazolopyridine where it was understood 
that the activity of compound 60 was driven by molecular electron density and not solely by 
the presence of the amino group as hypothesised. This was an important turning point for this 
study where the focus was shifted towards studying the electron density on the oxazolopyridine 
core. Given that activation is oxidation dependent, selected 2-aryloxazolopyridine analogues 
were found to produce N-oxides at the pyridine ring of the oxazolopyridine core. The 2-
phenyloxazolopyridine-N-oxides were also found to be genotoxic in cells and was thought to 
be the active species. However, it was found that the 2-aryloxazolopyridine-N-oxides still 
required further bio-activation by liver enzymes to be mutagenic in cells. This has led to further 
QSAR determination of the roles of the nitrogen atoms in the oxazolopyridine core. It was 
therefore proposed that upon the N-oxidation of the pyridine nitrogen, a second oxidation event 
on the oxazole nitrogen may occur to generate the active mutagen. Identification of the 
mutagenic species by enzymatic bio-activation of a 2-aryloxazolopyridine analogue was 
attempted using ultra pressure liquid chromatography and mass spectrometry (UPLC-MS). 
There was evidence that the 2-aryloxazolopyridine-N-oxide was formed under these conditions 
but more work was required to identify the mutagenic species. Therefore, the evidence 
presented in this thesis is the first detailing the mutagenic mode of action and liability of the 
oxazolopyridine compounds which has been widespread in drug development. In fact, this may 
have significant ramifications for the use of the oxazolopyridine scaffold in the future. 
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Chapter 1 Introduction 
1.1 Oxazolopyridines in medicinal chemistry 
1.1.1 Introduction to planar heterocycles 
Heterocycles are cyclic organic compounds which contain at least one non-carbon atom as part 
of the ring. These cyclic systems can be divided into aromatic and aliphatic heterocycles 
(Figure 1). For the aromatic heterocycles, the carbons and heteroatom are sp2 hybridised and 
results in a planar structure 1. Heterocycles can occur as single ring systems or fused ring 
systems consisting of two or more rings (Figure 1). Naturally occurring aromatic fused 
heterocycles (with some examples) include DNA bases (adenosine and guanine), amino acids 
(tryptophan), coenzymes (acetyl coenzyme A [Acetyl-CoA], nicotinamide adenine 
dinucleotide [NAD+] and flavin adenine dinucleotide [FAD+]) and vitamins (B2, B9 and E) 2. 
In synthetic chemistry, aromatic heterocycles have been exploited as molecular scaffolds for 
use as building blocks of biological active compounds such as drugs and pesticides 3. Due to 
their ability to mimic natural occurring compounds they can be tuned to have improved 
selectivity and/or affinity to key biological targets which highlights the importance of this 
group of molecules in medicinal chemistry and agriculture 2,3.  
  1  2  3  4 
Figure 1: Examples of heterocycles. Heterocycles can be divided into different groups: 
unsaturated (pyridine 1), saturated (piperidine 2), fused unsaturated (guanine 3) and fused 
saturated (pyrrolizidine 4). 
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Figure 2: Heterocycle drugs. Nine heterocycle drugs which made the top 10 drugs by retail 
sales in the US in 2010 4. The brand, generic name and indication of these drugs are as follows: 
Nexium (Esomaprazole) 5, anti-ulcer; Lipitor (Atorvastatin) 6, cholesterol regulator; Abilify 
(Aripiprazole) 7, anti-psychotic; Plavix (Clopidogrel) 8, platelet aggregation inhibitor; Singulair 
(Montelukast) 9, anti-histamine; Seroquel (Quetiapine) 10, anti-psychotic; Crestor 
(Rosuvastatin) 11, cholesterol regulator; Actos (Piolitazone) 12, anti-diabetic; Cymbalta 
(Duloxetine) 13, anti-depressant. 
 3 
 
In the United States, more than 80% of top small molecule drugs prescribed in 2010 contain a 
heterocycle as part of the structure 4. In fact, most of the top small molecule drugs in the US 
contain heterocycles (Figure 2). Other common and widely prescribed commercial drugs 
containing heterocycles include diazepam, isoniazid, metronidazole, azidothymidine, 
chlorpromazine, antipyrine, methorrexate and captopril 5. 
In drug discovery, the main advantage of working with heterocycles lie within their structural 
versatility enabling structural variation to effect biological activity in terms of potency and 
selectivity via bio-isostearic replacements, lipophilicity, polarity and aqueous solubility 4. For 
these reasons, heterocyclic compounds make up the largest group of compounds researched in 
medicinal chemistry 6. Of the approximately 20 million compounds identified until the early 
2000s, more than 60% are fully or partially aromatic and half from this population are 
heterocyclic. Among them, sulphur and nitrogen-containing heterocycles are most commonly 
synthesised 6. Other heterocycles containing oxygen, phosphorus and selenium have also been 
synthesised 5. Benzoxazoles are heterocycles containing oxygen and nitrogen in a five 
membered ring fused to a benzene and are commonly featured in medicinal chemistry. The 
benzoxazole scaffold can be manipulated by substituting the heteroatoms with sulphur and 
nitrogen to give benzothiazoles, benzimidazoles and oxazolopyridines, all of which have been 
reported to possess biological activity. A SciFinder® search of these molecules indicate that 
numerous compounds with reported biological activity as of January, 2018 (Figure 3). 
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Figure 3: The frequency of biologically active benzoxazole and its substituted analogues. 
Report frequencies were based on a search on SciFinder®. R= hydrogen or any group. 
 
1.1.2  Bio-activities of benzoxazoles 
Benzoxazoles play an important role in drug discovery due to multiple bio-activities such as 
anti-microbial 7-9, anti-viral 10, anti-parasitic 11,12, anti-inflammatory 13,14, anti-cancer 15,16  
activity and compounds of this type play a role in regulating blood glucose levels in diabetic 
patients 17 (Table 1). The synthesis of benzoxazole analogues can be achieved by a single step 
via the condensation of 2-aminophenol and various aldehydes 18,19. The convenience and 
efficiency of synthesising this scaffold makes benzoxazole analogues ideal drug candidates for 
the pharmaceutical industry 4. Among the various benzoxazoles reported, it was found that in 
the benzoxazole fused ring system, substitution at position C2 has the largest effect on the 
biological activity of the molecule while the substitution at position C6 modulates the 
biological activity 20-22.  
 
 
 
Benzoxazole 14              
4213 reported 
Benzothiazole 15           
3052 reported 
Benzimidazole 16              
4363 reported 
Oxazolopyridine 17            
2429 reported 
1 
2 
3 
4 
5 
6 
7 
8 
9 
 5 
 
Table 1: The structures of benzoxazole analogues which are biologically active.  
Activity/target Biologically active structure(s) 
Anti-microbial 
Staphylococcus aureus 7 
 
 
Bacillus subtilis 8 
 
 
Pseudomonas aeruginosa 8 
 
 
Candida albicans 8 
 
 
Mycobacterium tuberculosis 9 
 
 
 
 
 
 
 
 
 
 
Anti-viral 
HIV-reverse transcriptase 
inhibitor 10 
 
                                                      R= (CH2)2CH3 (25a), CH2C6H5 (25b) 
 
Anti-parasitic 
Leishmania donovani 11 
 
 
 
Hymenolepis 
Nana (tapeworm) 12  
                                
                                                  R=               (26a) ,                       (26b)                          
                  26                                                                
 
 
                                                        27 
 
 
                  18                                                                19 
20 
 
 
21 
 
                  22                                                                23 
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Nematospiroides dubius 
(nematode) 12 
 
Analgesic and anti-
inflammatory  
13 14                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
 
 
 
 
R= 4-fluorophenyl (29a), 2-flurophenyl (29b),                                                        
     4-chlorophenyl (29c), 2-chlorophenyl (29d)                            30 
Anti-cancer 15 16 
 
 
 
 
Anti-diabetic 
Hypoglycaemic agent 17 
 
 
 
 
Due to the high bio-activities and easy synthesis of benzoxazoles, some benzoxazoles have 
been developed as non-steroidal anti-inflammatory drugs (NSAIDs) such as Benoxaprofen® 
and Flunoxaprofen® and muscle relaxants such as Zoxazolamine®. Despite their effectiveness, 
these drugs have been recalled due to adverse side effects that included kidney failure 23, 
hepatoxicity 24-26 and gastrointestinal abnormalities 27. Despite the toxicity reported on some 
benzoxazoles, the benzoxazole scaffold is generally not considered toxic nor is it a structural 
motif to avoid which may cause unwanted adverse effects 28,29. In fact, benzoxazoles are not 
classified under the pan assay interference compounds (PAINS), which is a group of structural 
motifs to be avoided in medicinal chemistry 28. These toxicity reports however prompted the 
need to discover alternatives to benzoxazoles. Therefore, this has led to the recent discovery of 
a closely related class of compounds, the oxazolopyridines. 
28 
 
 
 
 
                     29 
 
                                                                                                           
 
 
 
                  31                                                        32 
                            33                                                         
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1.1.3  Discovery and synthesis of oxazolopyridines 
Oxazolopyridines are characterised by the fusion of an oxazole ring and a pyridine ring and are 
derivatives of benzoxazoles. Replacement of one carbon atom in the benzene ring of the 
benzoxazole with nitrogen results in an oxazolopyridine. This is an attractive strategy in the 
drug discovery field. This structural change increases the polarity of the molecule and 
influences the adsorption of the compound, which can be manipulated during the molecular 
design phase 30. The presence of nitrogen in the molecule increases the likelihood of hydrogen 
bond formation with water molecules or polar receptors in biological systems. This in turn 
enhances the target selectivity of the molecule 31. The stable and rigid properties of 
oxazolopyridines as well as the many sites for the addition of functional groups also make this 
group of compounds a versatile scaffold for synthetic chemistry 32. The synthesis of 
oxazolopyridine analogues 17 can be achieved readily, with the most common method of 
synthesis involving the condensation of 2-amino-3-hydroxypyridine 34 and carboxylic acids 
35 under strong acidic conditions such as polyphosphoric acid and boric acid at high 
temperatures (Figure 4) 33.  
 
 
 
Figure 4: The condensation reaction of 2-amino-3-hydroxypyridine and carboxylic acids. 
 
However, due to the harsh conditions and long reaction times, various strategies have been 
employed to overcome these issues. The efficient synthesis of oxazolopyridine can be achieved 
in two steps by reaction of 2-amino-3-bromo-5-methyl-pyridine 36 with an acid chloride, 37 
followed by the cyclisation of the intermediate, 38 into the oxazolopyridine, 39 catalysed by 
                            34                              35                                               17 
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Cu(I) and in the presence of the ligand, 1,10-phenanthroline 34. This method is conducted at 
lower temperatures and provides high yields but requires the use of Cu(I) catalyst (Figure 5). 
 
 
 
 
Figure 5: The CuI catalysed two steps reactions of 2-amino-3-bromo-5-methylpyridine and 
acid chlorides. Reaction conditions: I. 4-dimethylaminopyridine, CH2Cl2, 0 °C to room 
temperature (RT) and II. CuI catalyst, 1,10-phenanthroline, Cs2CO3, tetrahydrofuran (THF), 24 
hours. 
 
A one step microwave reaction method to synthesise oxazolopyridines that does not require 
solvents or additional catalysts and acts through the condensation reaction of 2-amino-3-
hydroxypyridine and carboxylic acid was described previously 32. Given the different strategies 
to conveniently obtain oxazolopyridines, upscaling of synthesis in a pharmaceutical setting 
becomes economically feasible 30. Similar to benzoxazoles, analogues of oxazolopyridines are 
biologically active ranging from anti-bacterial 35,36, anti-fungal 37, anti-parasitic 38,39, anti-
inflammatory 40 effects and a sirtuin modulator 41. Most importantly, pre-clinical screens using 
human cell lines and animal models indicated that oxazolopyridines are generally non-toxic 
38,39. For these reasons and especially their low toxicity, oxazolopyridines have become a major 
focus for drug discovery as an alternative scaffold to benzoxazoles. 
 
 
 
                   36                            37                                             38                                                    39 
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1.1.4  Bio-activities of oxazolopyridines 
1.1.4.1  Anti-bacterial effects 
A quantitative structure-activity relationship (QSAR) study manipulating the R group on the 
phenyl ring of the 2-aryloxazolopyridines 40 fused ring system was reported, with some 
analogues were highly potent against Gram negative bacteria. Analogues of 40a-b were most 
active when tested in Escherichia coli, Klebsiella pneumoniae and Pseudomonas aeruginosa 
where the minimum inhibitory concentration (MIC) values in these microorganisms (6.20 – 
12.5 µg/mL) were better than known antibiotics, chloramphenicol and erythromycin 35. The 
replacement with electron donating groups such as 4-OCH3 and 4-NH2 at this position was 
shown to increase the anti-microbial effect. 
 
 
40                                                                                                                                                                        
R = 4-OCH3 (40a), 4-NH2 (40b), 2-OCH3 (40c), 2-NO2 (40d), 3-OCH3 (40e) 
 
Compounds 40c-e with different R groups of the phenyl ring of the 2-aryloxazolopyridine fused 
ring system were tested in Gram negative bacteria 36. It was concluded that the anti-bacterial 
activity of oxazolopyridines were not specific. These analogues were effective against both 
Gram positive bacteria, namely methicillin-resistant Staphylococcus aureus (MRSA) and 
Bacillus subtilis, and Gram negative bacteria namely E.coli and Pseudomonas diminuta. The 
MIC values in these microorganisms (1.56 – 25 µg/mL), were more active than known 
antibiotics such as ampicillin and streptomycin. Furthermore, in silico analysis of these 
molecules indicated that the inhibition of MRSA was attributed to the docking of the 
oxazolopyridine derivatives on the Staphylococcal enterotoxin type A (SEA) protein 36. 
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1.1.4.2  Anti-fungal effects 
Both benzoxazoles and oxazolopyridines have demonstrated potent anti-fungal activity. 
Generally, oxazolopyridines were better anti-fungal agents as compared to benzoxazoles when 
tested in Candida albicans 37. Substitution at C5 of the oxazolopyridine fused ring system was 
found to be essential for its anti-fungal activity. Substituting this position with a strong electron 
withdrawing nitro group significantly increased reactivity 37. Consequently, compounds with 
the nitro group in position C6 of the fused ring system and different R groups at the phenyl 
ring such as compounds 41a-e potently inhibited against C. albicans with very low MIC values 
37.  
 
 
41                                                                                                                                                                   
R= H (41a), OCH3 (41b), Br (41c), Cl (41d), NO2 (41e) 
 
 1.1.4.3  Anti-parasitic effects 
High throughput screening (HTS) on 87,000 compounds against Trypanosoma brucei, which 
is responsible for causing the human African trypanosomiasis (HAT) disease, found the 2-
aryloxazolopyridine compound 42 to be very potent against the kinetoplastid of T. brucei with 
a half maximal inhibitory concentration (IC50) of 90 nM 
38. It also had a high selectivity index 
for the parasite as compared to other related parasites of the same family 38.  
 
 
                                                                                                             42 
 
1 
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Further to this, replacing the chlorine at position C2 of the phenyl of the 2-aryloxazolopyridine 
with fluorine to give compound 43a, significantly increased the anti-parasitic activity in T. 
brucei by approximately two-fold 39. Maintaining the fluorine group at this position but 
substitution at position C6 of the oxazolopyridine fused ring system with a phenyl, 4-
fluorophenyl and 3-chlorophenyl groups represented by compounds 43b-d further improved 
the potency represented by lower IC50 values 
39.  
 
 
 
43                                                                                                                                                                         
R= H (43a), phenyl (43b), 4-fluorophenyl (43c), 3-chlorophenyl (43d), 
 
1.1.4.4  Anti-inflammatory effects 
Oxazolopyridine derivatives were also found to be have anti-inflammatory effects in rats. 
Analogues of 2-aryloxazolopyridine 40 with different R groups on the phenyl ring effectively 
reduced oedema in rats by 62-66%. The substitution at C2 or C6 of the phenyl ring of the 2-
aryloxazolopyridine with fluorine and cyano (electron donating groups) represented by 
compounds 40f-h, enhanced the anti-inflammatory effect. The three analogues were also tested 
in other standard anti-inflammatory assays to test for analgesic, anti-pyretic and anti-arthritic 
effects and were more effective than known anti-inflammatory drugs namely phenylbutazone, 
aspirin and ibuprofen 40. 
 
40                                                                                                                                                                 
R= 2-F (17f), 2-CN (17g), 2,6-F2 (17h) 
1 
2 
3 
4 
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1.1.4.5  Sirtuin Modulation 
Some oxazolopyridine derivatives have been indicated to activate the sirtuin I (SIRT1) gene. 
SIRT1 is a protein deacetylase which is dependent on the levels of NAD+ essential in glucose 
and insulin homeostasis 41.  
 
 
 
 
44 
From a library of 2-aryloxazolopyridine compounds screened, compound 44 increased 
activation of SIRT1 at only 0.5 µM. An increase in mitochondrial content and survival in 
diabetic mice fed with a high fat diet was reported upon treatment with compound 44 at levels 
comparable to resveratrol, a supplement taken by diabetic patients 41. 
1.1.5  The development of oxazolopyridines in drug discovery 
The discovery of multiple bio-activities of oxazolopyridines have prompted the development 
of these compounds into drug candidates. Moreover, oxazolopyridines satisfy the criteria of a 
drug candidate owing to its lack of stereogenic carbon atoms preventing the complication of 
stereoisomers, its convenience in synthesis and having drug-like features like low molecular 
weight which complies with the Lipinski rule-of-five 39. The versatility of this molecular 
scaffold in terms of functionalisation by chemical substitution and its stability also makes the 
synthesis of these structural analogues to be practical and economically feasible. Most reports 
on the anti-bacterial, anti-fungal and anti-parasitic effects of oxazolopyridines were only 
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conducted on test pathogens and there was still a lack of reports on the cytotoxicity in human 
cells. Some studies have attempted to establish the toxicity profiles in mammalian cells such 
as rat skeletal myoblast L6 38,39, human lymphoblast CRL8155 39 and human hepatocellular 
carcinoma HepG2 39 cells, where oxazolopyridines were found to be non-cytotoxic. Moreover, 
only one study has been conducted in mice, which interestingly demonstrated the permeability 
of the oxazolopyridine analogues into the central nervous system 39. Furthermore, a series of 
2-arylimidazopyridine analogues have been identified to have potent anti-parasitic activity 
against Trypanosoma spp. with compound 45 showing highest potency 39. This discovery was 
initiated by the discovery of anti-parasitic activity reported in 2-aryloxazolopyridines 38,39. 
Similar to the oxazolopyridines, the anti-parasitic 2-arylimidazopyridine 45 was also found to 
be non-cytotoxic in vitro and in vivo 38,39. Despite the potential medicinal properties of 
imidazopyridines, they are structurally related to the known carcinogen 2-amino-1-methyl-6-
phenylimidazo[4,5-b]pyridine (PhIP) 46 (Figure 6). Given the potential of oxazolopyridines 
and imidazopyridines to be developed into drugs, more biological screenings are required to 
fully determine the potential toxicity of this group of compounds. Screening using mammalian 
cells may give a more reliable indication on toxicity and the effect upon acute exposure to the 
test compounds. However, chronic exposure to oxazolopyridine in more complex organisms 
such as in animal models and humans are required to fully understand its pharmacokinetic and 
adverse toxicities.  
 
 
 
 
Figure 6: Structural similarities (blue box) of the anti-parasitic 2-arylimidazopyridine 45 as 
reported previously 39 and the carcinogen, PhIP 46.  
                                     45                                                                                  46 
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1.2  PhIP, a carcinogenic heterocyclic amine 
1.2.1  Introduction to carcinogenic heterocyclic amines  
Numerous amides and amines are found in the smoke emitted from industrial areas, cigarette 
and the burning of meat products such as beef, chicken or fish 42. These compounds are 
converted into heterocyclic amines (HCAs) via incomplete combustion and nitroreduction 43 
and 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) belongs to this group of 
compounds. HCAs have been found to be mutagenic when tested on Salmonella thyphimurium 
TA98 in the Ames test. HCAs are classified into six main classes (Figure 7). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7: The six classes of heterocyclic amines. Heterocyclic amines can be divided into: 2-
amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) 46, 2-amino-3-methylimidazo[4,5-
f]quinoline (IQ) 47, 2-amino-3,4-dimethylimidazo[4,5-f]quinoline (MeIQ) 48, 2-amino-3-
methylimidazo[4,5-f]quinoxaline (IQx) 49, 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline 
(MeIQx) 50 and 2-amino-3,4,8-trimethylimidazo[4,5-f]quinoxaline (DiMeIQx) 51. 
 
 
 
47 
 
 
 
 
49 
 
 
 
51 
 
 
 
46 
 
 
 
 
48 
 
 
 
50 
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1.2.2  Carcinogen derived from food, PhIP 46 
The most abundant and common HCAs derived from the cooking of meat are PhIP, 46 and 
MeIQX, 50 44. Creatine or creatinine in meat are converted to HCAs when heated at high 
temperatures during grilling or roasting through the Maillard reaction 45. The N-methyl-amino-
imidazo moiety of PhIP, 46 is derived from creatine or creatinine while the source of the other 
rings are derived from amino acids and monosaccharides often found in flavourings and other 
marinades added to the meat 46,47. The amount of PhIP 46 detected in meat usually ranges from 
nearly undetectable levels to levels as high as a few hundred nano grams per gram of meat 
depending on the cooking method 48. For example, the composition of food additives affect the 
amount of PhIP 46 formed during cooking. It was found that the amount of amino acids and 
sugars in marinades added during the cooking of meat correlated with the amount of PhIP 46 
detected 49. Cooking temperatures also play an important role where temperature-dependent 
increases in PhIP 46 were detected between 160- 250 °C 50. 
The discovery that cooking of meat produced compounds which are mutagenic have led to a 
series of studies conducted on this group of compounds. Through the Ames test and analytical 
techniques, it was found that the main causative agent is PhIP 46 and this has led to the 
intensive research in this area using animal models and human studies 51,52 . In support of this 
finding, increased incidence of tumours was reported in rats exposed to PhIP 46 53. Specifically, 
the mutagen targeted the mammary glands in female rats, prostate glands and colon in male 
rats and lymphoid cells in both males and females 53. Similarly, PhIP 46 also increased the 
incidence of lymphoma in mice regardless of gender 54. Further studies conducted on rats have 
revealed that PhIP 46 potently targeted the prostate and seminal vesicles in male rats leading 
to the formation of tumours at those regions 55,56.  
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In humans, there was a correlation between the incidence of cancer and the type of food 
frequently consumed. The high intake of grilled meat has been associated with an increased 
incidence of cancer affecting the colorectal region 57 and stomach 58 and the high intake of fried 
food has been associated with higher risk of lung cancer 59. The high intake of HCAs derived 
from food has been associated with breast cancer affecting the female population 60. In the male 
population, the intake of PhIP 46 has been associated with an increased risk in prostate cancer 
by 1.2-fold 61. The increased risk of various cancers with the intake of cooked meat and 
processed meat in humans has been widely reported (Table 2).  
The association of cancer with PhIP 46 has been long established with the accepted mode of 
action understood to involve the formation of mutagenic PhIP-DNA adducts in non-malignant 
cells leading to the formation of cancer 52. 
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Table 2: Association of different types of cancer with the intake of cooked meat in humans 
Site of cancer Findings* N (Age or gender group if stated) References          
Colon OR = 1.8 
RR = 2.0 
OR = 2.0 
OR = 1.4 
2707 (Above 30) 
13894 (male) 
1658 (40-80) 
3402 (30-79, male) 
62 
63 
64 
65 
Colorectal HR = 1.4 
OR = 4.6 
OR = 2.0 
OR = 8.8 
OR = 4.4 
519978 (35-70) 
893 (23-80) 
2164 (45-80) 
1454 
460 (20-88) 
66 
67 
68 
69 
70 
Lung RR = 1.2 
OR = 1.7 
5368 
900  
71 
72 
Breast RR = 1.1 
OR = 1.5 
HR = 1.6 
OR = 2.4 
OR = 1.9 
OR = 3.4 
31552 
4089 (25-75, female) 
35372 (35-69, female) 
635 (female) 
3015 (25-64, female) 
683 (post-menopause) 
73 
74 
75 
76 
77 
78 
Prostate HR = 1.1 
HR = 1.5 
RR = 1.4 
OR = 8.3 
RR = 1.6 
Positive correlation 
175343 (50-71, male) 
3892 (Above 35, male) 
29361 (55-74, male) 
923 
51529 (40-75, male) 
787 
79 
80 
61 
81 
82 
83 
Bladder HR = 1.2 
HR = 1.1 
RR = 1.6 (bacon) 
OR = 2.7 
300933 (50-71) 
82002 
173229 (30-75) 
720 (40-89) 
84 
85 
86 
87 
Stomach HR = 1.7 
RR = 1.3 (bacon) 
OR = 1.6 
61433 (Female) 
120852 (55-69) 
8735 (Below 75) 
88 
89 
90 
Pancreas OR = 2.2 867 (20-65) 91 
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1.2.3  The formation of PhIP-DNA adduct 
PhIP 46 is a pro-carcinogen whereby metabolic bio-activation in the liver is required for its 
carcinogenicity. The liver produces metabolic enzymes which are involved in the chemical 
modification of xenobiotics mainly for detoxification and excretion and can be divided into 
two phases (Figure 8) depending on their roles.  
 
 
 
Figure 8: Flow diagram to show the metabolism of xenobiotics by liver enzymes. Metabolism 
catalysed by microsomes in the liver can be categorised into phase I reactions such as 
oxidation, hydrolysis, reduction and phase II reactions such as conjugation, sulphonation, 
acetylation and glucuronidation. 
 
The current understanding on the activation of PhIP 46 is through phase I hepatic cytochrome 
P450-mediated N-hydroxylation and proceeded by phase-II esterification of the N-
hydroxylamines into reactive hydroxamate esters which are reactive and covalently bind to 
DNA causing DNA damage (Figure 9). In phase I, the exocyclic primary amino group of PhIP 
46 is converted into a hydroxyamino group to give PhIP N-hydroxylamine 52  by cytochrome 
P450 (CYP) 1A2 due to its high specificity and catalytic activity for N-hydroxylation 92,93 
(Figure 9). Other cytochrome P450 species such as CYP1A1, CYP1B1, CYP2A3 and CYP3A4 
are involved in the N-hydroxylation reaction but at a lower capacity 94-98. The PhIP N-
hydroxylamine 52 reacts poorly with DNA and undergoes esterification by phase II enzymes 
namely N-acetyltransferase (NAT), sulfotransferase, prolyl tRNA synthetase and 
phosphorylase to give rise to PhIP esters 53 such as N-acetoxy, N-sulphonyloxy, N-prolyloxy 
and N-phosphatyl 99-101 (Figure 9). 
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Figure 9: Schematic representation of the formation of PhIP-DNA adduct. The bio-activation 
of PhIP 46 is initiated via N-hydroxylation by CYP1A2 to form the N-hydroxy PhIP 52 
intermediate. The N-hydroxy PhIP 52 undergoes esterification to form PhIP esters 53 and then 
decomposition to form the reactive intermediate, PhIP arylnitrenium ion 54. The PhIP 
arylnitrenium ion 54 reacts with deoxyguanosine 55 to give the dG-C8 PhIP-DNA adduct 56. 
N-hydroxylation 
CYP1A2 
N-acetyltransferase 
Sulphotransferase 
Phosphorylase               
Aminoacyl-tRNA synthetase 
 Decomposition 
PhIP 46 PhIP N-hydroxylamine 52 
PhIP arylnitrenium ion 54 
Deoxyguanosine (dG) 55 
dG-C8 PhIP-DNA adduct 56 
PhIP esters 53 
(53a)    (53b)    (53c)    (53d) 
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NAT is the major enzyme involved in the esterification of PhIP and HCAs mainly by NAT1 
and NAT2 isoforms. Among the two isoforms, N-hydroxylamines more readily bind to NAT2 
where the precursor undergoes O-acetylation to form the N-acetoxy metabolites 102,103. The 
PhIP N-acetoxy esters 53 produced are transient where the ester moieties of these metabolites 
serve as leaving groups to giving rise to electrophilic PhIP arylnitrenium ions 54 (Figure 9). 
The PhIP arylnitrenium ion 54 reacts with the nucleophilic DNA base (with preference for dG 
55) 52,104 (Figure 9). It has been considered for many years that the generation of PhIP 
arylnitrenium ion 54 is only through the activity of phase II enzymes. However, the PhIP 
arylnitrenium ions 54 can also be generated from PhIP N-hydroxylamines 52 through the 
protonation of the N-hydroxylamino group 105,106. The PhIP arylnitrenium ion 54 forms a 
covalent bond (an N-C bond) with the C8 of dG, 55 hence forming a dG-C8 PhIP-DNA adduct 
56 107-112 which is the basis for its DNA damaging ability (Figure 9). The arylnitrenium ion is 
the mode of action of PhIP and other HCAs that cause DNA damage. 
The levels of the phase I enzyme, particularly CYP1A2, determines the activation of PhIP 46. 
The liver is the main site for bio-activation and metabolism in vivo of PhIP 46 and other HCAs 
due to the high expression of CYP1A2 enzymes 93. The level of CYP1A2 expression in the 
liver has been shown to affect the PhIP-DNA adduct levels in both hepatic and extrahepatic 
tissues. Studies conducted in rodents and monkeys have shown that in animals with 
overexpression of CYP1A2 and treated with PhIP 46, the levels of PhIP-DNA adducts in 
hepatic and extrahepatic tissues increased 113-115. This highlights the importance of the N-
hydroxylation step in the activation of PhIP 46. However, PhIP-DNA adducts were also 
detected in extrahepatic tissues with lower metabolic capacity such as the colon in rats fed with 
PhIP 46 115. N-Acetoxy-PhIP 53a was also found in blood samples of the rat which indicates 
that the PhIP metabolites produced in the liver can leave the liver and circulate in the 
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bloodstream and affect other organs 115. PhIP-DNA adducts were also reported in other organs 
such as the mammary gland 116. In the urinary bladder, PhIP-DNA adducts were not detected 
in rats which also implies that the non-conjugated N-hydroxylamines are not excreted through 
the urine 117. 
Extrahepatic phase II enzymes also contribute to the bio-activation of PhIP 46 leading to 
formation of PhIP-DNA adducts in other tissues where they are involved in the modification 
of N-hydroxylamines and N-acetoxy derivatives in the bloodstream or those generated in situ 
115,116,118. Although the expression of phase I enzymes such as cytochrome P450 are lower in 
extrahepatic tissues, this does not apply to phase II enzymes where the rate of esterification 
reactions by these enzymes in extrahepatic tissues matches that of the liver or are even higher 
114-116. In female rats, the rate of enzymatic activity of NAT in the esterification of N-hydroxy-
PhIP 52 was found to be 16 times higher in the mammary glands than the liver 116. The level 
of PhIP-DNA adducts detected in the mammary glands were 10 times higher than in the liver 
116,119. The expression of NAT1 and NAT2 were detected in human mammary epithelial cells 
where the catalytic activity of NAT1 enzymes for the N-hydroxy-PhIP 52 metabolite was 
reported 120,121. Sulphotransferases were also reported to be expressed in the human mammary 
epithelial cells, where both NAT1 and sulphotransferases contributed to the increase in PhIP-
DNA adducts in those cells upon exposure to PhIP 46 121,122.  
1.2.4  Mutagenic properties of PhIP 
In the bacterial cells, the presence of DNA adducts has been used as an indicator of the severity 
of mutagenesis 52,123. The presence of these adducts has been shown to be associated in the 
increase in mutagenicity in the Salmonella system. The induction of mutagenicity in 
Salmonella TA98 was found to be very efficient where around 25 adducts are required to cause 
a mutation event 123. In Salmonella TA1538, the preference of PhIP 46 for guanine in DNA 
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adduct formation was verified through the deletion of GC in a run of GCs in the histidine (hisD) 
gene 124,125. Moreover, in Salmonella TA100 used to evaluate base substitution specificity, 
GCTA transversion was predominantly detected where the error-prone bypass of the dG-C8 
adduct appeared to be related to the induction of this type of mutation 126. The lack in affinity 
for other DNA bases commonly associated with mutagenesis such as adenine was also verified 
using other Salmonella strains which are specific for AT frameshift alterations 127.  
In mammalian cells, PhIP 46 is a potent DNA damaging agent where it has been associated 
with the formation of DNA adduct formation, DNA strand breaks and chromosomal aberrations 
128,129. While the predominant mode of action for mutagenesis in Salmonella systems is 
frameshift mutations, base substitutions at guanine bases have been reported to be more 
common in mammalian cells. Mutations induced by PhIP 46 have been evaluated in Chinese 
hamster ovary (CHO) cells through the hypoxanthine phosphoribosyltransferase (hprt), 
dihydrofolate reductase (dhfr) and adenine phosphoribosyltransferase (aprt) genes and in 
lymphoblastoid cells through the hprt gene. In these studies, GT transversion occurred most 
frequently with preference for guanine nucleotides adjacent to other guanine or adenine 
nucleotides. In cells with proficient DNA repairing capabilities, approximately 25% of the 
mutations caused by PhIP 46 occurred at guanine specifically at the 5’-GCAGA-3’ sequence 
detected in the tyrosine amber suppressor tRNA (supF) vector. Similarly, in CHO cells via the 
dhfr gene, mutations at guanine nucleotides were detected mainly at the CAGG sequence while 
one of the mutants contained mutations at the CAGA sequence. Frameshift mutations induced 
by HCAs in mammalian cells have been detected and similar to the base substitution scenario, 
guanine nucleotides adjacent to other guanine or adenine nucleotides were affected. A guanine 
deletion causing a -1 frameshift mutation has been reported in CHO cells exposed to PhIP 46 
which accounted for approximately 57% of the frameshift mutations detected in that study.  
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The role of PhIP-DNA adducts in mutation was further studied using the supF shuttle vector 
in mammalian cells. It was reported that the frequency of mutation linearly increased with the 
levels of PhIP-DNA adducts where 85-93% of the mutations induced consisted of base 
substitutions while the remainder were base deletions. Further analysis using 32P-post-labelling 
of the supF plasmid revealed that PhIP 46 preferentially formed adducts with guanine 
nucleotides with dG-C8 PhIP-DNA adducts 56 forming the majority of it. The guanine adducts 
formed with PhIP were also found to be distributed in a non-random manner in the supF 
plasmid where the adduct concentrations differed    between guanine sites. Mutations were 
detected at the adduct sites where adduct concentrations did not affect the presence of 
mutations at a particular site.  While these studies reported mainly on GCTA transversion-
type of base substitution, a site-specific mutagenesis study using oligodeoxynucleotides with a 
single dG (5’-TCCTCCTXGCCTCTC-3’, where X= A,T,C or G) reported that dG-C8 PhIP-
DNA adducts 56 were involved in GT transversions 130. 
In animals, cytogenic assays to detect for chromosomal aberrations, exchanges of sister 
chromatid and micronucleated normochromatic erythrocytes have been conducted on 
peripheral and bone marrow samples from rodents dosed with HCAs. These studies reported 
that HCAs and their respective adducts are weakly clastogenic in vivo where alteration in the 
chromosomal structure was not detected 131-135. Consistent with findings in vitro, HCAs have 
been reported to cause base modifications namely substitution and/or deletion in vivo in 
transgenic mice using the lac repressor (lacI) or β-galactosidase (lacZ) reporter genes for 
mutation, where the majority of these reports were on PhIP 46 and MeIQX 50 131,136-140. Similar 
findings were also reported in mouse colonic crypt cells 141-143 and in a microbial animal-
mediated assay system 144.  
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1.3 Cellular response to DNA damage 
1.3.1 DNA repair mechanism following base modifications  
The formation of DNA adducts following base modification is repaired via two mechanisms 
namely the base excision repair (BER) and nucleotide excision repair (NER) 145,146. Out of the 
two, BER is the pre-dominant repair mechanism, which is initiated by the activation of DNA 
glycosylases 145. The damaged base (in the case of HCA-induced damage it is guanine) is 
removed from the DNA structure by cleaving of the N-glycosidic bond, which links the 
damaged base to the deoxyribose of the DNA backbone structure. Despite the fact that DNA 
glycosylases have diverse structures, they act in a similar fashion. This involves a base flipping 
mechanism where the targeted damaged base is ‘flipped’ to an extra helical position away from 
the DNA to allow the cleavage of the N-glycosidic bond 147. The resulting intermediate product 
of BER is the formation of apurinic/apyrimidic (AP) or abasic sites which are repaired by 
apurinic/apyrimidic endonuclease I (APE1) 148,149. The role of APE1 is to cleave the 
phosphodiester bond rapidly at the 5’ direction towards the AP site which in turn creates a 
single-strand break with exposed 3’-OH and 5’-deoxyribose phosphate termini 150. In addition, 
some glycosylases have associated AP lyase activity, which targets the AP site via β-
elimination and result in the formation of a 3’-phospho-α,β-unsaturated aldehyde and 5’-
phosphate 151. The endonuclease VIII-like type I (NEIL1) and type II (NEIL2) enzymes belong 
to the family of these bifunctional glycosylases that are specific for oxidised bases. They 
therefore target the AP sites and facilitate β- and δ- eliminations, where 3’-phospho-α and β-
unsaturated aldehydes are converted to  3’-phosphates 151. 
Irrespective of whether the AP sites are targeted by APE1 or bifunctional glycosylases, the 
cleavage of the phosphodiester bond results in the formation of a BER intermediate strand, 
which consists of 3’- and 5’ blocking lesions 152. To finalise DNA repair via DNA synthesis 
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and ligation by DNA polymerase and DNA ligase, these lesions need to be removed. APE1 is 
also a bi-functional enzyme in the BER pathway and has the 3’-phosphodiesterase activity. 
This allows the restoration of 3’-OH termini from 3’-phospho-α and β-unsaturated aldehyde 
lesions generated by glycosylases. In contrast, 3’-phosphate lesions generated by NEIL1 and 
NEIL2 are converted to 3’-OH by polynucleotide kinase phosphatase (PNKP), which has 3’-
phosphatase activity 150,153. Finally, the 5’-deoxyribose phosphate termini is removed by DNA 
polymerase β with its associated 5’-deoxyribose phosphate lyase activity 153. 
Following the removal of the DNA lesions, DNA polymerase and DNA ligase are recruited to 
the sites of damage to allow the replacement of the nucleotide on the single strand breaks (i.e 
the sites of repair) formed in the process of BER. There are two pathways that replace 
nucleotides at sites of DNA damage namely short-patch BER and long-patch BER 154. Short-
patch BER constitutes 80-90% of cellular BER and involves single nucleotide gap filling. The 
5’-deoxyribose phosphate termini  is removed by DNA polymerase β during DNA synthesis, 
while ligation of the incorporated nucleotide is carried out by DNA ligase I or III and the X-
ray repair cross-complementing protein (XRCC1) 154,155. In contrast, long-patch BER involves 
the filling of a multiple nucleotide gap and is initiated due to 5’-blocking lesions that DNA 
polymerase β lyase activity. Long-patch BER involves DNA polymerase δ and ε, flap 
endonuclease I (FEN1), replication factor C (RFC), proliferating cell nuclear antigen (PCNA) 
and DNA ligase I 154,155. The 3’-OH termini are elongated by the incorporation of nucleotides 
into the gap, while the 5’-lesion is removed by DNA polymerase β,δ and ε in the presence of 
PCNA. This results in the formation of ‘flap’ oligonucleotide which is then removed by FEN1 
before DNA ligase I sequentially repairs the DNA strand via DNA ligation 151,155,156. 
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Figure 10: Schematic representation of short-patch base excision repair (BER). A DNA adduct 
is removed by the sequential activity of APE1, NEIL1, NEIL2, DNA polymerase, DNA ligase and 
XRCC1. [Abbreviations not mentioned in the figure: NEIL 1 (Endonuclease VIII-like), polyλ 
(DNA polymerase λ), HMGB1 (High-mobility group protein B1) and OHP (OH terminal)]. 
 
Other secondary proteins are also involved in the BER repair cascade. XRCC1 is involved as 
a molecular scaffold, which aids in the assembly of the enzymes involved in the BER cascade 
which includes DNA glycosylases, APE1, DNA polymerase β, PNKP, DNA ligase III and 
aprataxin 157 (Figure 10). XRCC1 binds to the nicked and gapped DNA at its N-terminal 
domain which allows the recruitment of the BER enzymes 158. Poly-ADP ribose polymerase 1 
(PARP1) binds to XRCC1 in response to DNA damage and acts in a synergistic manner. 
PARP1 also detects DNA strand breaks and activates itself and modifies other protein 
substrates by rapid ADP-ribosylation. This post-translational protein modification allows the 
recruitment of XRCC1 to the sites of DNA damage and activate XRCC1. Due to the negative 
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charge of the activated poly-(ADP-ribose) residues, PARP1 slowly detaches from the DNA 
structure to allow the recruitment of other BER proteins to the site of repair 159 (Figure 10). 
1.3.2  Base excision repair leading to the formation of double strand breaks  
DNA adducts are typically considered less detrimental to DNA structure and cell survival 
compared to DNA double strand breaks (DSBs). However, in most instances more than one 
DNA adduct will occur, some of them in close vicinity, which can lead to clustered DNA 
damage. If these sites are opposed to each other, near simultaneous BER on opposing strands 
can lead to two DNA single strand breaks (SSBs) which indirectly produce a DSB 160 (Figure 
11). This is supported by numerous in vitro studies using DNA plasmids where DSBs were 
formed when the irradiated DNA plasmids have been treated with end lesion recognising 
enzymes 161-164. Clustered DNA damage in bacterial cells that is repaired via the BER pathway 
was reported to give rise to DSBs 165. Glycosylases involved in BER facilitate this conversion 
since DSBs were detected in wild type cells but not in mutant cells that lacked these enzymes 
165. Similar results were obtained from gamma-irradiated human cells 166. Cells with down-
regulated expression of the two major glycosylases, human endonuclease III (hNTH1) and 
human 8-oxoguanine DNA N-glycosylase I (hOGG1) showed less radiation-induced 
cytotoxicity and were less prone to show DSBs 166.  
Cells are able to overcome the induced DNA damage to maintain survival using nucleosomes 
which suppress the formation of DSBs caused by BER. However, this suppression is not 
efficient and only work to a certain extent depending upon factors such as the type of lesion or 
DNA glycosylase involved, the orientation of the oxidative lesion with reference to the histone 
octamer, the distance between the lesion cluster and the local sequence and the stagger between 
opposing lesions found on the DNA strand determine the rate of suppression 167. PARP-1 was 
also found to reduce the frequency of the production of DSBs from clustered DNA damage by 
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extending the ability of BER enzymes to process DNA single strand breaks 168. Taking these 
into consideration, the formation of DSBs is not a straight-forward one and can arise from 
many factors.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11: Schematic 
representation on the 
formation of DSBs from 
clustered DNA damages. The 
simultaneous occurrence of 
two opposing BER events and 
the activity of the glycosylases 
result in the formation of DSBs. 
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1.3.3  The formation of γH2AX foci following DSBs and its significance 
Upon the formation of DSBs, a cascade of reactions take place involving various proteins to 
maintain the genomic integrity but also to reduce the probability of mutagenesis which will 
lead to cell death or carcinogenesis 169 (Figure 10). One protein which is of interest is the H2A 
in histone, which is bound to the chromosomal DNA in mammalian cells 170. The H2A protein 
is rapidly modified by phosphorylation within seconds after the formation of DSBs resulting 
in the formation of a γH2AX complex 171. Therefore, detection of the γH2AX complex is a good 
indicator for DNA damage in cells. The mechanism of modification of this protein will be 
explained in detail in this section.  
The γH2AX complex is formed when serine 139 (S139) on the carboxy-terminal tail of the 
H2AX histone variant is rapidly phosphorylated by the ataxia telangiectasia mutated (ATM) 
kinase or ataxia telangiectasia mutated Rad3 related (ATR) in response to DNA damage 171,172 
(Figure 12). The formation of this complex ensures that a microenvironment is generated to 
recruit different repair proteins in the form of the breast cancer I (BRCA1), mediator of DNA 
damage checkpoint (MDC1), tumour suppressor p-53 binding protein I (53BP1) and Rad51 to 
the site of DNA damage for repair 173 (Figure 12). Despite many studies aimed at understanding 
the regulation of the formation of the γH2AX complex, it is still poorly understood to date. 
While preliminary studies have been focused mainly on the identification of the repair proteins 
and histone modifications downstream of the γH2AX complex, other studies have identified 
that upstream modifications play an important role in the regulatory mechanism 174. For 
example, tyrosine 142 (Y142) on the carboxy-terminal tail of the H2AX, situated only three 
amino acids away from S139 is phosphorylated prior to DNA damage. Once DNA damage is 
sensed, Y142 first has to be dephosphorylated, which is a prerequisite for the phosphorylation 
of S139 by ATM/ATR 174,175. 
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The formation of γH2AX is extremely rapid and is the immediate response following DNA 
damage 176. The γH2AX therefore acts as an intermediate prior to the recruitment of other repair 
machineries to restore the damage at the site such as homologous recombination and non-
homologues end joining depending on the nature of the DSB formed on the DNA 177. The 
γH2AX is therefore seen as a bio-marker of DNA damage and repair 176. In DNA repair studies, 
cells were irradiated to induce DNA damage and was verified through the detection of γH2AX 
proteins on the DNA 178-180. These lesions were found to be repaired rapidly in vitro, typically 
within 24 hours shown by the reduced detection of γH2AX proteins 178-180. Therefore, this 
allowed colonogenic survival of the cells tested 179. 
 
 
 
 
 
 
 
 
 
Figure 12: Schematic representation of the formation of γH2AX protein complex during 
repair of DNA damage. Upon the detection of a DSB; (A) Ataxia telangiectasia mutated (ATM) 
kinase binds to the site of DNA damage, (B) The carboxy terminal of S139 in H2AX is rapidly 
phosphorylated by ATM forming γH2AX and (C) The γH2AX complex formation recruits other 
repair proteins such as breast cancer I (BRCA1), mediator of DNA damage checkpoint (MDC1), 
tumour suppressor p-53 binding protein 1 (53BP1) and Rad51 to the site. 
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1.3.4  Consequences of DNA mutations leading to cancer development 
Gene mutations arising from erroneous cellular DNA repair do not necessarily lead to the 
development of cancer. Cells can employ strategies to remove these mutations to maintain 
genomic integrity by utilising DNA polymerases for DNA replication proof-reading 181 or post-
replication DNA repair pathways such as trans-lesion synthesis (TLS) and template switching 
(TS) 182,183. However, mutations on the DNA polymerase genes will not only alter the proof-
reading capabilities of the enzyme but further exacerbate the problem by wrongly incorporating 
nucleotides amplifying the amount of mutations. Mutations of DNA polymerase genes such as 
DNA polymerase delta I (POLD1) and DNA polymerase epsilon (POLE) have been associated 
with polymerase associated polyposis (PPAP) in colorectal adenomas and carcinomas 181,184. 
An inactivating mutation of DNA polymerase kappa (POLK) was found to cause erroneous 
TLS repair leading to the development of cancer in cells exposed to carcinogens 185. 
Another consequence of mutation is the overexpression of B-cell lymphoma II (BCL2) proteins 
which inhibit cell death. The mutation of the BCL2 family gene has been associated with the 
translocation and activation of the BCL2 protein linked to the development of B-cell lymphoma 
186,187, prostate 188, breast 189 and colorectal 190 cancers. BCL2 proteins have been identified to 
localise at the outer mitochondrial membrane 191,192. This in turn affects mitochondrial 
integrity, which inhibits the release of mitochondrial cytochrome c (cyt c), a prerequisite for 
apoptotic cell death 193. Mutations of proto-oncogenes in cells result in oncogenes, which 
transform normal cells to become cancerous 194. Oncogenes are typically overexpressed to 
produce proteins, which stimulate cell division, inhibit cell differentiation and prevent cell 
death 194. The mutation of proto-oncogenes has been associated with different types of cancer 
(Table 3). 
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Table 3: Mutation of proto-oncogenes in the development of human cancers.  
Proto-oncogene Protein function Type of mutation Associated cancers References 
Retrovirus 
associated (RAS) 
family [KRAS, 
HRAS and NRAS]. 
Signal transduction 
during mitosis. 
Mutation in 
codons 12, 13 or 
61. 
Lung, colorectal, 
pancreatic, oral 
carcinoma and 
leukaemia. 
195-198 
Rearranged during 
transfection (RET).  
Tyrosine kinase 
receptor. 
Activating point 
mutation. 
Thyroid. 199 
Sarcoma (SRC). Non-receptor 
tyrosine kinase. 
Mutation in 
codon 531. 
Colorectal.  200,201 
Rapidly 
accelerated 
fibrosarcoma 
homolog B (BRAF). 
Serine/threonine 
kinase. 
Activating point 
mutation. 
Melanoma, 
colorectal and 
thyroid. 
202-204 
 
Gene mutations are not only involved in activating proto-oncogenes but also the inhibition of 
tumour suppressor (TS) genes in cancer development. TS genes regulate cell growth by 
inhibiting cell proliferation and tumour development 205. Cells respond to gene mutations by 
undergoing apoptopic cell death as a result of TS gene activation 206. In cancer cells, TS genes 
are typically mutated, which removes negative regulators of cell proliferation resulting in 
abnormal cell proliferation and in the development of solid tumours 205. The inhibition of TS 
genes has been associated with different types of cancers due to the absence of the regulatory 
proteins they encode (Table 4). 
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Table 4: Mutation of some TS genes in the development of human cancers 207,208. 
TS gene Protein function Associated cancers 
Tumour protein p53 
(p53) 
DNA transcription factor and cell cycle and 
apoptosis regulator. 
Most forms of sporadic 
tumours. 
E-cadherin Intercellular communications and signal 
transduction activation of p53. 
Most forms of sporadic 
tumours. 
Adenomatous 
polyposis coli (APC) 
Inactivation of cytoplasmic β-catenin and 
prevents the formation of the DNA 
transcription complex. 
Colorectal and familial 
adenomatous polyposis. 
BRCA1 Activates p53 and other DNA transcription 
factors and involved in DNA repair by 
binding to Rad51. 
Breast and ovary. 
Breast cancer II 
(BRCA2) 
Transcription factor with histone acetyl-
transferase activity and involved in DNA 
repair by binding to Rad51. 
Breast and ovary. 
Von Hippel-Lindau 
(VHL) 
Suppresses the expression of vascular 
endothelium growth factor (VEGF) gene. 
Clear-cell carcinoma and 
von Hippel-Lindau 
syndrome. 
Neurofibromin I 
(NF1) 
Inactivates the RAS oncogene. Neurofibromas. 
Neurofibromin II 
(NF2) 
Involved in membrane-cytoskeleton 
interactions. 
Schwannomas and 
meningiomas. 
 
Cancer development, although typically multi-factoral, shares one thing where gene mutations 
are the pre-requisite for the onset of cancer. The main strategy to minimise human exposure to 
mutagens is to conduct stringent toxicology screening of environmental chemicals, 
pharmaceuticals and food products using guidelines established by the regulatory bodies. 
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1.4  Screening for mutagens and carcinogens 
1.4.1  In vitro toxicology screening of compounds in drug discovery 
Toxicology screening plays an important role in the field of drug discovery to evaluate the 
safety of compounds isolated from natural sources, crude extracts and novel chemical entities. 
The United States Food and Drug Administration (USFDA) demands comprehensive toxicity 
screens for drug and food products before they are allowed to be marketed. Whether the tested 
compounds have protective or deleterious effects, in vitro screening is conducted prior to 
testing in more complex systems such as animal models and human clinical trials. Moreover, 
in vitro results can provide a rapid indication of the toxicity profile of the compound before its 
use in animals and humans, which conforms to ethical principles and is also a significant 
economic consideration. The cytotoxicity profile together with the pharmacokinetics of a 
compound are important to estimate dose ranges to be tested in pre-clinical models and 
subsequently in patients. The IC50 is used as a measure of cytotoxicity if the test compound 
follows a dose-dependent response within the tested range. A wide array of assays are used to 
determine cell viability by measuring different end-points. These assays are commonly divided 
into the measurements of cell proliferation, metabolic activity and plasma membrane integrity 
(Table 5). 
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Table 5: Assays commonly used in the determination of cell viability, principle and limitations. 
Assay Principle of measurement Limitations 
Cell proliferation 
assays 
  
Colony formation 
assay 
 
Considered the “gold standard” in the 
determination of cell viability 209. 
Measures the reproductive integrity of 
the cells, testing the ability of cells to 
undergo unlimited divisions to form 
colonies of at least 50 cells which is 
later enumerated 210,211. 
 
Cannot discriminate from other 
natural causes of loss in cellular 
clonogenic potential such as 
apoptosis and necrosis 212. 
Affected by sub-optimal growth 
medium, error in colony counting 
and loss of cell during 
trypsinisation 211,213. Time 
consuming and does not work in 
all cell types. 
DNA synthesis 
measurement 
 
The integration of bromodeoxyuridine 
(BrdU) and radiolabelled (3H-
thymidine) nucleosides in the DNA 
synthesised de novo during cell 
replication indicative of cellular 
proliferation 214. 
False positives caused by DNA 
repair, gene duplication and 
abortive cell cycle re-entry 214. 
Quantification is labour intensive 
and radioisotopes are health 
hazards 215.  
Metabolic activity 
assays 
  
Tetrazolium-based 
assays (MTT, WST-1 
or similar) 
 
 
 
 
 
Most widely used cell viability assay. 
Tetrazolium salts such as 3-(4,5-
dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) 
and  water soluble tetrazolium I (WST-
1) are used as redox sensors and 
reduced into formazan by NADPH 
produced by metabolically active cells 
216,217. Formazan can be quantified 
spectrophotometrically and its amount 
Tetrazolium can be reduced by 
anti-oxidants such as ascorbic 
acid and polyphenols and 
superoxides 218-220. Pro-oxidants 
increases the expression of 
glucose-6-phosphate 
dehydrogenase which artificially 
increases NADPH levels in the cell 
causing survival overestimation 
221. Tetrazolium can be reduced 
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is proportional to the number of 
metabolically active cells 216. 
 
by high amounts of mitochondria 
in growth II to mitosis (G2/M) 
cycle arrest cells which are non-
viable 222. 
ATP content assay The amount of ATP present in 
metabolically active cells is quantified 
by measuring the bioluminescence 
emitted by the conversion of luciferin 
by luciferase where ATP is the co-
factor for the enzyme. The amount of 
light emitted is proportional to the 
amount of ATP in the cell 223,224. 
Fatty acids, luciferin-like products 
and resveratrol which may be 
present in the growth medium 
inhibit luciferase activity 225. 
Quenching of luminescence by 
test compounds may occur 212. 
Direct inhibitors of enzymes of 
the electron transport chain in 
the mitochondria reduces the 
amount of ATP produced but not 
necessarily viability such as 
capsaicin 226 and quercetin 227. 
Plasma membrane 
integrity 
  
Lactate 
dehydrogenase 
(LDH) release 
measurement 
 
 
 
 
This method measures the release of 
the cytoplasmic enzyme, LDH into the 
supernatant of the cell culture due to 
cell membrane damages in non-viable 
cells 228. In the assay, LDH converts 
lactate into pyruvate and where the 
co-factor, NAD+ is reduced to NADH. 
The amount of NADH can be quantified 
using tetrazolium-based dyes 229. 
LDH inhibitors that may be 
present in the test vessel may 
lead to underestimation of LDH 
levels such as chloroquine 230. 
Detergent-like molecules like 
sapnonins increase the 
permeability of viable cell 
membrane leading to the leak of 
LDH into the supernatant which 
leading to overestimation 231. 
Trypan blue 
exclusion test 
Non-viable cells and cells undergoing 
necrosis have compromised membrane 
integrity which allows the penetration 
of the trypan blue dye into the cell 
staining it blue. The proportion of non-
Only detects intact non-viable 
cells. Compromised cell 
membrane integrity by 
detergent-like molecules may 
cause false positive results 230. 
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viable (blue) and viable (clear) cells is 
determined microscopically 232. 
Trypan blue is a weak acid and 
has affinity for basic proteins 
where stained extracellular 
proteins may cause false 
determination of non-viable cells 
233. 
 
1.4.2  In vitro screening of carcinogens required by regulatory bodies  
In addition to direct toxicity that leads to cell death, another type of toxicity relates to DNA 
integrity. Some compounds can either directly or indirectly cause DNA damage. The general 
perception is that all genotoxic compounds are potently cytotoxic resulting in cell death. 
However, this is only true to a certain degree depending on the type of DNA damage induced 
by the genotoxic agent. Genotoxic agents that cause detrimental types of DNA damage such as 
DNA double strand breaks are easily picked up during cytotoxicity screening 234. However, 
genotoxic agents that cause slight modifications to the DNA by affecting DNA base and 
nucleotide structure can be missed during cytotoxicity screening 235. However, it is especially 
these small lesions in the DNA that pose the biggest danger to the organism since base and 
nucleotide modifications are the major source of gene mutations 236. Therefore, sensitive 
genotoxicity assays should be conducted in addition to pure cytotoxicity screening to identify 
mutagens and carcinogens early in the drug development process. The USFDA, International 
Conference on Harmonisation of Technical Requirement for Registration of Pharmaceuticals 
for Human Use (ICH) and Committee of Mutagenicity (COM) have provided guidelines for 
the genotoxicity screening of drugs and consumables 237-240 (Table 6). The general approach 
for genotoxicity screening should assess mutagenicity using the bacterial reverse gene mutation 
test, also known as the Ames test 241. This method has the demonstrated ability to detect agents 
that cause genetic changes and will identify most of the known carcinogenic compounds to 
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humans and rodents. The second approach involves the determination of in vitro genotoxicity 
using mammalian cells and/or in vivo animal models 238.  
Table 6: The summary of two recommended workflow options in the screening of carcinogens 
by the ICH and USFDA. 
Recommended workflows 
Option 1 Option 2 
i. Evaluating gene mutation in bacteria 
(such as Ames test via the Salmonella 
system). 
ii. Evaluating chromosomal damage via 
cytogenetic tests in vitro (such as 
chromosome aberration, micronucleus or 
mouse lymphoma L5178Y thymidine 
kinase (TK) gene mutation assays) 
iii. Evaluating chromosomal damage in vivo 
using rodent hematopoietic cells (for the 
detection of chromosomal aberrations or 
micronuclei in metaphase cells).  
i. Evaluating gene mutation in bacteria 
(such as Ames test via the Salmonella 
system). 
ii. Evaluating genotoxicity in vivo using 
rodent hematopoietic cells (for the 
detection of micronuclei) and liver tissues 
(for the detection of DNA strand 
breakage). 
 
 
The suggested in vitro screening such as the Ames test coupled with chromosome aberration, 
micronucleus and mouse lymphoma L5178Y TK gene mutation assays in mammalian cells are 
considered sufficiently validated and are commonly used. Option 1 is typically utilised during 
drug screening although option 2 is equally suitable since both options assess both in vitro and 
in vivo conditions (Table 6). Option 1 is preferred due to the high throughput capability of in 
vitro systems as compared to in vivo especially in the screening of large compound libraries 
238. Although a positive mutagenicity result is obtained from one in vitro assay, it is sufficient 
to reject this when negative results are obtained from at least two subsequent in vivo assays 238. 
In the European Union (EU), animal testing of cosmetic products is prohibited by the EU 7th 
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Amendment Directive due to animal ethics concerns 237. Therefore, in vivo screenings are not 
conducted and in vitro screens play a more important role in determining the safety of these 
products. 
The recommended bacterial mutation assay is the Ames test which is considered the “gold 
standard” in genotoxicity testing and is usually conducted prior to tests on mammalian cells 
and rodents. The Ames test is a widely accepted short-term assay due to its simplicity and high 
throughput capability for screening compound libraries. This assay uses Salmonella strains, 
which have mutations in the gene for histidine synthesis, an essential amino acid needed for 
cell growth. Therefore, these mutated bacteria cannot grow in substrates that lack histidine. 
New mutations induced at the site of these pre-existing mutations or in nearby regions of the 
gene have the potential to restore gene function, which would allow the bacteria to synthesise 
histidine and to subsequently grow to form colonies. Therefore, the Ames test is referred to as 
a mutation reversion assay. The Salmonella strains used carry mutations in different genes in 
the histidine operon. It is important to note that these mutations were designed to respond to 
mutagens, which act via different mechanisms, mainly frameshift, base substitution mutations 
and transitions/transversions (Table 7). However, this also highlights one of the potential 
limitations of this assay where other mutations caused by a mutagen other than those listed 
cannot be picked up by this assay. 
The recommended Salmonella strains for genotoxicity screening by USFDA are TA100, TA98, 
TA1535, TA1537 and TA102 238. USFDA guidelines stipulate that a single bacterial mutation 
Ames test which clearly shows the presence of a mutation is sufficient and repeats using other 
Salmonella strains are not required 238. The TA98 and TA100 strains are commonly used in 
screens as they can accurately determine up to 90% of population mutagens 242,243. 
Subsequently, in vitro screens using mammalian cells are conducted to complement or confirm 
the findings of the Ames test. This involves the detection of chromosomal changes by detecting 
 40 
 
chromosomal aberrations, micronuclei but also by mutation detection in the mouse lymphoma 
L5178Y TK reporter gene 238,240. 
 
Table 7: The different type of genes which are manipulated in Salmonella strains used in the 
Ames test and type of mutations these strains are used to detect  244. 
Allele Salmonella strain DNA target sequence Type of mutation 
hisG46 
hisD3052 
hisC3076 
hisD6610 
hisG428 
TA100 , TA1535 
TA98 , TA1538 
TA1537 
TA97 
TA102 , TA104 
GGG 
CGCGCGCG 
+1 frameshift near CCC run 
+1 cytosine at a run of Cs  
TAA (ochre) 
Base pair substitution 
Frameshift 
Frameshift 
Frameshift 
Transitions/transversions 
 
 
Micronuclei are whole chromosomes or chromosome fragments that are left behind during 
mitotic cell division. These whole chromosomes or chromosome fragments develop a nuclear 
membrane in the cytoplasm and are usually detected during interphase as an additional small 
nucleus 245. The formation of micronuclei is caused by genotoxic agents that induce 
chromosomal breaks, in the case of clastogens and/or the gain/loss of chromosomes in the case 
of aneugens 245,246. The presence of chromosomal breakage or loss is determined through 
microscopic analysis using fluorescent dyes that stain DNA such as 2-(4-amidinophenyl)-1H -
indole-6-carboxamidine (DAPI) and Hoechst. Using the fluorescence in situ hybridisation 
(FISH) method, the origin of whole chromosomes and chromosome fragments can be identified 
247,248. Overall, the micronucleus test is sensitive and can be used to determine genotoxicity at 
very low concentrations and the determination of the end-point is easy and straight forward 247. 
Therefore, the ICH highly recommends the micronucleus test assay among all in vitro assays 
due to its reliability 249. 
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The in vitro chromosomal aberration test is used to detect for structural abnormalities of the 
chromosome in mammalian cells and is therefore only used for the detection of clastogens 250. 
Structural aberrations can occur on the chromosome or chromatid where the latter is the 
common type of aberration caused by mutagens 251. In this test, cells are exposed to the test 
compound (with or without metabolic pre-activation) for approximately 1.5 normal cell cycle 
lengths 251,252. At different pre-determined intervals after exposure to the test compound, a 
metaphase-arresting substance is added, DNA is stained using Hoechst or Giemsa stains and 
viewed under the microscope for chromosomal structure analysis 251. Similar to the 
micronucleus test, very low concentrations of the test compound can be used in this assay as it 
is highly sensitive and reliable 253. 
The TK gene mutation assay uses mouse lymphoma cells L5178YTK+/-. The assay detects the 
genetic changes in the TK gene caused by base pair substitutions and frameshift mutations 
254,255. TK is responsible for the phosphorylation of thymidine deoxyriboside to form a 
deoxythymidylate, which is salvaged for DNA replication. Mutated cells deficient in thymidine 
kinase activity cannot phosphorylate the cytotoxic thymidine analogue, trifluorothymidine 
(TFT) and incorporate it into the DNA during replication 254. Therefore, the mutants survive in 
the presence of TFT 254. The level of mutagenicity induced by the compound is measured by 
the number of growing mutant colonies after treatment. Alternatively, BrdU can used as the 
selective agent for this assay although TFT is preferred as it is 50 times more potent and more 
sensitive than BrdU 256. 
1.4.3  Limitations of the “gold standard” Ames test 
The onset of effects caused by mutagens such as the formation of a tumour requires a significant 
amount of DNA damage to develop. Therefore, not every mutagen can be identified by short 
term in vitro assays. Despite the reliability of these assays as claimed by many studies, in vitro 
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systems are artificial systems and cannot be used to represent the more complex systems of an 
organism. In addition, there is considerable interspecies variations between bacterial or animal 
models and humans, which can lead to the identification of false negative results.  For these 
reasons, many false negative results have been reported for compounds that could potentially 
be mutagenic 257.  
First developed in the 1970s, the Ames test is still extensively used today to screen for potential 
mutagens and is considered the “gold standard” due to its reliability, reproducibility and 
accuracy 241. In the classic method, bacteria are exposed to the test compound to test for 
mutagenicity. However, bacteria are prokaryotes, which cannot replicate eukaryotic conditions 
due to differences in structure, physiology and metabolic processes. One key difference is the 
inability of bacteria cells to produce metabolic enzymes such as microsomes. For this reason, 
this method is unable to detect the mutagenicity of some azo dyes, polychlorinated pesticides 
and heterocylic amines, which require enzymatic bio-activation by microsomes. 
In the 1980s, microsomes were incorporated into the Ames test 258,259 for this limitation and a 
revised method is used in toxicology screens to this day. In this improved Ames assay, test 
compounds are pre-incubated with rat S9 liver microsome extract, which can be purchased 
commercially 258. The rats for the production of the S9 extract were specifically pre-treated 
with phenobarbital or Aroclor 1254 to increase the production and enhance the bio-activation 
capacity of their hepatic microsomes 258,260,261. Due to the introduction of this pre-incubation 
step with S9 extract, pro-mutagens previously reported to be non-mutagenic were identified to 
be indeed mutagenic 258,262,263. The metabolic bio-activation of pro-mutagens by microsomes 
increases the likelihood of short-lived mutagenic metabolites reacting with bacterial test strains 
244,264. It is important to note that the addition of liver extract into the system may contribute to 
artefacts since it was reported that liver extract can induce spontaneous mutations in Salmonella 
test strains 258. The effect of S9 liver extract on the number of revertant colonies caused by 
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spontaneous mutations has been determined previously (Table 8). Some Salmonella strains 
(TA97, TA102 and TA104) were in fact sensitive to the presence of S9 liver extract in a dose 
dependent manner 258,265.  
 
Table 8: Number of spontaneous revertant colonies according to the type of Salmonella 
strains with or without S9 liver extract in the Ames test 258,265. 
Salmonella strain Number of spontaneous revertant colonies 
-S9 extract +S9 extract 
TA97 
TA98 
TA100 
TA102 
TA104 
TA1535 
TA1537 
TA1538 
75-100* 
20-50 
75-200 
100-300* 
200-300* 
5-20 
5-20 
5-20 
100-200* 
20-50 
75-200 
200-400* 
300-400* 
5-20 
5-20 
5-20 
 *key differences in the number of spontaneous revertant colonies 
 
In addition, the use of pooled human S9 liver extract is thought to provide a more representative 
toxicological result 263,266. Rat S9 liver extract has been shown to behave differently to those 
isolated from human liver when reacted with carcinogens isolated from smoke condensate 267. 
This could be attributed by the differences in microsome isoforms found in extracts of rat and 
human origin 260. A comparative study of rat and human S9 liver extracts suggested that human 
liver extracts are more sensitive than rat due to the increase in mutagenicity seen when exposed 
to known carcinogens 263. The use of human S9 liver extract is limited due to the obvious 
difficulty in acquiring human liver samples in sufficient quantity with the significant human 
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associated ethical concerns. The use of human S9 liver extract in toxicology studies has 
attracted more attention recently due to advances in the commercial production of human S9 
liver extract and the realisation of its value in providing more representative data to evaluate 
genotoxicity in humans 263. However, rat S9 liver extract is still widely used today as it is 
significantly cheaper and more readily available. 
Despite the advantages of adding a pre-incubation step, many recent studies in the field of drug 
discovery that utilise the Ames test, still do not incorporate this pre-incubation step. Often, this 
work focuses on bioactive compounds isolated from natural products or newly synthesised 
compounds, which have the potential to be developed into drug candidates. Consequently, there 
may be a significant element of bias against the detection of any mutagenic activity in the way 
these analyses were conducted. Moreover, the genotoxicity screening of these studies do no 
follow the recommended ICH and USFDA guidelines and their conclusion are often based on 
only one toxicity assay. Conclusions on genotoxicity should be based on the parallel use of 
different bio-assays, since some assays are more sensitive than others and can detect different 
types of DNA damage as discussed (refer to section 1.4.2). As no single in vitro assay is 
perfect (including the ones recommended by ICH and USFDA), other in vitro assays should be 
used to complement them to obtain robust and reliable results. 
1.4.4  Alternative in vitro screening methods for genotoxicity 
The onset of mutagenesis leading to cancer is a complex process and many factors come into 
play in the genotoxicity response by bacterial and mammalian test systems in vitro. To improve 
the genotoxicity screening of test compounds and to acknowledge the limitations of the “gold 
standard” Ames test, additional testing paradigms such as the γH2AX, comet and soft agar 
invasion assays have been developed.  These assays have been demonstrated to be more 
accurate, robust and sensitive to detect genotoxicity 268-274. Moreover using the γH2AX assay 
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in liver cells to complement the Ames test significantly improved the accuracy in detection of 
genotoxicity by 15  % compared to performing the Ames test alone 268. The γH2AX and comet 
assays are regarded to be as or even more sensitive than other mammalian cell based assays 
such as micronucleus and chromosomal aberration assays 268,273. While the Ames test measures 
the indirect end-point of genotoxicity (as in the onset of mutations leading to the formation of 
revertant colonies), the γH2AX and comet assays measure the direct damage on the structure 
of DNA itself such as the detection of cellular response to DNA breaks and the presence of 
DNA breaks respectively 275. 
The γH2AX protein is the phosphorylated form of H2A histone subunit in response to DNA 
damage caused by single or double strand breaks 176 and therefore acts as a biomarker for 
potential genotoxicity activity. The immunofluorescence assays employs the use of 
monoclonal antibodies that will specifically detect nuclear γH2AX sites. The primary antibody 
binds specifically to the γH2AX protein and to allow visual detection of these sites, a secondary 
antibody tagged with a fluorophore is added to bind specifically to the primary antibody. Under 
the microscope, the illuminated spots represent the sites of DNA damage called foci and the 
severity of genotoxicity is measured by determining the number of foci in the nucleus. The 
γH2AX assay is a very sensitive method that is capable of detecting a single foci in the nucleus 
276 and is able  to detect DNA damage levels 100-times lower than the detection limit of the 
comet assay 277. The induction of γH2AX is one of the earliest cellular responses to DNA 
damage, occurs within a few seconds following the exposure to DNA damaging agents and 
reaches maximum levels after 30 minutes 278. This assay also allows the analysis of individual 
intact cells attached to the test vessel omitting the additional step of preparing cell suspensions 
or lysates, which is required for other bio-assays 237. Since the sample is not heavily disrupted 
post-treatment, cellular morphology and distribution can be determined to reveal more 
information about the mode of action of the test compound. 
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Aside from γH2AX, other repair proteins such as 53BP1, MRE11, RAD50, BRCA1 and 
Nijmegen breakage syndrome I (NBS1) co-localise at the same DNA damage site 279-282. To 
verify the reliability of the γH2AX assay, detection of these co-localised proteins can be 
conducted 283,284. However, the detection of γH2AX foci alone is sufficient for the 
determination of genotoxicity. MRE11, 53BP1 and NBS1 proteins dissociate from the protein 
complex at different stages of mitosis, while γH2AX is formed throughout the cell cycle 285-287. 
Moreover, the SQ motif found in the carboxy terminal tail of the H2AX histone subunit is 
highly conserved in plants and animals making it a universal DNA damage marker 172. As with 
many bio-assays, the γH2AX also has its limitations such as the presence of background γH2AX 
staining due to spontaneous DNA damage occurring in the cell and false positive results have 
been reported for some phenolic compounds, which are known to be non-carcinogenic 288,289. 
Indirect mechanisms associated with cytotoxic concentrations of the test compound such as 
DNA fragmentation in cells undergoing apoptosis and necrosis may induce the production of 
γH2AX foci leading to false positive results 212. As the γH2AX foci appear as fluorescent spots 
under microscopic observation, overlapping of γH2AX foci may cause an under reporting of 
genotoxicity 178.  
The comet assay or also known as the single-cell gel electrophoresis assay is another test that 
can be utilised to evaluate genotoxicity. The method is used for the detection and quantification 
of DNA damage caused by single or double strand breaks, oxidative base damage, alkali-labile 
sites and cross-linking events between DNA and protein 290. There are two variants of the assay, 
which are widely used: the neutral comet assay is more sensitive for the detection of single and 
double strand DNA breaks while the alkaline comet assay is more sensitive for the detection 
of single strand DNA breaks, base damage and alkali-labile sites 291-294. Under very alkaline 
conditions (pH 13), denaturation and unwinding of the DNA can occur allowing the detection 
of more subtle forms of DNA damage such as single stranded breaks 291,294,295. In the comet 
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assay, individual cells are exposed to the test compound to induce DNA damage, then embeded 
in an agarose matrix, lysed and electrophoresed in an electric field based on charge differences 
(Figure 13). Genotoxic agents that induce DNA strand breaks forming DNA fragments, will 
migrate away from the nucleus towards the anode. DNA can be stained using propidium iodide 
or N',N'-dimethyl-N-[4-[(E)-(3-methyl-1,3-benzothiazol-2-ylidene)methyl]-1-phenylquinolin-
1-ium-2-yl]-N-propylpropane-1,3-diamine (SYBR) Green and viewed using fluorescence 
microscopy. The stained migrating DNA fragments form a tail from the nucleus that appears 
like a comet, which gives the assay its name 290,291. The “head” of the comet represents the 
nucleus with intact DNA, which is too large to migrate in the electric field and the “tail” of the 
comet represents the DNA fragments (Figure 13). The extent of genotoxicity is measured by 
determining the proportion of DNA in the “tail” in comparison to the “head” via visual 
examination or by using image analysis and integration of intensity profiles using imaging 
software 291,296,297 (Figure 13).  
The advantages of the comet assay are its simplicity, high sensitivity, speed, versatility in the 
detection of different types of DNA damage and is a well-established method 291,296,298. Similar 
to the γH2AX assay, the comet assay is also affected by DNA fragmentation during apoptosis 
and necrosis at cytotoxic concentrations of the test compound 299. Due to the high sensitivity 
of the comet assay, spontaneous oxidative DNA damage due to reactive oxygen species (ROS) 
also affects the readout 212. The length of the comet “tail” is proportional to the amount of DNA 
damage up to where the amount of DNA damage reaches saturation point. The increased 
amount of DNA fragments produced at the saturation point affects their migration on the 
agarose gel 298. 
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Figure 13: Schematic representation of the comet assay. Exposure of the cell to a DNA 
damaging agent results in the formation of DNA fragments. Small negatively charged DNA 
fragments travel away from the nucleus, which is the comet head in the electric field towards 
the positively charged anode forming the comet tail. 
 
Unlike the γH2AX and comet assays, which measures the response to and presence of DNA 
damage, the soft agar invasion (SAI) assay measures the end-point of the mutation process: 
cell transformation. The SAI assay is performed in vitro and used as an indicator of 
mutagenicity prior to in vivo testing. This method is widely used and represents the preferred 
mutagenic transformation assay as it is quicker than in vivo testing and relatively simple to 
perform.  
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Figure 14: Schematic representation of the soft agar invasion assay. Cells embedded in an 
agar matrix upon exposure to a mutagen, undergoes mutation and able to grow 
uncontrollably in an anchorage-independent manner forming large colonies. Some cells 
however experience spontaneous mutation resulting in the formation of small colonies in the 
agar matrix in untreated cells. 
 
The SAI assay embeds mammalian cells in a soft agar layer supplemented with growth 
medium, which sits on a base agar layer with a higher concentration of agar supplemented with 
growth medium as well (Figure 14). The addition of the base agar layer prevents the cells from 
adhering to the culture plate creating a “floating” environment for the cells. Normal adherent 
cells are not able to grow in the agar matrix due to anchorage-dependent growth where cells 
depend on extracellular matrix contacts to grow and divide (Figure 14). This is because the 
detachment of cells from the correct extracellular matrix disrupts integrin ligation and forces 
the cells to undergo apoptotic cell death, called anoikis 300. Mutated and transformed cells are 
able to grow and divide regardless of the extracellular environment where they are able to form 
colonies in an anchorage-independent manner (Figure 14). For toxicology screens, test 
compounds are supplemented in the agar layers and cells are continuously treated with the test 
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compound for 20-30 days. Mutagenic compounds that are able to transform cells result in 
increased colony numbers and size 301 (Figure 14). Although the SAI assay is quicker than in 
vivo assays, the assay still requires almost a month to complete 274. Cell retrieval upon 
completion for DNA or protein analysis cannot be done as the cells are trapped in the agar 
matrix 274.  
Alternative methods for the detection of genotoxicity measure different end-points of DNA 
damage and each is associated with specific advantages and disadvantages. However, these 
methods give a better indication of the nature of DNA damage in a more sensitive and 
representative manner as they are directly conducted on mammalian cells. The main advantage 
of in vitro screens is the speed at which results can be obtained. However, these methods can 
only be used as complementary and confirmatory assays to the Ames test at the early stages of 
drug development and further in vivo screening is required prior to clinical trials in humans to 
minimise long term health hazards in patients. 
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1.5  The mutagenic potential of oxazolopyridines 
1.5.1  Reported genotoxicity in benzoxazoles and related analogues 
Benzoxazoles as discussed previously are a popular molecular scaffold for drug discovery as 
they are both synthetically versatile and biologically active. Therefore, benzoxazoles have been 
developed into commercial drugs such Benoxaprofen, Flunoxaprofen and Zoxazolamine but 
were soon recalled due to toxicity issues 23-27. These are good examples to illustrate that 
stringent drug screening and understanding of the association between chemical structure and 
adverse side effects are essential to ensure drug safety. Genotoxicity and mutagenicity are 
adverse side effects, which are not easily detected given their complexity and sometimes non-
obvious nature. Especially mutagenicity, which typically requires a long time to manifest and 
is not rapidly detected by standard in vitro screening methods. The genotoxicity of 
benzoxazoles has only been reported recently and our understanding of how they interact with 
DNA is very limited. This however justifies the need to investigate the genotoxic and 
mutagenic liabilities of benzoxazole related analogues (such as benzimidazoles, benzothiazoles 
and oxazolopyridines). Particularly when they have structural similarities to known 
carcinogens such as PhIP 46. 
Derivatives of 2,5-disubstituted benzoxazole and benzimidazole derivatives have been shown 
to be genotoxic in the Bacillus subtilis rec assay 302. Compounds 57a-c were most genotoxic 
with the ratio of 50% lethal dose (Rec50) values of 2.22, 1.74 and 1.61 respectively. Compound 
57a was closely related to the known DNA damaging agent, 4-nitroquinoline-1-oxide (4-NQO) 
with a Rec50 value of 2.22 
302. Between the two benzoxazoles, the presence of the amine group 
at position C4 of the phenyl ring in 57a as compared to position C6 of the benzoxazole fused 
ring system in 57b enhanced the mutagenicity of the compound. The Rec50 values of 
benzimidazoles were generally lower than the benzoxazoles. 
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ID X Y R1 R2 
57a 
57b 
57c 
O 
O 
NH 
CH2 
CH2 
CH2O 
CH3 
NH2 
H 
NH2 
CH3 
H 
 
Similarly, benzoxazole and benzimidazole derivatives with anti-microbial and anti-viral 
activities were also found to be genotoxic and the genotoxicity of benzimidazoles was inferior 
compared to benzoxazoles 303. Benzoxazole compounds 58a-d were most genotoxic with Rec50 
values of 1.85, 1.74, 1.60 and 1.50 respectively, although not as genotoxic as 4-NQO 
(Rec50=2.21) 
303.  
ID X Y R1 R2 
58a 
58b 
58c 
58d 
- 
CH2 
- 
- 
C6H4 
C6H4 
C6H5 
C6H4 
6-CH3 
5-NH2 
5-(p-fluorobenzamido) 
H 
2-Cl 
4-CH3 
H 
4-NHCH3 
    
The genotoxicity of benzoxazole derivatives was further investigated in HeLa cells using the 
comet assay and in the Salmonella system using the Ames test 304. Compounds 59a and 59b 
were mildly mutagenic compared to the mutagen, 2-aminofluorene when tested in the Ames 
test using Salmonella TA98 and TA 100 strains. These compounds also required enzymatic 
bio-activation (in the presence of S9 liver extract) to be mutagenic. Compound 59a was mildly 
genotoxic in HeLa cells via the comet assay at 25 µM but the study was limited by the lack of 
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understanding of the mode of action in  genotoxicity and mutagenicity of these compounds 
from a molecular perspective 304. 
 
 
 
59                                                                                                                                                                             
R= H (59a), NO2 (59b) 
These studies have demonstrated that increasing the electron density at position C2 of the 
benzoxazole or benzimidazole fused ring systems led to an increase in genotoxicty. 
Substituting amino or nitro groups at position C6 of the fused ring systems or at any position 
on the phenyl ring attached to C2, significantly enhanced the genotoxicity and mutagenicity of 
these compounds. 
1.5.2  Oxazolopyridine as a potential mutagen  
A collaborative multi-disciplinary study between Baell’s group at Monash Institute of 
Pharmaceutical Sciences (Monash University, Melbourne, Australia), Eskitis Institute for Cell 
and Molecular Therapies (Griffith University, Brisbane, Australia) and our group (University 
of Tasmania, Hobart, Australia) synthesised a small library of oxazolopyridines from a lead 
compound, which was identified by HTS of 87,000 compounds. This screen was designed to 
identify compounds active against Trypansoma brucei rhodesiense, which is responsible for 
Human African trypanosomiasis (HAT) also known as sleeping sickness. This approach 
identified the 2-aryloxazolopyridine compound 42, which potently inhibited the growth of T.b. 
rhodesiense in vitro 38. Importantly, unlike other pharmacological approaches against HAT, 
compound 42 showed no overt cytotoxicity in mammalian cells up to high micromolar 
concentrations. At the same time compound 42 was also described as non-mutagenic in the 
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Ames test (without S9 extract) 38, which made the compound an ideal development candidate 
against HAT. This study is one of many in the field of medicinal chemistry that supports the 
potent bio-activity of oxazolopyridine compounds and their potential as safe and effective drug 
candidates. 
However, a full toxicological characterisation of oxazolopyridines had not been conducted yet 
since this molecular scaffold is only slowly gaining popularity in medicinal chemistry over the 
past decade. Toxicity tests are commonly conducted in vitro and only some in vivo screens 
have been reported to date 38-41. Therefore, more in-depth investigations were needed to identify 
oxazolopyridine-related toxicities that may have been missed in the primary screens or may 
manifest only with time. Importantly, the modes of action of these biologically active 
oxazolopyridines are not fully understood and their detailed interactions with biological 
molecules are unknown. This lack of knowledge therefore impairs the ability to predict any 
putative adverse effects of these compounds. Benzoxazoles have been studied extensively over 
many years but reports of genotoxicity have only surfaced recently 302-304. Therefore, there is 
the risk that the closely related oxazolopyridines could also be genotoxic.  
The 2-(3-aminophenyl)oxazolopyridine 60 for the current study showed some structural 
resemblance to the known carcinogen, PhIP 46 (Figure 15A). Both 2-(3-
aminophenyl)oxazolopyridine 60 and PhIP 46 share similar heterocyclic cores and an attached 
amino group (Figure 15A). Moreover, the imidazopyridine molecular core 61 is isoelectronic 
with that of the oxazolopyridine 17 (Figure15B). In fact, the imidazopyridine compounds 
showed similar anti-parasitic activity as the oxazolopyridines and also low toxicity as shown 
by the development of imidazopyridines from the initial compound library screen (Refer to 
Figure 6, section 1.1.5). The amino group is responsible for the mutagenicity in PhIP 46 
through the formation of PhIP arylnitrenium ion 54, which reacts with the guanine base of the 
DNA to form mutagenic DNA adducts as previously reviewed (refer to section 1.2.3). For 
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these reasons, the safety of oxazolopyridines developed as anti-parasitic agents was questioned 
as hydrolysis of the amide would generate a free amino group (Figure 16), which has led to the 
research questions that was addressed in the current study. 
 
 
 
 
 
 
 
 
Figure 15: Structural relatedness of imidazopyridine (such as PhIP) and oxazolopyridine 
compounds. (A) The 2-(3-aminophenyl)oxazolopyridine 60 is structurally similar to the 
carcinogen, PhIP 46 due to the presence of the aromatic heterocyclic core (blue box) and the 
attached amino group (red box). (B) The heterocyclic core of oxazolopyridine, 17 is 
isoelectronic to that of imidazopyridine, 61. 
 
 
 
 
 
 
 
 
Figure 16: Hydrolysis of amide containing oxazolopyridine compounds. For example, the 
anti-parasitic compound, 2-aryloxazolopyridine 42 can undergo hydrolysis to generate a free 
amino group (red box) such as in compound 62. 
 A  
 
 
 B 
                                      60                                                                              46 
                                                 17                                                         61 
Isoelectronic 
                                      42                                                                              62 
H2O 
Mutagenic? 
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1.5.3  Significance of study and research questions. 
The mutagenicity of oxazolopyridines has not been tested and reported to date although this 
group of compounds are structurally similar to the carcinogen, PhIP 46. Moreover, reports of 
genotoxicity and mutagenicity of the very closely-related group of molecules, the benzoxazoles 
have started to surface only recently 302-304. The investigation and understanding of the 
mutagenic potential of the oxazolopyridines are very important especially in the field of drug 
discovery to prevent any unforeseen adverse effects if drugs belonging to this family were to 
be developed clinically. The lack of cytotoxicity, high biological activity and versatile nature 
of oxazolopyridines for chemical synthesis make this scaffold attractive for developing drug 
candidates.  
Prior to the current study, some 2-aryloxazolopyridine analogues were observed to be 
genotoxic during a preliminary study conducted at the University of Tasmania (unpublished 
data). The current study is the first to determine the mutagenicity of oxazolopyridines and will 
provide the basis for a better understanding of their mutagenicity. This could also inform about 
the potential risks of other closely related medicinally important molecular scaffolds namely 
benzoxazoles, benzimidazoles and benzothiazoles used in drug discovery and ultimately could 
lead to the development of safer drugs. In addition, this study will highlight the importance of 
developing efficient and sensitive methods to determine compound mutagenicity. Due to the 
structural similarities between the 2-(3-aminophenyl)oxazolopyridine 60 and PhIP 46, it was 
hypothesised that:  The 2-(3-aminophenyl)oxazolopyridine 60 may be genotoxic and 
mutagenic to cells due to the presence of the amino group using PhIP 46, as a model. 
Chronic exposure of organisms to these compounds may lead to the development of cancer. 
Therefore, the aims of the current study are to investigate the following research questions. 
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Research question 1:  
Is the lead oxazolopyridine compound 60 toxic and mutagenic to cells? 
It was hypothesised that 2-(3-aminophenyl)oxazolopyridine 60 maybe genotoxic and 
mutagenic to cells. To evaluate the cytotoxicity, genotoxicity and mutagenicity of 
oxazolopyridine compounds, in vitro assays were carried out using mammalian cell lines such 
as HepG2 and human colorectal carcinoma (HCT116) cells as these two tissues are involved 
in the metabolism and absorption of xenobiotic agents in the body. PhIP 46 was used as the 
carcinogenic reference compound in the in vitro assays for the current study. 
Research question 2:  
Is there a structural correlation for oxazolopyridines in genotoxicity and mutagenicity? 
If oxazolopyridines are found to be genotoxic and mutagenic, what structural aspects of the 
molecular scaffold is responsible for their genotoxicity? Therefore, the determination of QSAR 
of different oxazolopyridine analogues was carried out in vitro. Results obtained from previous 
experiments led to the synthesis of other oxazolopyridine analogues and related compounds to 
determine structural moieties in the oxazolopyridine scaffold responsible for its genotoxicity 
and mutagenicity. 
Research question 3:  
What is the mode of action of oxazolopyridines in mutagenicity? 
The QSAR experiments may provide a correlation on the mutagenic mode of action of the 
oxazolopyridine compounds. However, to obtain solid evidence, the mutagenic active species 
of the oxazolopyridine needs to be identified. Therefore, the mode of action of the bio-
activation of oxazolopyridines was determined by combining chemical and biological 
approaches such as synthesis, analytical chemistry, enzymatic reactions and in vitro assays.  
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Chapter 2 Methodology 
2.1  Chemical synthesis of molecular probes 
2.1.1  General experimental  
2.1.1.1  Solvents and reagents 
All reagents and standards used for chemical synthesis were purified by standard laboratory 
methods. For drying, anhydrous magnesium sulphate was used as the drying agent for organic 
extracts unless stated otherwise and solvents removed using rotary evaporation under reduced 
pressure. 
2.1.1.2  Thin layer chromatography (TLC) 
Thin layer chromatography (TLC) was performed using Merck silica gel 60 F254 aluminium 
backed sheets. Separated spots on the TLC plate were visualised using a 254 nm ultra-violet 
lamp and/or by treatment with phosphomolybdic acid (37.5 g), ceric acid (7.5 g), sulphuric acid 
(37.5 mL and water (750 mL) dip. 
2.1.1.3  Column chromatography 
Column and flash chromatography was performed using Merck flash grade silica (32-63 µm) 
according to the general methods as previously described 305.  
2.1.1.4  Nuclear magnetic resonance (NMR) 
Synthesised compounds were dissolved in deuterated chloroform (CDCl3), methanol (CD3OD) 
or dimethylsulphoxide (DMSO-D6). NMR spectra were recorded using a Bruker Avance III 
(Billerica, Massachusetts, US) operating at 400 MHz for proton (1H) and 100 MHz for carbon 
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(13C). Chemical shifts were recorded as δ values in parts per million (ppm) and referenced to 
the solvent used. For instance, CDCl3 solvent references were at 7.26 ppm (
1H) and 77.16 ppm 
(13C), CD3OD solvent references were at 3.31 ppm (
1H) and 49.3 ppm (13C), DMSO-D6 solvent 
references were at 2.50 ppm (1H) and 39.52 ppm (13C). Proton resonances were annotated using 
these abbreviations on the 1H spectra, s = singlet; d = doublet; t= triplet; m = multiplet; bs = 
broad singlet; dd = doublet of doublet; tt= triplet of triplets; ddd = doublet of doublets of 
doublets; ttt= triplet of triplets of triplets, J = coupling constant (Hz) and number of protons. 
The interpretation of NMR spectra with respect to chemical shifts and solvents peaks were 
based on previously published values 306. 
2.1.1.5  Mass Spectrometry (MS) 
MS was performed using the Kratos Concept ISQ (Wharfside, Manchester, UK) using electron 
ionisation with 70eV electrons with an accelerating voltage of 5.3 kV or a Waters Xero Triple 
Quadrupole (Rydalmere, NSW, Australia) using 2.5 kV needle voltage with direct infusion 
electrospray ionisation measuring positive ions. Accurate mass was also measured by ‘peak 
matching’ at 10,000 resolution against perfluorokerosene. The mass was determined via the 
low resolution MS (LRMS) mode. The mass spectrometry analyses were performed by the 
Central Science Laboratory at the University of Tasmania. The molecular ions and fragments 
are quoted with the relative intensities of the peaks referenced to the most intense (100 %). 
2.1.1.6  X-ray crystallography 
X-ray diffraction data for the compound were collected with monochromated Cu Kα radiation 
(λ = 1.54178 Å) from an Incoatec IS Cu microsource on a Bruker D8 Quest (Billerica, 
Massachusetts, US), equipped with a PHOTON 100 CMOS detector (Bruker, Billerica, 
Massachusetts, US). Single crystals were mounted on nylon loops with viscous immersion oil, 
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and placed into a chilled nitrogen stream (Oxford Cryosystems Cobra), and the data were 
collected at 100(2) K with the APEX3 software. Series of  and  scans were performed to a 
maximum resolution of 0.81 Å. The structure was solved using charge flipping methods in 
SUPERFLIP 307 and refined using full-matrix least-squares on F2 with SHELXL 308 within the 
OLEX2 suite 309 as previously described. Non-hydrogen atoms were refined with anisotropic 
displacement parameters. Hydrogen atoms on carbon were visible in the diffraction map, but 
were included at calculated positions and ride on the atoms to which they are attached. 
Molecular graphics were produced with OLEX2 as previously described 309. The x-ray 
crystallography analyses were performed by the Inorganic Chemistry group at the University 
of Tasmania. 
2.1.1.7  Microwave assisted reactions 
Reactions which involved the use of a microwave reactor were conducted in a sealed glass tube 
heated in a CEM Discover Microwave reactor (Matthews, North Carolina, US). 
2.1.1.8  Syntheses of compounds 
Test compounds used in this study were synthesised based on methods previously described 
32,38,310,311. Compounds were arranged based on sequence of appearance in chapters 3 to 5. 
Synthesis of 3-(oxazolo[4,5-b]pyridine-2-yl)aniline (60). A 
mixture of 2-amino-3-hydroxypyridine (1.00 g, 9.08 mmol) and 
m-aminobenzoic acid (1.25 g, 9.08 mmol) in polyphosphoric 
acid (30 g, 14.5 mL) was heated at 180 °C for 5 hours, poured into an ice bath while hot and 
neutralised with solid NaHCO3. The resulting precipitate was filtered, washed with water and 
dried under vacuum. The crude precipitate was purified via flash chromatography on silica gel 
(Eluent: dichloromethane: hexane, 50:50) to give compound 60 as a beige solid. Whole spectral 
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data matches that of previously reported 38. 1H NMR (CDCl3/DMSO-d6) δ: 5.02 (bs, 2H), 6.63 
(ddd, J = 1.2, 2.4, 8.1 Hz, 1H), 7.03 (m, 2H), 7.31 (m, 2H), 7.61 (dd, J = 1.2, 8.1, 1H), 8.24 
(dd, J = 1.2, 4.8 Hz, 1H). 13C NMR (CDCl3/ DMSO-d6) δ: 113.1, 116.7, 117.6, 118.4, 119.4, 
126.3, 129.2, 142.3, 145.7, 147.0, 155.5, 165.3. LRMS [M=H]+: 212 m/z. 
Synthesis of 2-phenyloxazolo[4,5-b]pyridine (61). A mixture 
of 2-amino-3-hydroxypyridine (1.11 g, 10 mmol) and benzoic 
acid (1.22 g, 10 mmol) in polyphosphoric acid (30 g, 14.5 mL) 
was heated at 180 °C for 5 hours, poured into an ice bath while hot and neutralised with solid 
NaHCO3. The resulting precipitate was filtered, washed with distilled water and dried under 
vacuum. The crude precipitate was purified via flash chromatography on silica gel (Eluent: 
ethyl acetate: hexane 50:50) to give compound 61 as a yellow solid. Whole spectral data 
matches that of previously reported 32. 1H NMR (CDCl3) δ: 7.30 (dd, J = 5.0, 8.2 Hz, 1H), 7.54-
7.56 (m, 2H), 7.58-7.60 (m, 1H), 7.87 (dd, J = 1.4, 8.1 Hz, 1H), 8.33 (dd, J = 0.9, 7.8 Hz, 2H), 
8.59 (dd, J = 1.4, 4.9 Hz, 1H). 13C NMR (CDCl3) δ: 118.2, 120.1, 126.6, 128.3, 129.1, 132.5, 
143.2, 146.8, 156.5, 165.8. 
Synthesis of 2-cyclohexyloxazolo[4,5-b]pyridine (62). A 
mixture of 2-amino-3-hydroxypyridine (0.22 g, 2 mmol) and 
cyclohexane carboxylic acid (0.26 g, 2 mmol) was heated in the 
microwave reactor at 250 °C for 12 minutes. Saturated NaHCO3 was added and the mixture 
was extracted with dichloromethane, dried with anhydrous MgSO4 and evaporated to dryness. 
The crude product was purified using flash chromatography on silica gel (Eluent: ethyl acetate: 
hexane, 30:70) to give compound 62 as a white solid. Whole spectral data matches that of 
previously reported 32. 1H NMR (CDCl3) δ: 1.27-1.46 (m, 3H), 1.67-1.77 (m, 3H), 1.84-1.88 
(m, 2H), 2.16 (dd, J = 2.7, 13.3 Hz, 2H), 2.99 (ttt, J = 3.6, 7.3, 11.3, 15.0 Hz, 1H), 7.21 (dd, J 
 62 
 
= 5.0, 8.1 Hz, 1H), 7.72 (dd, J = 1.1, 8.1 Hz, 1H), 8.49 (d, J = 4.8 Hz, 1H). 13C NMR (CDCl3) 
δ: 25.3, 25.5, 25.7, 30.3, 38.3, 45.5, 117.8, 119.5, 142.8, 146.0, 156.0, 173.5. 
Synthesis of 2-phenylbenzo[d]oxazole (63). A mixture of 2-
aminophenol (1.09 g, 10 mmol) and benzoic acid (1.22 g, 10 
mmol) in polyphosphoric acid (30 g, 14.5 mL) was heated at 180 
°C for five hours, poured into an ice bath while hot and neutralised with solid NaHCO3. The 
resulting precipitate was filtered, washed with water and dried under vacuum. The crude 
precipitate was purified via flash chromatography on silica gel (Eluent: ethyl acetate: hexane, 
25:75) to give compound 63 as a yellow solid. Whole spectral data matches that of previously 
reported 312. 1H NMR (CDCl3) δ: 7.34-7.38 (m, 2H), 7.53 (d, J = 1.8 Hz, 1H), 7.54 (d, J = 2.0 
Hz, 2H), 7.59 (dd, J = 3.5, 6.5 Hz, 1H), 7.78 (dd, J = 3.3, 6.3 Hz, 1H), 8.27 (dd, J = 2.0, 6.5 
Hz, 2H). 
Synthesis of 2-cyclohexylbenzo[d]oxazole (64). A mixture of 
2-aminophenol (0.22 g, 2 mmol) and cyclohexane carboxylic 
acid (0.26 g, 2 mmol) was heated in the microwave reactor at 
250 °C for 12 minutes. Saturated NaHCO3 was added and the mixture was extracted with 
dichloromethane, dried with anhydrous MgSO4 and evaporated to dryness.  The crude product 
was purified using flash chromatography on silica gel (Eluent: ethyl acetate: hexane, 10:90) to 
give compound 64 as a white solid. Whole spectral data matches that of previously reported 
312. 1H NMR (CDCl3) δ: 1.26-1.37 (m, 3H), 1.65-1.74 (m, 3H), 1.84 (tt, J = 3.7, 7.5, 13.1 Hz, 
2H), 2.16 (dd, J = 2.9, 13.1, 16.0 Hz, 2H), 2.93 (ttt, J = 3.6, 7.1, 11.3, 14.9 Hz, 1H), 7.24-7.25 
(m, 1H), 7.26-7.27 (m, 1H), 7.42-7.47 (m, 1H), 7.65-7.69 (m, 1H). 13C NMR (CDCl3) δ: 25.6, 
25.8, 30.4, 27.9, 110.2, 119.6, 123.9, 124.3, 141.2, 150.6, 170.3. 
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Synthesis of 2-(3-methoxyphenyl)oxazolo[4,5-b]pyridine 
(40e). A mixture of 2-amino-3-hydroxypyridine (0.36 g, 3.29 
mmol) and m-methoxybenzoic acid (0.50 g, 3.29 mmol) was 
heated in the microwave reactor at 170 °C for 8 minutes. Saturated NaHCO3 was added and 
the mixture was extracted with dichloromethane, dried with anhydrous MgSO4 and evaporated 
to dryness. The crude product was purified using flash chromatography on silica gel (Eluent: 
ethyl acetate: hexane, 50:50) to give compound 40e as a white solid. Whole spectral data 
matches that of previously reported 36. 1H NMR (CDCl3) δ: 3.87 (s, 3H), 7.08 (d, J = 7.6 Hz, 
1H), 7.25 (t, J = 6.0 Hz, 1H), 7.40 (t, J = 7.6 Hz, 1H), 7.81-7.86 (m, 3H), 8.54 (d, J = 4.6 Hz, 
1H). 13C NMR (CDCl3) δ: 55.5, 112.4, 118.2, 119.2, 120.1, 120.5, 127.6, 130.1, 143.1, 146.7, 
156.3, 160.0, 165.6. 
Synthesis of N-(3-(oxazolo[4,5-b]pyridine-2-
yl)phenyl)acetamide (65). Compound 60 (0.10 g, 0.47 mmol) 
was dissolved in dichloromethane and pyridine (0.5 mL) and 
then acetyl chloride (51 µL, 0.71 mmol) to the mixture and the 
reaction stirred at room temperature, overnight. The reaction mixture was diluted with ethyl 
acetate (5 mL) and washed with water, concentrated HCl (2 M) and saturated NaHCO3, dried 
with anhydrous MgSO4 and evaporated to dryness. The crude product was purified via flash 
chromatography on silica gel (Eluent: ethyl acetate: hexane, 60:40) to give compound 65 as a 
white solid. 1H NMR (CDCl3) δ: 2.25 (s, 3H), 5.28 (s, 1H), 7.30 (dd, J = 4.9, 8.0 Hz, 1H), 7.40 
(t, J = 7.9 Hz, 1H), 7.83 (d, J = 7.9 Hz, 1H), 7.92 (t, J = 7.5 Hz, 2H), 8.39 (s, 1H), 8.54 (bs, 
1H), 8.71 (bs, 1H). 13C NMR (CDCl3) δ: 24.6, 118.8, 119.3, 120.4, 123.6, 124.2, 126.7, 129.8, 
139.2, 143.3, 146.2, 155.9, 165.7, 169.4. LRMS [M=H]+: 254 m/z. 
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Synthesis of N,N-dimethyl-3-(oxazolo[4,5-b]pyridin-2-
yl)aniline (66). A mixture of compound 60 (0.10 g, 0.47 mmol), 
formaldehyde (0.04 g, 1.18 mmol) and formic acid (0.5 mL) was 
heated under reflux at 90 °C for 4 hours. Saturated NaHCO3 was added and the mixture was 
extracted with dichloromethane, dried with anhydrous MgSO4 and evaporated to dryness. The 
crude product was purified via flash chromatography on silica gel (Eluent: ethyl acetate) to 
give compound 66 as a white solid. 1H NMR (CDCl3) δ: 3.07 (s, 6H), 7.00 (d, J= 8.8 Hz, 1H), 
7.28 (dd, J = 5.0, 8.0 Hz, 1H), 7.40 (t, J = 8.0 Hz, 1H), 7.68 (d, J = 7.6 Hz, 1H), 7.73 (s, 1H), 
7.85 (d, J = 7.6 Hz, 1H), 8.56 (d, J = 4.6 Hz, 1H). 13C NMR (CDCl3) δ: 41.0, 112.1, 117.0, 
118.1, 120.0, 127.2, 129.8, 143.2, 146.7, 150.4, 156.6, 166.4. LRMS [M=H]+: 240 m/z. 
Synthesis of 2-(4-methoxyphenyl)oxazolo[4,5-b]pyridine 
(40a). A mixture of 2-amino-3-hydroxypyridine (0.36 g, 3.29 
mmol), p-methoxybenzoic acid (0.50 g, 3.29 mmol) and boric 
acid (0.20 g, 3.29 mmol) was heated in the microwave reactor at 170 °C for 8 minutes. 
Saturated NaHCO3 was added and the mixture was extracted with dichloromethane, dried with 
anhydrous MgSO4 and evaporated to dryness. The crude product was purified using flash 
chromatography on silica gel (Eluent: ethyl acetate: hexane, 30:70) to give compound 40a as a 
white solid. Whole spectral data matches that of previously reported 32. 1H NMR (CDCl3) δ: 
3.86 (s, 3H), 7.00 (d, J = 8.4 Hz, 2H), 7.22 (dd, J = 4.9, 8.0 Hz, 1H), 7.79 (d, J = 8.0 Hz, 1H), 
8.22 (d, J = 8.9 Hz, 2H), 8.50 (s, J = 4.0 Hz, 1H). 13C NMR (CDCl3) δ: 55.5, 114.5, 118.0, 
118.8, 119.6, 130.1, 143.1, 146.1, 156.6, 163.2, 166.0. 
Synthesis of 4-(oxazolo[4,5-b]pyridine-2-yl)aniline (40b). A 
mixture of 2-amino-3-hydroxypyridine (2.20 g, 20 mmol) and 
p-aminobenzoic acid (2.70 g, 20 mmol) in polyphosphoric acid 
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(30 g, 14.5 mL) was heated at 185 °C for five hours, poured into an ice bath while hot and 
neutralised with solid NaHCO3. The resulting precipitate was filtered, washed with water and 
dried under vacuum. The crude precipitate was dissolved in ethyl acetate and methanol, then 
recrystallized with hexane to give compound 40b as a yellow solid. Whole spectral data 
matches that of previously reported 310. 1H NMR (CD3OD) δ: 4.87 (bs, 2H), 6.77 (d, J = 8.4 
Hz, 2H), 7.33 (dd, J = 4.9, 7.8 Hz, 1H), 7.98-8.01 (m, 3H), 8.39 (d, J = 4.9 Hz, 1H). 13C NMR 
(CD3OD) δ: 114.1, 115.0, 119.4, 120.6, 131.0, 144.4, 146.3, 154.9, 157.6, 168.9. 
Synthesis of 2-(4-methoxyphenyl)oxazolo[4,5-b]pyridine 4-
oxide (67). A mixture of compound 40a (0.10 g, 0.44 mmol) 
and m-chloroperbenzoic acid (0.085 g, 0.49 mmol) in 
dichloromethane was stirred at room temperature for 3 hours. Saturated NaHCO3 was added 
and the mixture was extracted with dichloromethane, dried with anhydrous MgSO4 and 
evaporated to dryness. The crude product was purified using flash chromatography on silica 
gel (Eluent: methanol: dichloromethane, 12:88) to give compound 67 as a white solid. 1H NMR 
(CD3OD) δ: 3.92 (s, 3H), 7.16 (d, J = 8.3 Hz, 2H), 7.46 (t, J = 7.6 Hz, 1H), 7.90 (d, J = 8.3 Hz, 
1H), 8.29 (d, J = 8.3 Hz, 2H), 8.35 (d, J = 6.4 Hz, 1H). 13C NMR (CD3OD) δ: 56.2, 113.7, 
116.0, 118.4, 122.0, 131.7, 137.1, 148.5, 148.6, 165.8, 167.9. LRMS [M=H]+: 243 m/z. 
Synthesis of 2-phenyloxazolo[4,5-b]pyridine 4-oxide (68). A 
mixture of compound 61 (0.10 g, 0.51 mmol) with m-
chloroperbenzoic acid (0.097 g, 0.56 mmol) in dichloromethane 
was stirred at room temperature for 24 hours. Saturated NaHCO3 was added and the mixture 
was extracted with dichloromethane, dried with anhydrous MgSO4 and evaporated to dryness. 
The crude product was purified using flash chromatography on silica gel (Eluent: methanol: 
dichloromethane, 10:90) to give compound 68 as an off-white solid. Crystals suitable for single 
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crystal x-ray analysis were grown by dissolving the solid in ethyl acetate and recrystallized 
with hexane. The compound crystallises in the triclinic space group P-1, with two molecules 
in the asymmetric unit.  1H NMR (CD3OD) δ: 7.51 (dd, J = 6.6, 8.3 Hz, 1H), 7.62 (t, J = 7.80 
Hz, 2H), 7.69 (ttt, J = 1.2, 2.5, 6.9, 8.7 Hz, 1H), 7.94 (dd, J = 0.5, 8.3 Hz, 1H), 8.33 (dd, J = 
1.4, 8.8 Hz, 2H), 8.39 (dd, J = 0.5, 6.4 Hz, 1H). 13C NMR (CD3OD) δ: 113.9, 122.7, 126.4, 
129.5, 130.4, 134.7, 137.3, 148.4, 148.6, 167.5. LRMS [M=H]+: 212 m/z. 
Synthesis of N-(3-(oxazolo[4,5-b]pyridine-2-
yl)phenyl)acetamide 4-oxide (69). A mixture of compound 65 
(0.10 g, 0.40 mmol) with m-chloroperbenzoic acid (0.152 g, 
0.88 mmol) in dichloromethane was stirred at room temperature for 48 hours. Saturated 
NaHCO3 was added and the mixture was extracted with dichloromethane, dried with anhydrous 
MgSO4 and evaporated to dryness. The crude product was purified using flash chromatography 
on silica gel (Eluent: methanol: dichloromethane, 15:85) to give compound 69 as a yellow 
solid. 1H NMR (CD3OD) δ: 2.18 (bs, 3H), 7.52 (t, J = 7.5 Hz, 1H), 7.57 (t, J = 8.6 Hz, 1H), 
7.85 (d, J = 8.6 Hz, 1H), 7.96 (d, J = 8.6 Hz, 1H), 8.07 (d, J = 7.9 Hz, 1H), 8.40 (d, J = 6.2 Hz, 
1H), 8.62 (s, 1H). 13C NMR (CD3OD) δ: 24.1, 114.3, 120.7, 123.0, 125.2, 126.1, 127.2, 131.3, 
137.7, 141.5, 148.7, 148.9, 167.6, 172.2. LRMS [M=H]+: 270 m/z. 
Synthesis of 2-(4-methoxyphenyl)benzo[d]oxazole (70). A 
mixture of 2-aminophenol (0.36 g, 3.29 mmol) and m-
methoxybenzoic acid (0.50 g, 3.29 mmol) was heated in the 
microwave reactor at 250 °C for 2 minutes. Saturated NaHCO3 was added and the mixture was 
extracted with dichloromethane, dried with anhydrous MgSO4 and evaporated to dryness. The 
crude product was purified using flash chromatography on silica gel (Eluent: ethyl acetate: 
hexane, 20:80) to give compound 70 as a white solid. Whole spectral data matches that of 
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previously reported 312. 1H NMR (CDCl3) δ: 3.89 (d, J= 1.4 Hz, 3H), 7.03 (d, J= 7.5 Hz, 2H), 
7.30-7.35 (m, 2H), 7.55 (d, J= 7.6 Hz, 1H), 7.74 (d, J= 7.2 Hz, 1H), 8.20 (d, J= 7.2 Hz, 2H). 
13C NMR (CDCl3) δ: 55.5, 110.5, 114.5, 119.7, 119.8, 124.5, 124.7, 129.5, 142.3, 150.8, 162.5, 
163.3. 
Synthesis of 2-(4-methoxyphenyl)benzo[d]thiazole (71). A 
mixture of 2-aminothiophenol (0.41 g, 3.29 mmol) and p-
methoxybenzoic acid (0.60 g, 3.95 mmol) was heated in the 
microwave reactor at 220 °C for 4 minutes. Concentrated HCl (2 M) was added followed by 
saturated NaHCO3 and the mixture was extracted with dichloromethane, dried with anhydrous 
MgSO4 and evaporated to dryness. The crude product was purified using flash chromatography 
on silica gel (Eluent: ethyl acetate: hexane, 25:75) to give compound 71 as a white solid. Whole 
spectral data matches that of previously reported 313. 1H NMR (CD3OD) δ: 3.88 (s, 3H), 7.07 
(dd, J = 8.8 Hz, 2H), 7.39 (t, J = 8.1 Hz, 1H), 7.50 (t, J = 8.1 Hz, 1H), 7.96 (d, J = 9.0 Hz, 2H), 
8.02 (d, J = 9.0 Hz, 2H). 13C NMR (CD3OD) δ: 56.0, 115.9, 122.8, 123.1, 123.6, 126.5, 127.4, 
127.8, 128.6, 130.4, 136.1, 155.3, 164.1, 170.2. 
Synthesis of oxazolo[5,4-b]pyridine-2(1H)-one (72). A 
mixture of 2-amino-3-hydroxypyridine (1.00 g, 9.08 mmol) and 
1,1-carboyldiimidazole (2.20 g, 13.6 mmol) in THF (20 mL) 
was refluxed at room temperature for 7 hours. THF was removed through evaporation and 
residue was dissolved in dichloromethane (20 mL). Concentrated NaOH (2 M) was added and 
the aqueous layer was collected and neutralised using concentrated HCl (2 M) for the formation 
of precipitate. The precipitate was filtered, washed with water and dried under vacuum to give 
compound 72 as a white solid. Whole spectral data matches that of previously reported 311. 1H 
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NMR (CD3OD) δ: 7.11 (dd, J = 5.3, 8.1 Hz, 1H), 7.53 (d, J = 8.1 Hz, 1H), 8.02 (d, J = 5.3 Hz, 
1H). 
2.2  Reagents and test compounds in biological assays 
All reagents used in this study were obtained from Sigma-Aldrich (Castle Hill, NSW, 
Australia) unless otherwise specified. PhIP 46 was purchased from Toronto Research 
Chemicals Inc. (Ontario, Toronto, Canada) and dissolved in dimethyl sulphoxide (DMSO) to 
produce a 50 mM stock solution. Stock solution of DNA repair inhibitors, 3,4-dihydro-5-[4-
(1-piperidinyl)butoxyl]-1-(2H)-isoquinolinone (DPQ) (5 mM), methoxyamine hydrochloride 
(MxHCl) (5 M) and 2-(4-morpholinyl)-6-(1-thianthrenyl)-4H-pyran-4-one (KU55933) (10 
mM) were prepared in DMSO. A stock solution of 6-hydroxy-2,5,7,8-tetramethylchromane-2-
carboxylic acid (Trolox) (0.5 M) was prepared in DMSO. All compounds synthesized in this 
study (refer to section 2.1.1.7) were prepared in DMSO to produce stock solutions of 10 mM 
or 50 mM depending on compound solubility. Stock solutions were aliquoted into single-use 
Eppendorf tubes and stored at -20 °C until use. All plastic materials used for cell culture were 
obtained from Corning-In Vitro Technologies (Mulgrave, Victoria, Australia) and for bacterial 
culture were obtained from LabServ-Thermo Fisher Scientific (Scoresby, Victoria, Australia) 
unless otherwise specified. 
2.3  Cell culture 
HepG2 and HCT116 cells were obtained from the European Collection of Cell Culture 
(EACC). HepG2 cells were maintained in Dulbecco’s Modified Eagle’s medium (DMEM) and 
HCT116 cells were maintained in McCoy’s 5A medium supplemented with glucose (1 g/L), 
fetal bovine serum (FBS) (10 %), penicillin (100 U/mL) and streptomycin (100 mg/mL) under 
standard culture conditions (37 °C, 5% CO2, 95% air). Both cell lines were routinely cultured 
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in T-25 flasks and were passaged every three to four days or when the culture reached 
approximately 80% confluency. During each passage, cells were washed with phosphate 
buffered saline (PBS) without Ca2+ or Mg2+ (5 mL, 0.8% NaCl), followed by a brief wash with 
ethylenediaminetetraacetic acid (EDTA) (1 mL, 1mg/mL) and then incubated with a 
trypsinising mixture (1 mL, 0.5 g/L trypsin and 0.2 g/L EDTA) (Gibco, Life Technologies, 
Victoria, Australia) for 3 minutes under normal conditions to allow cell detachment from the 
surface of the flask. A cell suspension was then prepared by the addition of growth medium (9 
mL) to obtain a trypsin to growth medium dilution ratio of 1:9 to deactivate the further 
proteolytic activity of trypsin. The cell density was determined via manual counting using the 
Neubauer chamber. Cells were diluted using growth medium to obtain the desired density per 
T-25 flask for HepG2 (2.0 × 106 cells) and HCT116 (1.0 × 106 cells). To exclude toxic effects, 
the concentration of DMSO was maintained at or below 0.1% (v/v) for all cell culture 
experiments. 
2.4  Cryopreservation of cells 
HepG2 (6.0 × 106 cells)  or  HCT116 (3.0 × 106 cells) were seeded in T-75 flasks, grown to 
80% confluency, trypisinised and resuspended in growth medium to achieve a final volume of 
10 mL. The cell suspension was centrifuged using an Elmi CM-6MT swinging bucket 
centrifuge (Skyline Ltd, Riga, Latvia) (500× g, RT, 5 minutes). The supernatant layer was 
removed and the pellet was resuspended in growth medium (1mL, 20% FBS and 10% DMSO), 
then placed into a cryotube. The temperature of the cryotube was lowered to -80 °C over a 
period of 24 hours in an isopropanol-containing tube box prior to long-term storage in liquid 
nitrogen. 
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2.5  Thawing of cells 
Cryopreserved cells were thawed in a water bath (37 °C, 2 minutes) and carefully added into a 
T-75 flask containing pre-warmed growth medium (15 mL). The cells were grown under 
standard conditions for 24 hours to allow cell attachment to the surface before the growth 
medium was replaced to remove residual DMSO. Standard protocols of cell culture were 
carried out when the cells reached approximately 80% confluency. 
2.6  Cell culture assays 
2.6.1  Preparation of controls used in assays 
The hydrogen peroxide stock (200 mM) was prepared in PBS and was used as the positive 
control for genotoxicity assays. The hydrogen peroxide stock was always prepared fresh and 
discarded after each experiment. The stock solution was diluted in growth medium (1:1000) to 
obtain a working concentration of 200 µM. The blank control consisted of growth medium and 
DMSO (0.001%). In all cell culture experiments, the DMSO content was standardised to 
0.001% for all wells to allow comparisons. 
2.6.2  Colony forming assay 
The cytotoxicity of compounds was tested using the colony formation assay, which measures 
the reproductive ability of a single cell to form a colony of at least 50 cells in the continued 
presence of a potential toxin 210. The colony formation assay was chosen for this study due to 
its high sensitivity and the inclusion of all cells in determining their reproductive ability when 
exposed to the test compounds. A fraction of cells will retain the capacity to produce colonies 
depending on the cytotoxic properties of the compound they are exposed to 210. The colony 
forming assays were performed as previously described 314 with modifications outlined below. 
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2.6.2.1  Methods for the colony forming assay 
HepG2 cells were grown in six-well plates and HCT116 cells in 100 mm petri dishes. 
Depending on cell type, HepG2 cells (1000 cells/well) and HCT116 cells (400 cells/dish) were 
seeded in the growth vessels. To ensure even distribution of cells, the growth vessels were 
moved gently at the north-south and east-west directions several times. Cells were then grown 
under standard conditions for 24 hours. After 24 hours, the growth medium was removed and 
replaced with pre-warmed growth medium containing test compounds and grown for a further 
12 days under standard conditions. Hydrogen peroxide (200 µM) was used as the positive 
control). 
After 12 days, cells were washed with PBS (HepG2, 1 mL or HCT116, 10mL) twice. Cells 
were then fixed (RT, 15 minutes) with PFA (2% in PBS; HepG2, 1mL or HCT-116, 5 mL). 
Then, Coomassie blue dye (HepG2, 1 mL or HCT116, 5 mL), which consisted of Brilliant Blue 
R-250 (0.25 %), methanol (40%), acetic acid (10%) and deionised water was added to each 
well or petri dish respectively and cells were stained (RT, 10 minutes). The dye was then 
removed by gentle washing with PBS once followed by distilled water twice. The stained cells 
were left to air dry for at least 24 hours prior to colony counting. 
Viable colonies consisting of 50 cells or more were manually counted under an INV-100 light 
microscope BEL INV-100 light microscope (Aktivlab, Mount Barker, SA, Australia). Colony 
formation was expressed as percentage viability of the untreated control cells using the formula 
below: 
Percentage viability =
Number of colonies per treatment group
Number of colonies in the untreated control
 × 100 % 
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Three replicates were prepared and used to calculate the mean for each independent 
experiment. Three independent experiments were conducted and the average of mean for three 
experiments (± standard deviation) was reported. 
2.6.2.2  Cytotoxic dose-response relationship 
Cells were treated with increasing concentrations of compound 60 (0.001, 0.01, 0.1, 1, 10 and 
100 μM). Growth media containing the desired concentrations of test compounds were added 
respectively. The same steps were repeated for PhIP in growth medium to achieve the 
concentrations of 0.001, 0.01, 0.1, 1, 10 and 100 μM. The assay was then conducted as per 
section 2.6.2.1. 
2.6.2.3  DNA repair inhibitors and compound 60 treatment in HepG2 cells 
HepG2 cells were pre-treated with growth media (2 mL) containing the DNA repair inhibitors, 
DPQ (1.5 µM), KU55933 (2.1 µM) or MxHCl (1.4 µM) for one hour under normal conditions. 
Growth media containing the inhibitors was removed and replaced with fresh growth media (2 
mL) supplemented with or without compound 60 (10 µM) as indicated. The assay was then 
conducted as per section 2.6.2.1. 
2.6.3  Immunofluorescence assay in HepG2 cells 
Immunofluorescence assays are highly sensitive and can be used to detect the expression of 
cellular proteins. This technique was used for the detection of γH2AX and 53BP1 proteins, 
where positive staining indicates the presence of DNA damage. Due to the close relationship 
of γH2AX and 53BP1 proteins in the repair complex 179, co-localisation staining can be 
conducted to confirm the presence of DNA damage to assess the reliability of the results 
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obtained. Immunofluorescence staining was performed as previously described 283,315 with 
modifications outlined below. 
2.6.3.1  Methods for the immunofluorescence assay 
Round glass coverslips (18 mm diameter and 0.17 mm thickness) were sterilised through 
immersion in ethanol (70 %) and placed into individual wells of a 12-well plate. Each coverslip 
was washed with PBS (1 mL) twice and residual PBS was removed. HepG2 cell suspension (1 
mL, 2.0 × 105 cells) was added to the centre of the coverslip in the well. To ensure even 
distribution of cells, the vessel was moved gently at the north-south and east-west directions 
several times. The cells were grown under normal conditions for 24 hours to allow cell 
attachment onto the coverslip. 
After 24 hours, the growth medium was removed and cells on the coverslip were treated 
accordingly and grown under standard conditions for 30 minutes. Hydrogen peroxide (200 µM) 
was used as the positive control. At the end of the treatment period, the coverslip was washed 
with pre-warmed PBS (1 mL) twice, drained and fixed with PFA (4 % in PBS and NaOH added 
to improve solubility) at RT for 10 minutes.  The PFA solution was removed and the cells were 
permeabilised with buffer A (1 mL) made of Triton-X100 (0.15 %), horse serum (10%) and 
PBS. The coverslip was incubated at RT on an orbital shaker (100 rpm, 1 hour). The cells were 
then washed with buffer A (1 mL) twice and the coverslip was removed from the wells, dabbed 
dry on a clean tissue without disrupting the coverslip surface where the cells are attached to 
and placed in a humidified chamber. On the centre of the coverslip, Merck mouse anti-
phospho-histone H2A.X (Ser139) antibodies [JBW301] (50 µL, 1:1000 in buffer A) was added 
and the humidified chamber was gently swirled in circular motion to ensure the antibodies 
covered the entire surface of the coverslips. The samples were incubated with the primary 
antibodies in the humidified chamber (4 °C, 24 hours). 
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After 24 hours, the coverslips were placed back into empty wells of a 12-well plate and were 
washed thrice with buffer B (1 mL) made of Triton-X100 (0.15 %), FBS (5%) and PBS (0.5×) 
at RT with 10 minutes incubation per washing step. Under darkened conditions, Abcam Alexa 
Fluor 488 conjugated goat anti-mouse antibodies [ab150117] (50 µL, 1:10000) in buffer C 
made of Triton-X100 (0.15 %), FBS (10%) and PBS, was added to the centre of the coverslip 
ensuring full surface coverage. Samples were exposed to the secondary antibody in the dark 
(RT, 1 hour). The coverslips were washed thrice with buffer C (1 mL) and once with PBS (1 
mL) at RT with 10 minutes incubation per washing step. Then, DAPI solution (50 µL, 1:10000 
in PBS) was added to the coverslips and incubated (RT, 2 minutes). Finally, the coverslips in 
the wells were washed twice with PBS (1 mL, 0.5×) at RT, removed from the wells with a pair 
of forceps, dabbed dry on a clean tissue and mounted on a glass microscope slides with Thermo 
Fisher Slow Fade® Gold anti-fade mounting reagent (50 µL). The mounted coverslip was left 
to air-dry for at least 12 hours in the dark at RT before conducting fluorescence microscopy. 
Fluorescent images were captured using a Nikon DS-Qi digital camera (Melville, New York, 
US) attached to a Nikon Eclipse 50i fluorescent microscope set at 60× magnification (Melville, 
New York, US) 
The captured images were edited using a the Photoscape® photo-editing software (Version 3.7, 
App Team, London, UK) by altering three parameters namely sharpness, brightness and 
contrast using the same parameters for all images. Using the batch editor function of the 
program, all images were in parallel standardised with regards to sharpness, brightness and 
contrast levels of +8, +9 and +10 respectively. The images were then opened using the 
Microsoft Paint program (Washington, US) where green foci within the DAPI stained nucleus 
were manually scored. Each foci forming unit regardless of its size was considered as one foci. 
Genotoxicity was expressed as the average number of foci/cell in a cell population. For each 
independent experiment, 80 nuclei were haphazardly sampled in the captured images and 
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scored per treatment condition. The average number of foci per nucleus (± standard deviation) 
obtained from 80 cells was reported. 
2.6.3.2  Co-localisation of γH2AX and 53BP1 proteins 
HepG2 cells were treated with compound 60 (10 µM) and PhIP 46 (10 µM) for 30 minutes 
under standard conditions as per section 2.6.3.1. To the standard protocol, an additional 
immunostaining step using a 53BP1 antibody was included. For co-staining experiments, 
Abcam rabbit anti-53BP1 antibodies [ab36823] (50 µL 1:500 in buffer A) was performed 
together with Merck mouse anti-phospho-histone H2A.X (Ser139) antibodies as per section 
2.6.3.1. Similarly, the secondary antibody used for the detection of the anti-53BP1 antibodies 
was Abcam Alexa Fluor 594 conjugated goat anti-rabbit antibodies [ab150084] (50 µL, 
1:10000 in buffer C) was together with Abcam Alexa Fluor 488 conjugated goat anti-mouse 
antibodies as per section 2.6.3.1.  
2.6.3.3  Genotoxic dose-response relationship 
HepG2 cells were treated with increasing concentrations of compound 60 or PhIP 46 (0.001, 
0.01, 0.1, 1, 10 and 100 μM) before cells were processed for immunostaining as per section 
2.6.3.1. 
2.6.3.4  Kinetics of DNA damage repair 
HepG2 cells were treated with compound 60 (10 µM) or hydrogen peroxide (200 µM) for 30 
minutes under standard conditions. At the beginning, four identical experimental sets 
corresponding to different time points (0.5, 8, 24 and 48 hours) with three replicates each were 
prepared. At the end of 30 minutes treatment, the first set of cells was fixed and stored in PBS 
at 4 °C. For the remaining batches, growth media was replaced with fresh medium (without 
 76 
 
test compound) and cells left to recover under standard growth conditions. Subsequently, cells 
were fixed at different time points (8, 24 and 48 hours) and stored in PBS at 4 °C. 
Immunostaining was then conducted as per section 2.6.3.1.  
2.6.3.5  QSAR studies and compound N-oxidation in genotoxicity 
HepG2 cells were treated with compounds 40a, 40b, 40e, 60, 61, 62, 63, 64, 65, 66, 68, 70, 71 
and 72 (10 µM) for 30 minutes. The assay was then conducted as per section 2.6.3.1. 
2.6.3.6  Effect of compound oxidation on genotoxicity 
HepG2 cells were pre-treated with Trolox (10 µM) under standard growth conditions (2 hours). 
After that, the Trolox-containing growth media was removed and replaced with growth media 
containing compound 60 (10 µM) and/or Trolox (10 µM) as indicated and the cells were 
incubated under standard growth conditions for another 30 minutes.  Immunostaining was then 
conducted as per section 2.6.3.1. 
2.6.4  Comet assay in HepG2 cells 
The comet assay is a sensitive method to determine the presence of DNA strand breaks by 
DNA damaging agents. In the presence of a genotoxic agent, DNA damage occurs forming 
fragments, which can travel away from the nucleus on the electric field during electrophoresis. 
As a result, a fluorescent comet motive appears after DNA staining, where the comet head 
represents the cellular nucleus and the tail represents released DNA fragments due to induced 
DNA strand breaks 291,292. In this study, the percentage tail length was used to determine the 
severity of DNA damage caused by the test compounds. The comet assays were performed as 
previously described 316 with modifications as outlined below.   
 77 
 
2.6.4.1  Methods for the comet assay 
In a 6-well plate, HepG2 cells (5.0 × 105 cells/ well) were seeded and grown under standard 
conditions for 3 to 4 days. The cells were treated with compound 60 or PhIP 46 (10 µM) under 
normal conditions for 30 minutes. After treatment, the growth medium was removed and PBS 
(500 µL) were added to each well to scrape the cells off the surface of the well with a cell 
scraper. The resulting cell suspension was mixed gently and the cell density was determined 
using a Neubauer chamber. Cell viability was determined using the trypan blue exclusion 
method. This was done by mixing the cell suspension (10 µL, 106 cells/mL) with trypan blue 
dye (5 µL, 0.4% in deionised water) in an Eppendorf tube. Cells were incubated with the dye 
at room temperature for two minutes and the numbers of viable cells (colourless) and dead cells 
(blue) were determined by manual scoring using standard light microscopy. 
Microscope slides coated with agarose were prepared a day prior to the experiment. This was 
done by dipping the microscope slides with ethanol (100 %) to remove impurities on the surface 
of the slide and subsequent flaming to remove the residual ethanol. The slides were then dipped 
in normal melt agar (1 % in milli-Q water, autoclaved) up to one third of the slide.  The 
underside of the slides were immediately wiped with a clean paper towel and the slides were 
air-dried overnight. To the agarose-coated slides, low melt agar (80 µL, 0.5% in milli-Q water, 
microwaved) was added and then covered with a coverslip. The thin layer of agar underneath 
the coverslip was left to solidify at room temperature for 30 minutes. The coverslip was then 
removed gently with a pair of forceps. The cell suspension (10 µL, 5.0 × 105 cells) was added 
to low melt agar (70 µL) in an Eppendorf tube and mixed by gentle flicking. Then, the low 
melt agar mixture containing cells (80 µL) was added onto the solidified layer of agar and 
covered with a coverslip. The second layer of agar underneath the coverslip was left to solidify 
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(RT, 30 minutes). The coverslip was removed gently with a pair of forceps. The third and fourth 
layers of low melt agar without cells were prepared following previous steps. 
Prepared slides containing the four layers were submerged in cold lysis buffer consisted of 
NaCl (2.5 M), EDTA (100 mM), Tris-base at pH 10 (10 mM), Triton X-100 (1%) and water. 
The slides were incubated (4 ºC, 1 hour) to allow cell lysis. The slides were then removed from 
the lysis buffer and placed side by side in the Fisher Biotech electrophoresis gel tank 
[OL120705143] (Wembley, WA, Australia). The buffer reservoirs of the gel tank were filled 
with electrophoresis buffer consisted of NaOH (300 mM), EDTA (1 mM) and water adjusted 
to pH 13 until slides were fully covered and incubated in the buffer at 4 ºC for 20 minutes to 
allow DNA unwinding. Electrophoresis was performed on the slides using the Bio-rad Model 
200/2.0 power supply (Hercules, California, US) (25 V, 300 mA, 4 ºC, 30 minutes). The slides 
were washed thrice with the neutralisation buffer (2 mL) consisted of Tris-base (0.4 M) and 
water adjusted pH 7.5 for 5 minutes during each washing step. 
DNA was stained by adding Invitrogen SYBR safe (80 µL) onto the top agar layer and 
incubated (RT, 5 minutes). Excess stain was removed by dipping the slides in chilled distilled 
water. Clean coverslips were placed on the agar layer side of the slides and viewed under the 
microscope immediately. Comet images were captured using a Nikon DS-Qi IMC digital 
camera (Melville, New York, US) attached to a Nikon Eclipse 50i fluorescent microscope 
(Melville, New York, US). The length of the comet head and tail were manually determined. 
Genotoxicity was expressed as the percentage of tail length of the entire comet calculated using 
the formula below: 
Percentage tail length =
Length of comet tail
Length of comet head + tail
 × 100 % 
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50 Nuclei were measured and used to calculate the mean for each independent experiment. 
Two independent experiments were conducted and the average of the mean for both 
experiments (± standard deviation) was reported. 
2.6.5  Soft agar invasion assay in HepG2 cells 
The soft agar assay was used to evaluate the cellular transformation potential of test 
compounds. This assay relies on the genetic transformation capacity of the cells by a mutagenic 
compound 274. Adherent cells such as HepG2, are normally not able to grow when embedded 
in soft agar due to their requirement of anchorage-dependent growth. This characteristic, can 
however be reversed as a result of gene mutations 300. Therefore, cells that are able to grow and 
form colonies in soft agar indicate the presence of mutation events leading to cellular 
transformation. The colony forming assays were performed as previously described 274 with 
modifications outlined below. 
2.6.5.1  Methods for the soft agar invasion assay 
Bacteriological grade agar broth (1% in Milli-Q water) was prepared by autoclaving (121 °C, 
5 minutes). The double strength medium made of DMEM (2×), FBS (20 %), glucose (2 g/L), 
penicillin (200 U/mL) and streptomycin (200 mg/mL) was maintained at 40 °C using a water 
bath along with the autoclaved agar broth. The agar broth (20 mL) was added to the double 
strength medium (20 mL) in a 50 mL tube to obtain an agar-growth media mixture of DMEM 
(1×), FBS (10 %), glucose (1 g/L), penicillin (100 U/mL), streptomycin (100 mg/mL) and agar 
(0.5%). Test compounds were added into the agar-growth media mixture to achieve final 
concentrations as indicated. The agar-growth mixture was transferred into 6-well plate (2mL/ 
well) and allowed to solidify (RT, 5 minutes), which formed the first agar layer of the assay. If 
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not used on the same day, agar-containing 6-well plates were stored at 4 °C and used within 
one week from the date of preparation.  
Next, agarose broth (0.7 % in Milli-Q water) was prepared by heating in a microwave and 
maintained, together with the double strength growth medium at 40 °C using a water bath. The 
agar broth (20 mL) was added to the double strength growth medium (20 mL) in a 50 mL tube 
to obtain the agarose-growth media mixture of DMEM (1×), FBS (10 %), glucose (1 g/L), 
penicillin (100 U/mL), streptomycin (100 mg/mL) and agarose (0.35%). Test compounds were 
added into the agarose-growth media mixture to achieve final concentrations as indicated. With 
the agarose-growth media mixture still in its liquid form, HepG2 cells (2500 cells/mL) were 
seeded and mixed gently to achieve an even distribution. The resulting mixture containing cells 
(2 mL) was added on the first agar layer prepared earlier and allowed to solidify (RT, 5 
minutes). This formed the second layer for the assay. Finally, the third layer, which consisted 
of standard DMEM growth media with/without test compounds as indicated, was added.  
Cells were grown under standard growth conditions for 20 to 30 days. The top medium layer 
was replaced every 3 to 4 days for cell maintenance. After 20 to 30 days, the top layer was 
removed, crystal violet solution (1 mL, 0.005% in PBS) containing ethanol (2 %) was added 
into each well and the colonies were stained (37 °C, 24 hours). Stained colonies were viewed 
under a BEL INV-100 light microscope (Aktivlab, Mount Barker, SA, Australia) and images 
were captured for analysis. Colonies with diameters above the pre-determined baseline value 
of 50 µm were included in the analysis. Colony formation was expressed as colony volume, V 
calculated using the formula 𝑉 =
4
3
𝜋𝑟3. Three independent experiments were conducted and 
the results from these experiments were represented as a scatter-plot. The mean colony volume 
(± standard deviation) from these experiments was also reported. 
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2.7  Growth of bacterial culture 
Salmonella typhimurium strain TA100 was grown in Luria-Bertani (LB) broth (2mL) 
supplemented with ampicillin (100 µg/mL) overnight (37 ºC, 18-24 hours) with shaking. 
2.8  Preparation of controls used in assays 
PhIP 46 (10 µM) was used as reference compound for mutagenicity in the Ames test while the 
blank control consisted of growth medium and DMSO (0.001%). In all bacterial culture 
experiments, the DMSO content was standardised to 0.001% for all wells to allow 
comparisons. 
2.9  Ames test 
The Ames test is regarded as the “gold standard” to assess mutagenicity and is required by the 
ICH and USFDA. Salmonella TA100 was used as the test organism in the Ames test because 
it is commonly used in toxicological screens 242,243 In addition, Salmonella TA100 can detect 
point mutations that can arise through chemical-induced DNA base modifications 244, which is 
the mutagenic mode of action of the reference compound, PhIP 46. The Salmonella TA100 
strain used in this study carries a defect in its hisD gene and hence is histidine-requiring (His-) 
and cannot grow in the absence of exogenous histidine 243. Thus, this strain can revert to 
histidine prototrophy (His+) under conditions of selection either spontaneously or else by 
chemical induction via a point mutation in the hisD gene 241. In this experiment, the number of 
revertant colonies recovered at the end of incubation was enumerated to evaluate the extent of 
mutagenicity (reflected by bacterial cells mutability) caused by the test compounds. The Ames 
assays with and without S9 liver extract were performed as previously described 241,258 with 
modifications outlined below. The minimal agar for the Ames test was prepared based on the 
composition previously described 317 with the omission of Na3C6H5O7. 
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2.9.1  Methods for the Ames test 
Overnight His- Salmonella TA100 culture was diluted in LB broth to 1:100 and grown at 37 ºC 
for three hours in a shaking incubator to mid-exponential to early stationary growth phase (106 
to 108 cfu/mL). The Ames test was performed by mixing His- Salmonella TA100 culture (100 
µL); Ames activation buffer (500 µL) consisted KCl (33 mM), MgCl2 (8 mM), glucose-6-
phosphate (5 mM), NADPH (4 mM) and Na3PO4 (102 mM); rat S9 liver extract [SLBR5811V] 
(100 µL); and test compounds as indicated. For treatments without S9 liver extract, the 
equivalent volume of PBS was used to replace the extract. The reaction mixture was incubated 
on a shaking incubator (37 ºC, 30 minutes). After incubation, the reaction mixture (100 µL) 
was spread plated on bacteriological agar supplemented with glycerol (0.2 %), histidine (0.5 
µg/mL), K2HPO4 (40 mM), KH2PO4 (15 mM), (NH4)2SO4 (7.5 mM), MgSO4 (0.41 mM) and 
Milli-Q water. The bacterial cells were grown (37 ºC, 4 days) and the number of revertant 
colonies were manually scored. The number of His+ revertant colonies in treatment plates (with 
or without S9 liver extract) were corrected by subtracting the number of revertant colonies 
formed in the non-treatment plates (with or without S9 liver extract) due to spontaneous 
mutation events. Mutagenicity reflected by bacterial cell mutability, was expressed as number 
of His+ revertant colonies per plate. Three replicates were prepared and used to calculate the 
mean for each independent experiment. Three independent experiments were conducted and 
the results reported represent the average of the mean (± standard deviation). 
2.9.2  Detection of pro-mutagens and effect of N-oxidation on mutagenicity 
His- Salmonella TA100 cells were treated with compound 60 (10 µM) or PhIP 46 (10 µM) (37 
ºC, 30 minutes). In another experiment, bacterial cells were treated with compounds 40a, 61 
and 65 (10 µM) and their corresponding N-oxides, 67, 68 and 69 (10 µM) (37 ºC, 30 minutes). 
The assay was then conducted as per section 2.9.1. 
 83 
 
2.10  Enzymatic bio-activation with S9 liver extract 
Upon the enzymatic bio-activation of the oxazolopyridine compound using S9 liver extract, 
UPLC-MS was used to monitor the reaction and identify the active species. UPLC-MS is the 
main method used for the detection of drug metabolites in complex biological matrices. This 
is due to the high sensitivity and specificity of the method, which can provide structural 
information for biochemical assays such as the one in this experiment using S9 liver extract in 
a buffered solution. Enzymatic bio-activation of the oxazolopyridine compounds were 
conducted as previously described for PhIP 46 318 with modifications outlined below. The 
UPLC-MS analyses were performed by the Central Science Laboratory at the University of 
Tasmania. 
2.10.1  Methods for enzymatic bio-activation with S9 liver extract 
In a stoppered tube placed on ice, the reaction buffer (1 mL), which consisted of  rat S9 liver 
extract [SLBR5811V] (1 mg/mL), MgCl2 (15 mM), NADP (10 mM), glucose-6-phosphate 
(150 mM), glucose-6-phosphate dehydrogenase (125 U/mL) and Na3PO4 (0.1 M) adjusted to 
pH 7.4 was prepared. To the buffer, the test compound (1 µM) was added and the reaction 
mixture was incubated on a shaking water bath (37 °C, 100 rpm, 3 hours). After incubation, 
equivalent volume of ice-cold methanol (500 µL) was added to the reaction mixture (500 µL) 
in a clean Eppendorf tube and incubated on ice (5 minutes) for protein precipitation. The 
precipitate was removed via centrifugation using the Eppendorf 5417R centrifuge machine 
(North Ryde, NSW, Australia) (1500× g, 4 °C, 5 minutes). The methanolic extract in the 
supernatant layer was stored at -80 °C until further analysis using ultra pressure liquid 
chromatography and mass spectrometry (UPLC-MS). 
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2.10.2  Analysis of enzymatic bio-activated metabolites via UPLC-MS 
The UPLC-MS analysis was conducted using the Waters Acquity H-class UPLC system 
(Milford, Massachusetts, US) instrument and chromatography was performed using a Waters 
Aquity BEH C18 column (2.1 × 100 mm × 1.7 μm) (Milford, Massachusetts, US). The UPLC 
was operated with mobile phases consisting of formic acid (0.1 % in water) (solvent A) and 
acetonitrile (solvent B). A gradient elution was carried out where initially, solvent A (100%) 
followed by a gradient to solvent B (52.5%) over 5 minutes. This was held for 1 minute before 
returning to initial conditions and re-equilibration for 3 minutes. The UPLC was operated at a 
flow rate of 0.35 mL/min, temperature of 45 ºC and the sample injection volume of 2 µL. The 
UPLC was coupled to a Waters Xevo® triple quadrupole mass spectrometer (Milford, 
Massachusetts, US). Analyses were undertaken using multiple reaction monitoring (MRM) in 
positive electrospray ionisation mode. Electrospray ionisation was performed with a capillary 
voltage of 2.7 kV, and individual cone voltages and collision energies for each MRM transition, 
as described (Table 9). Other parameters set include the desolvation temperature (450 °C), flow 
rate of the nebulising gas, N2 (950 L/h) and flow rate of the cone gas, N2 (50 L/h). MRM 
transition dwell times were 0.047 second. For the total ion count (TIC) mode, the operation 
conditions were the same except that it was operated in full scan mode, over the mass over 
charge ratio (m/z) of 100-300. 
Table 9: Quantitation and confirmation MRM and electrospray ionisation parameters of each 
analyte. 
 
Analytes Mass to charge ratio (m/z) Cone (V) Collision (V) 
Pre-cursor Products 
40a 227.2 184.1 / 212.2 61 39 / 31 
67 243.2 211.1 / 226.2 61 38 / 29 
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2.11  Computational methods 
Gaussian 16 319was used to fully optimize all the structures reported in this study at the B3LYP 
level 320-322 of density functional theory (DFT) using the CPCM 323 solvation model. The 6‐
31G(d) basis set (BS1) was used for all atoms. Frequency calculations were carried out at the 
same level of theory as those for the structural optimization. Transition structures were located 
using the Berny algorithm. Intrinsic reaction coordinate (IRC) calculations 324 were used to 
confirm the connectivity between transition structures and minima. To further refine the 
energies obtained from the B3LYP/BS1 calculations, we carried out single‐point energy 
calculations for all of the structures with a larger basis set (BS2) using the CPCM solvation 
model 320-322 at the M062X 325 level. BS2 utilizes def2‐ TZVP basis set on all atoms. All 
thermodynamic data were calculated at the standard state (298.15 K and 1 atm). To estimate 
the corresponding Gibbs free energies, entropy corrections were calculated at the B3LYP/BS1 
level and added to the single point potential energies. The computational analyses were 
performed by the Computational Chemistry group at the University of Tasmania. 
2.12  Statistical analyses 
Data was expressed as mean ± SD as indicated in the figure legends unless stated otherwise. 
Statistical significance was performed using Student t-test or one-way analysis of variance 
(ANOVA) where appropriate, followed by Bonferroni’s multiple comparison tests to 
determine the differences between control and treatment group or between treatment groups. 
The correlation coefficient (R2) analysis was also performed to determine the linearity of the 
relationship between two variables when necessary. In all the assays conducted, p< 0.005 was 
considered statistically significant. Statistical analyses were conducted using the GraphPad 
Prism version 7.01 program (GraphPad Software Inc, California, US).   
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Chapter 3 Cytotoxicity and genotoxicity of compound 60 
3.1  Overview and rationale 
To obtain more representative data on possible cytotoxicity in humans, the cytotoxicity 
screening of 2-(3-aminophenyl)oxazolopyridine, 60 was conducted in HepG2 and HCT116 
cells. The two cell lines were chosen on the basis that their tissue origins (liver and intestine) 
are involved in the pharmacokinetics of orally ingested drugs, mainly absorption and 
metabolism 326. The liver is the site for drug metabolism where hepatocytes produce 
microsomes required for phases I and II of drug metabolism 327. The colon is the main site for 
absorption of orally ingested drugs where colon epithelial cells produce metabolic enzymes 
involved in drug metabolism. Moreover, testing the lead compound in two cell lines also 
allowed the determination of cell line-dependent cytotoxicity. Cell line-dependent cytotoxicity 
is important to understand the mode of action of a compound due to the intrinsic differences 
between cell types such as the expression of functional proteins such as enzymes and receptors. 
Genotoxicity is also commonly linked to cytotoxicity where genotoxic agents damage the DNA 
of the cell and compromises the genomic stability of the cell preventing cell replication leading 
to apoptotic death. Genotoxicity screening was conducted on compound 60 due to the structural 
similarity to the known carcinogen, PhIP 46 and the positive genotoxicity of other 
oxazolopyridine analogues as observed previously at the University of Tasmania (unpublished 
data). An initial determination of genotoxicity of compound 60 was conducted in HepG2 and 
HCT116 cells. Among the two cell lines, the genotoxicity in HepG2 cells was more important 
since the liver is the main site for drug metabolism. Therefore, the genotoxicity of genotoxic 
or pro-genotoxic drugs can be detected in these cells.  
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3.2  Aims 
Only two cytotoxicity screens in mammalian cells 38,39 and one in a rodent model 39 have been 
conducted to date for oxazolopyridine compounds. These reports were not able to demonstrate 
cytotoxicity but are not sufficient to completely rule out the safety of oxazolopyridine 
compounds. There is still a lack of knowledge about the cytotoxicity of oxazolopyridines in 
mammalian cells which should be thoroughly examined before these compounds are further 
developed into drugs. Due to the preliminary data that highlight genotoxicity of some 
oxazolopyridine analogues conducted at the University of Tasmania (unpublished data), the 
following evaluations were conducted to reproduce and extend these findings. The overall aim 
of this section was to evaluate the cytotoxicity and genotoxicity of 2-(3-
aminophenyl)oxazolopyridine 60. In the experiments outlined in this section, the carcinogen, 
PhIP 46 was used as the reference compound for genotoxicity based on the hypothesis that 
compound 60 may be genotoxic and mutagenic due to structural similarities to PhIP 46. The 
following experiments were performed to address the objectives:  
 Dose-response cytotoxicity determination of compound 60 and PhIP 46 in HepG2 and 
HCT116 cells. 
 Dose-response genotoxicity determination of compound 60 and PhIP, 46 in HepG2 
cells. 
 Understanding the repair of DNA damage induced by compound 60, if present, in 
HepG2 cells. 
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3.3  Methodology 
The methods for chemical syntheses and analyses are described in section 2.1. The methods 
for the biological assays conducted in this chapter are described in sections 2.6.2, 2.6.3 and 
2.6.4.  
3.4  Results and discussion 
3.4.1  Cytotoxic determination of compound 60 
Most mutagens are also classed as cytotoxic but PhIP 46 is one of the few exceptions, being 
widely described as non-cytotoxic 328,329. The dose-response cytotoxicities of 2-(3-
aminophenyl)oxazolopyridine 60 and PhIP 46 in HepG2 and HCT116 cells were determined 
using different concentrations (0.001 to 100 µM) of the test compounds. Compound 60 only 
showed any cytotoxicity at 100 µM in HepG2 cells (Figure 18), while no cytotoxicity was 
detected up to 100 µM in HCT116 cells (Figure 18). In contrast, it was found that PhIP 46 
showed cytotoxicity from 0.001 µM in HepG2 cells but not cytotoxic in HCT116 cells at any 
concentration (Figure 18). The positive control, hydrogen peroxide was potently cytotoxic in 
both HepG2 and HCT116 cells with no residual viability detected after treatment (Figure 18).  
Based on the results shown, PhIP 46 was mildly cytotoxic in HepG2 cells at low nano-molar 
concentrations although not cytotoxic in HCT116 cells. This indicated that HepG2 cells were 
more sensitive to PhIP 46 compared to HCT116 cells, which suggests that the effect could be 
cell line selective. The liver is the centre for chemical metabolism and produces metabolic 
cytochrome P450 enzymes required for the bio-activation of PhIP 46 into arylnitrenium ions, 
which subsequently react with genomic DNA 105,106. Although intestinal cells also produce 
cytochrome P450 enzymes, the number of expressed isoforms that are actively involved in drug 
metabolism and their amounts are significantly lower in the intestine compared to the liver 
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330,331. The reaction of PhIP 46 and DNA may compromise cellular genomic integrity, which 
subsequently disrupt DNA replication leading to the initiation of apoptotic cell death 332. 
Therefore, it was not surprising that mild cytotoxicity was observed for PhIP 46 especially in 
HepG2 cells.  
In either HepG2 or HCT116 cells, compound 60 was not cytotoxic due to the lack of a dose-
response up to 10 µM. However at 100 µM, a decrease in cell viability was observed in HepG2 
cells and it is the threshold concentration where compound 60 becomes toxic. It is important 
to note that 100 µM is a relatively high concentration for cells to be exposed to and can likely 
cause non-specific toxicity. Compound screens for hit discovery are commonly performed at 
concentrations of up to 10 µM as concentrations beyond that will cause non-specific toxicity 
and exceed acceptable therapeutic doses in patients 333. High concentrations of test compound 
may lead to promiscuous inhibition of metabolic enzymes or surface proteins leading to 
unintended cell death 334. Chemical overloading can also disrupt the redox balance in cells that 
can lead to the production of ROS, which can damage DNA, proteins and lipids and can initiate 
cell death 335.  
At a high concentration (100 µM), HepG2 cells were more sensitive to compound 60 compared 
to HCT116 cells, which could support a role of chemical metabolism by liver enzymes for 
compound toxicity. The positive control used in these experiments, hydrogen peroxide was 
potently cytotoxic in HepG2 and HCT116 cells as no residual viability was detected in these 
cell lines. In a cellular context, hydrogen peroxide induces oxidative stress through the 
production of ROS and is rapidly converted to harmful free radicals resulting in cell death 336. 
The consistent cellular response to hydrogen peroxide indicated that the decrease in cell 
viability detected for the test compounds in this experiment were reliable results. 
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Figure 18: Cytotoxicity of compound 60 and PhIP 46. Viability of cells was assessed by colony 
formation assay. HepG2 and HCT116 cells were exposed to increasing concentrations (0 to 
100 µM) of: Compound 60 in HepG2 and HCT116 cells; and PhIP 46 over 12 days. Hydrogen 
peroxide (200 µM) was used as positive control. Viability data represent the mean of three 
independent experiments with three replicates per experiment and is expressed as % of 
untreated control. Error bars represent SD and ** denotes P<0.01. # denotes compound 
number. 
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Similar to reports on the lack of cytotoxicity of oxazolopyridine compounds, compound 
60 was also not cytotoxic. Despite the lack of cytotoxicity for compound 60, its genotoxicity 
is not known. Therefore, this can be investigated through the quantification of DNA damage 
induced by compound 60.  
3.4.2  Genotoxic determination of compound 60 
3.4.2.1  Immunostaining of genotoxicity indicator proteins, γH2AX and 53BP1 
Immunostaining was conducted to detect γH2AX and 53BP1 foci, which are DNA damage 
markers indicative of genotoxic activity. For this reason, genotoxicity assessment was only 
performed in HepG2 cells since these cells are widely used in biochemical and nutritional 
studies, and are regarded to closely resemble primary cultured hepatocytes 337. Moreover, liver 
cells are actively involved in drug metabolism, which allow the sensitive detection of pro-
genotoxins which may not be detected in other cell lines 337. Due to the lack of cytotoxicity of 
2-(3-aminophenyl)oxazolopyridine 60 and mild cytotoxicity of PhIP 46,  the following 
experiments were conducted at 10 µM, which is the commonly accepted concentration in HTS 
by the pharmaceutical industry 338 unless stated otherwise.    
The presence of nuclear γH2AX and 53BP1 protein foci was determined through the detection 
of the characteristic nuclear immunopositive after staining (Figure 19). Cells treated with 
compound 60 (10 µM), PhIP 46 (10 µM) and the positive control, hydrogen peroxide (200 µM) 
showed the presence of γH2AX and 53BP1 foci (Figure 19). Little to no γH2AX and 53BP1 
foci were detectable in untreated cells (Figure 19). Only cells with intact nuclei were analysed 
in this experiment shown by DAPI-stained nuclear DNA (blue) (Figure 19). Panels 
corresponding to γH2AX, 53BP1 and DAPI signals were merged to confirm the location of the 
foci within the nucleus of the cell. This can be seen by the presence of γH2AX (green) and 
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53BP1 (red) foci within a DAPI-stained nucleus (blue) (Figure 19). The merged panels shows 
the co-localisation of γH2AX and 53BP1 foci illustrating the close relationship of the two 
proteins (Figure 19).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19: DNA damage detection in HepG2 cells. Cells were incubated with compound 60 
(10 µM) or PhIP 46 (10 µM) for 30 minutes prior to immunofluorescence detection of γH2AX 
and 53BP1 foci indicative of DNA damage. Green: γH2AX protein staining (γH2AX foci); Red: 
53BP1 protein staining (53BP1 foci), Blue: DAPI staining of nuclear DNA and Merged: Co-
localisation of 53BP1 and γH2AX foci. Hydrogen peroxide (200 µM) was used as positive 
control. Panels show exemplary images of the 80 nuclei analysed in one independent 
experiment. Scale bar represents 10 µm. # denotes compound number. 
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In the presence of DNA damage such as strand breaks, a homologous recombination repair 
cascade is initiated leading to the formation of the γH2AX protein 339,340. The H2AX subunit 
of the histone protein located in the nucleus of the cell is phosphorylated to form γH2AX by 
the ataxia telangiectasia mutated (ATM) protein 341. This process recruits additional proteins 
such as 53BP1 to the site of damage 283,339. The co-localisation of γH2AX and 53BP1 foci 
allowed the evaluation of the fidelity and accuracy of the immunostaining method used in the 
proceeding experiments. When the cells were exposed to hydrogen peroxide (200 µM), γH2AX 
foci were detected. This was expected as hydrogen peroxide damages the DNA to form strand 
breaks 342,343. The presence of γH2AX foci in cells treated with PhIP 46 is consistent with 
previous reports that have reported similar findings 344 although PhIP 46  is a base modifier 
and does not form strand breaks 345. This however is supported by reports that γH2AX can be 
produced by other sources of DNA damage aside from DNA strand breaks and the γH2AX 
assay should only be used as an indirect means of monitoring of double strand breaks 346.  For 
these reasons, the presence of the γH2AX foci was used as an indicator of DNA damage, even 
though the nature of that damage is not known. Surprisingly, compound 60 (10 µM) caused 
γH2AX and 53BP1 foci indicative of DNA damage and genotoxicity. 
3.4.2.2  Genotoxic dose-response determination of compound 60 
To accurately determine the extent of genotoxicity of 2-(3-aminophenyl)oxazolopyridine 60 
and PhIP 46, a dose-response relationship was established using different concentrations (0 to 
100 µM) in HepG2 cells. The magnitude of genotoxicity was determined by manual scoring of 
γH2AX foci per nucleus expressed as foci/cell. Since the fidelity of the assay was verified using 
the positive control, hydrogen peroxide and co-localisation staining explained in the previous 
section, the quantification of genotoxicity for the following experiments focused only on the 
different concentrations of compound 60 and PhIP 46. 
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For compound 60, a significant increase in genotoxicity was already detected from 0.001 µM 
onwards (Figure 20A). However, the amount of genotoxicity remained constant between 0.01 
and 1 µM but then continued to increase from 10 µM onwards (Figure 20A). Similar to 
compound 60, PhIP 46, significantly increased genotoxicity from 0.001 µM onwards and 
progressively increased further up to 100 µM (Figure 20B). Generally, genotoxicity induced 
by PhIP 46 was higher compared to compound 60 at the concentrations tested (0.001 – 100 
µM). For example, at 10 and 100 µM, the amount of genotoxicity detected for compound 60 
were 46 and 59 foci/cell respectively (Figure 20A), while for PhIP 46, 71 and 96 foci/cell were 
detected respectively (Figure 20B).  
Compound 60 and PhIP 46 showed genotoxicity although the levels detected in PhIP 46 were 
higher than compound 60. For PhIP 46, the genotoxicity detected is consistent with previous 
studies conducted using the γH2AX assay 344,347. The higher genotoxicity potential as shown 
in this experiment is also consistent with the higher cytotoxicity of PhIP 46 in HepG2 cells 
(refer to section 3.4.1). Moreover, based on the results from the colony forming and γH2AX 
assays, it indicates that high levels of genotoxicity are required for observable cytotoxicity. 
This was consistent with previous reports for some carcinogens including PhIP 46 348,349. For 
example, 10 µM of compound 60 and 0.001 µM of PhIP 46, caused a significant decline in cell 
viability was detected in the colony forming assay (Figure 18, section 3.4.1). In parallel, the 
amount of genotoxicity at 10 µM of compound 60 and 0.001 µM of PhIP 46 (where a 
significant increase in genotoxicity was detected), were similar around 46 (Figure 20A) and 45 
(Figure 20B) foci/cell respectively. In other words, PhIP 46 was approximately 1 × 105 times 
more genotoxic than compound 60. Highly genotoxic agents, such as PhIP 46 can compromise 
the structure of the DNA, which in turn affects cell replication and growth, ultimately leading 
to cell death 350. These results also demonstrated that the γH2AX assay is a highly sensitive 
assay that detects DNA damage responses at very low drug concentrations. However, other 
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tests should be conducted to confirm the genotoxicity of compound 60 as it is common practice 
to include two or more tests for compound characterisation 238. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 20: Genotoxicity of compound 60 and PhIP 46. Cellular genotoxicity was assessed by 
manual scoring of γH2AX foci via immunofluorescence. Cells were treated with increasing 
concentrations (0 to 100 µM) of (A) compound 60 and (B) PhIP 46 for 30 minutes. Genotoxicity 
data represent the mean number foci per cell from 80 nuclei scored per condition from one 
independent experiment. Error bars represent SD and ** denotes P<0.01. # denotes 
compound number. 
A  
 
                               
 
 
 
B 
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3.4.2.3  Confirmatory genotoxicity of compound 60 
The comet assay was chosen to complement the γH2AX assay because of its high sensitivity 
to detect genotoxic activity 273 and it can be conducted in HepG2 cells. The comet assay is used 
for the detection of DNA damage resulting from single and double-strand breaks, which 
produce DNA fragments that migrate in an electric field to form a ‘comet’ 273,298. The extent of 
genotoxicity was quantified by determining the proportion of the comet tail length with regards 
to the total comet length consisting of the comet tail and head (nucleus) 273. A significant 
increase in genotoxicity was detected for 2-(3-aminophenyl)oxazolopyridine 60 and PhIP 46 
compared to untreated cells (Figure 21A). Generally, the amount of genotoxicity induced by 
PhIP 46 (10 µM) was higher than compound 60 (10 µM) (Figure 21). The positive control, 
hydrogen peroxide (200 µM) also showed a significant increase in genotoxicity compared to 
untreated cells (Figure 21A). The amount of genotoxicity was reflected by the increase in the 
proportion of the comet tail length with regards to the total comet length as viewed under the 
microscope (Figure 21B). 
Hydrogen peroxide was chosen as the positive control for this assay because it induces single 
and double-strand DNA breaks by generating detrimental ROS and free radicals 342,343. The 
severity of cellular DNA damage caused by hydrogen peroxide at a high concentration have 
led to the formation of DNA fragments reflected by the long comet tail (Figure 21Bii) as 
compared to untreated cells (Figure 21Bi). Since both compound 60 and PhIP 46 were tested 
at the same concentration, the results from the comet assay were consistent with the γH2AX 
assay (refer to section 3.4.2.2). The amount of genotoxicity detected for PhIP 46 was higher 
than compound 60, which is shown by the larger comet tail to total comet length ratio for PhIP 
46 (Figure 21Biii) as compared to compound 60 (Figure 21Biv).  Unlike hydrogen peroxide, 
which causes DNA strand breaks, PhIP 46 causes base modifications 107-109, which is 
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considered a less severe form of DNA damage 351. However, the repair of the modified base 
can induce the formation of DNA strand breaks as previously reviewed (refer to section 1.3.3). 
In fact, PhIP 46 was most genotoxic in human B-lymphoblastoid cells (MCL-5) using the 
comet assay among all the HCAs tested 352. Therefore, aside from DNA strand breaks, the 
comet assay is sensitive enough to detect structural modifications of the DNA such as DNA 
adducts caused by thymine dimers and oxidative damage, alkali-labile sites, DNA cross-links 
and incomplete base or nucleotide excision repairs 290,353.  
The results of the γH2AX and comet assays strongly indicate that compound 60 induces 
DNA damage at very low concentrations. Despite its genotoxicity, the levels induced by 
compound 60 were consistently lower than those induced by PhIP 46, which partly explains its 
lack of cytotoxicity. This could be attributed by the cells’ ability to respond to DNA damage 
caused by repairing it through various DNA repair pathways 235,354. Cellular response to the 
DNA damage induced by compound 60 can therefore be monitored to account for its lack of 
cytotoxicity. 
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Figure 21: Genotoxicity of compound 60. Genotoxicity in HepG2 cells was assessed by 
measurement of the tail length of the comet. (A) Cells were treated with compound 60 (10 
µM) and PhIP 46 (10 µM) for 30 minutes. Hydrogen peroxide (200 µM) was used as positive 
control. Genotoxicity data represent the mean percentage comet tail length per cell where 
50 nuclear comets were scored per condition for two independent experiments. Error bars 
represenet SD and ** denotes P<0.01. (B) Stained nuclear comets (green) of (i) untreated cells 
and cells treated with (ii) hydrogen peroxide (200 µM), (iii) PhIP 46 (10 µM) and (iv) compound 
60 (10 µM). Panel shows exemplary images of 50 nuclear comets analysed in one out of two 
independent experiments. Scale bar represents 10 µm. # denotes compound number. 
 
A  
 
                               
 
 
 
 
B 
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3.4.3  Cellular responses to DNA damage 
3.4.3.1  Repair kinetics of DNA damage induced by compound 60 
Although genotoxic, 2-(3-aminophenyl)oxazolopyridine, 60 lacked cytotoxicity, which was 
rather surprising given that genotoxic agents are generally also cytotoxic. To understand this, 
the repair kinetics of the DNA damage induced by compound 60 was determined. Moreover, 
the ability of the cell to repair the lesion caused by compound 60 may provide more information 
on the nature of the damage. To determine DNA damage repair kinetics, the amount of DNA 
damage after treatment cessation (with 30 minutes incubation) was determined at different time 
points of cell recovery over 48 hours. 
Generally, after 30 minutes of exposure the cells were able to repair DNA damage induced by 
compound 60 (10 µM) and the positive control, hydrogen peroxide (200 µM) (Figure 22). After 
24 hours, the number of γH2AX detected in the cells was significantly reduced for compound 
60 (solid triangle) and hydrogen peroxide (solid square) (Figure 22). After 48 hours, the 
number of γH2AX foci detected in the cells continued to decrease for hydrogen peroxide, 
whereas for compound 60, the amount of γH2AX foci detected in the cells remained constant 
(Figure 22). It is important to note that 24 and 48 hours after treatment cessation, the amount 
of residual genotoxicity detected for compound 60 (14-15 foci/cell) and hydrogen peroxide 
(12-19 foci/cell) was close to the baseline levels detected in untreated cells (cross) (7-9 
foci/cell) (Figure 22). 
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Figure 22: Repair kinetics of DNA damage induced by compound 60. Genotoxicity in HepG2 
cells was assessed by manual scoring of γH2AX foci. Cells were treated with compound 60 (10 
µM) for 30 minutes. Hydrogen peroxide (200 µM) was used as positive control. Cells were 
fixed and analysed at different time points: 0.5 hour after treatment and 8, 24 and 48 hours 
after treatment cessation. Genotoxicity data represent the mean number foci per cell where 
80 nuclei were scored per condition for one independent experiment. Error bars represent 
SD. Comparing the amount of DNA damage at 0.5 hour, a significant increase in DNA damage 
was observed for compound 60 and hydrogen peroxide when compared to untreated cells 
where P<0.01 (indicated by *). A significant decrease in DNA damage was observed for both 
compound 60 (indicated by **) and hydrogen peroxide (indicated by ***) after 24 or 48 hours 
when compared to levels detected at 0.5 hour where P< 0.01. # denotes compound number. 
 
The results from this experiment indicate that the DNA damage induced by compound 60 and 
hydrogen peroxide is efficiently repaired by the cells after 24 hours. This result is consistent 
with the ability of cells to effectively repair the DNA damage caused by hydrogen peroxide 
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after 24 hours, as previously demonstrated 316,342. This seems to be in contrast with the 
cytotoxicity data reported for hydrogen peroxide (200 µM), where it was shown to be potently 
cytotoxic and genotoxic to cells and therefore the induced DNA damage should not be repaired 
(refer to sections 3.4.1 and 3.4.2). Moreover, hydrogen peroxide causes mainly strand breaks, 
which are very detrimental to cells 342. However, it is important to note that the cellular 
exposure to hydrogen peroxide (200 µM) in the γH2AX assay was only for 30 minutes, while 
the cellular exposure in the colony forming assay was over 12 days. Chronic exposure to potent 
genotoxic agents such as hydrogen peroxide can lead to cell death. This is because the amount 
of DNA damage induced during long periods of exposure can exceed the rate of cellular DNA 
repair to maintain genomic integrity 355,356. Moreover, cells are able to repair the DNA damage 
induced upon chronic or acute exposure depending on the amount and the severity or type of 
DNA damage induced 356. It is also important to note that the concentration of hydrogen 
peroxide (200 µM) tested in these experiments was higher than compound 60 (10 µM). This 
further contributed to the severity of the DNA damage caused by hydrogen peroxide, which 
resulted in its cytotoxicity. This could also the contributing factor to the higher residual 
genotoxicity detected for hydrogen peroxide was higher than compound 60 after 24 and 48 
hours from treatment cessation. 
In cells, compound 60 (10 µM) was non-cytotoxic and hydrogen peroxide (200 µM) was 
cytotoxic upon chronic exposure while the DNA damage induced by either compounds was 
repaired effectively after 24 hours. The long term build-up of DNA damage induced by 
hydrogen peroxide cannot be repaired by cells leading to death, but in the case of compound 
60, can be tolerated by cells allowing them to proliferate for the reasons mentioned.  Therefore, 
the type DNA damage caused by compound 60 appears to be less detrimental and can be 
repaired efficiently within 24 hours. The identification of cellular DNA repair response to 
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the damage caused by compound 60 can therefore provide information on the type of damage 
induced and its mode of action. 
3.4.3.2  DNA repair response to compound 60 
Cell survival upon exposure to genotoxic compounds is a result of their ability to repair the 
DNA damage induced. Cells respond to DNA damage through various DNA repair 
mechanisms depending on the nature of the damage. In this experiment, cells were treated with 
2-(3-aminophenyl)oxazolopyridine 60 (10 µM) in the presence of inhibitors for enzymes and 
sites involved in different DNA repair pathways. The test inhibitors consisted of DPQ and 
KU55933, which inhibit PARP1 and ATM respectively, while MxHCl bind to AP sites. If the 
cellular DNA repair mechanism involved in the repair of damage induced by compound 60 is 
inhibited, the cell is unable to maintain genomic integrity resulting in detectable loss of cell 
viability. The concentrations which inhibit cell viability by 5% for DPQ, Ku55933 and MxHCl 
were pre-determined to be 1.5, 2.1 and 1.4 µM respectively (Appendix 1) and were used for 
this experiment. There was a significant decrease in cell viability detected for compound 60 + 
DPQ and compound 60 + Ku55933 when compared to treatment with DPQ and Ku55933 only 
respectively (Figure 23). Cell viability remained unchanged when cells were treated with either 
MxHCl or MxHCl + compound 60 (Figure 23). Similar trends were obtained when comparing 
between the combination of compound 60 + inhibitor and treatment with compound 60 only 
(Figure 23). The positive control, hydrogen peroxide (200 µM) was consistently cytotoxic 
(Figure 23). 
The decreased cell viability in the presence of compound 60 + DPQ indicate that cellular DNA 
repair could rely on the activity of PARP1.  PARP1 is known to play a vital role in the base 
excision repair (BER) of modified DNA bases and the repair of SSBs 357-359. However, PARP1 
is a multi-faceted enzyme and is also involved in other DNA repair pathways and chromatic 
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remodelling in the cell 360. For example, PARP1 initiates the onset of homologous 
recombination (HRC) 361 by preventing the inhibitory effects of the Ku protein, which shunts 
the DNA repair towards non-homologous end joining (NHEJ) 362. PARP1 has also been 
implicated in the “alternative” NHEJ pathway although its exact role is unclear at present 363. 
HRC and NHEJ pathways are involved in the repair of DSBs which reflects the non-exclusive 
role of PARP1 in repairing SSBs and base modification of DNA. 
 
  
 
 
 
 
 
 
 
 
 
Figure 23: Cellular repair of DNA damage induced by compound 60. Viability of cells was 
assessed by colony formation assay using HepG2 cells. Cells were treated with compound 60 
(10 µM) and/or sub-lethal concentrations of DNA repair inhibitors: DPQ (1.5 µM), KU55933 
(2.1 µM) or MxHCl (1.4 µM) as indicated for 12 days. Hydrogen peroxide (200 µM) was used 
as positive control. Viability data represents the mean of three independent experiments with 
three replicates per experiment and is expressed as % of untreated control. Error bars 
represent SD, ** and ns denote P<0.01 and P>0.05 respectively. # denotes compound 
number. 
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Similarly, the decreased cell viability in the presence of compound 60 + Ku55933 indicates 
that repair of compound 60-induced DNA damage involves the activity of ATM. KU55933, an 
inhibitor of ATM 364,365 is involved in the phosphorylation of H2AX histone for the recruitment 
of mediator proteins to the site of damage prior to repair by either NHEJ or HRC 365,366. ATM 
is also involved in the repair of DSBs arising from nucleotide excision repair (NER) 367, which 
also suggests the multi-faceted nature of the enzyme in DNA repair. Regardless of the nature 
of the DNA damage, the reliance on ATM during cellular DNA repair supports the detection 
of γH2AX foci upon exposure to compound 60 in the γH2AX assay reported earlier. However, 
there was also no way to exclude the possibility that γH2AX foci is also produced via ataxia 
telangiectasia mutated Rad3 related (ATR) 339 since an ATR-specific inhibitor was not used in 
this experiment.  
Unlike DPQ and Ku55933, MxHCl specifically binds to AP sites preventing the activity of AP 
site endonuclease (APE1), which prevents BER of AP sites 368. The lack of cellular sensitivity 
to compound 60 and MxHCl suggest that the repair of AP sites was not required by the cell. 
Therefore, this indicates that compound 60 does not produce AP sites. Apart from alkylated 
and oxidatively modified bases, AP sites represent a form of base modification 368. Therefore, 
base modification by compound 60 produces cannot be ruled out completely. 
In principle, it is convenient to determine the cellular responses by inhibiting specific DNA 
repair pathways. However, this is often difficult to achieve due to the multi-faceted nature of 
enzymes involved in several cellular DNA repair pathways. Nevertheless, the results of this 
experiment indicate that compound 60 induces DNA damage which is repaired by the cells to 
maintain viability. Although the DNA repair is mediated by an unknown mechanism, the 
results from this experiment suggest that it requires the presence of DNA repair and signalling 
enzymes, PARP1 and ATM. 
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3.5  Chapter summary 
It was hypothesised that 2-(3-aminophenyl)oxazolopyridine 60 is genotoxic due to the 
structural similarities with the known carcinogen, PhIP 46. Compound 60 was not dose-
dependently cytotoxic up to 100 µM indicating its lack of cytotoxicity. However, compound 
60 was found to be genotoxic and induced DNA damage at concentrations as low as 0.001 µM, 
although it was not as genotoxic as PhIP 46. The genotoxicity of compound 60 was surprising 
given that genotoxic agents are commonly associated with significant cytotoxicity. More 
intriguingly, PhIP 46 is also a genotoxic agent, which is not cytotoxic. This supports the close 
relationship of the oxazolopyridine compound 60 and PhIP 46.  Further work was conducted 
to understand the lack of cytotoxicity of compound 60. DNA damage caused by compound 60 
was effectively repaired after 24 hours. The DNA damage induced by compound 60 was also 
found to be not very severe, which partly explained its lack of cytotoxicity. Finally, the 
importance of repair of DNA damage caused by compound 60 was supported. The results 
implicate the activities of PARP1 and ATM in the protection against compound 60-induced 
genotoxicity. In summary, compound 60 induces DNA damage but is not cytotoxic. This 
is rather concerning as compounds of similar properties are difficult to detect during standard 
toxicology assessments. These genotoxic agents may cause gene mutations in normal cells 
through the accumulation of DNA damage and erroneous DNA repair. Subsequently, these 
mutation-inducing mechanisms have a high likelihood to initiate the development of 
malignancies. This is the basis of how PhIP 46, which shares similar genotoxic and cytotoxic 
properties with compound 60 as shown in the current study, causes the development of 
tumours. The discovery of significant genotoxicity of the oxazolopyridine compound 60 
provided insights into its mutagenic potential. Mutagenic evaluation of compound 60, which 
is an important end-point measure for carcinogenesis risk will be discussed in chapter 4.  
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Chapter 4: Mutagenicity of compound 60 
4.1 Overview and rationale 
In chapter 3, 2-(3-aminophenyl)oxazolopyridine 60 was found to be genotoxic at low 
concentrations but not cytotoxic and these characteristics were similar to the known 
carcinogen, PhIP 46. These results seem to support the hypothesis that compound 60 and PhIP 
46 may act by a similar mechanism due to their structural similarities, with the amino group 
being key to activity. Moreover, the ability of the cells to withstand exposure to compound 60 
was determined by their ability to efficiently repair the compound-induced DNA damage by a 
currently unknown mechanism.  
The DNA damaging ability of compound 60 coupled with virtually no cytotoxicity prompted 
the need to investigate the mutagenicity of this compound. DNA damage induced by 
xenobiotics can be repaired by cells but the consequence of erroneous repair will lead to 
mutations resulting that predispose to the formation of cancer. Cytotoxicity and genotoxicity 
assessments are very important in the drug development process and these liabilities often 
manifest in a straightforward manner. Mutagenicity however, requires a longer time to develop 
and is not easily detected during standard compound characterisation. Consequently, some 
drugs pass these screens but are later recalled due to long-term adverse effects that sometimes 
include elevated cancer risk 369.  Cancer was the second leading cause of death globally in 
2013, with a steady increase since the 1990s 370. Lifestyle changes such as smoking, sedentary 
behaviour, increased reliance on conventional medications 371,372 and the increased 
consumption of artificial additives in processed food 373,374 were thought to be contributing 
factors. Therefore, it is even more important to conduct mutagenic drug assessment, especially 
when the compound has DNA damaging properties, such as compound 60.  
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In this section, the “gold standard” Ames test was used to determine the mutagenicity of 
compound 60 and PhIP 46 in the Salmonella TA100 strain characterised by the rapid and 
sensitive nature of the assay 241,265. The carcinogen, PhIP 46 is not only mutagenic but also a 
pro-mutagen where bio-activation by liver enzymes is required for mutagenicity 92,97. For this 
reason, the Ames test was also conducted with S9 liver extract for the detection of pro-
mutagens. Due to time constraints, the Salmonella TA100 strain alone was tested as it is widely 
used to screen for mutagenic molecules. Moreover, the USFDA and ICH recommended that a 
positive result obtained from one strain in the Ames test is sufficient to report mutagenic 
activity 238. Compound 60 and PhIP 46 were also tested in the soft agar invasion (SAI) assay 
using HepG2 cells where the role of enzymatic bio-activation was also taken into consideration. 
The SAI assay is a good in vitro alternative to animal studies as it is more convenient to conduct 
and rapid. The SAI assay takes approximately 20-30 days to perform, allowing the 
development of malignant and invasive cell colonies. 
4.2  Aims 
The carcinogen, PhIP 46 was previously characterised as a pro-mutagen, which causes base 
modifications leading to DNA damage and mutations 112. The carcinogenic potential of PhIP 
46 has also been well documented in animal studies and clinical studies where it leads to the 
formation of tumours in colon, breast and prostate tissues 53-56.  
For these reasons, PhIP 46 was used as the reference compound for mutagenicity in the assays. 
The mutagenicity of oxazolopyridines has not been reported and this will be the first study 
dedicated to evaluate the mutagenic potential of this class of compounds. Therefore, the overall 
aim of this section was to evaluate the mutagenicity of the oxazolopyridine compound 60. The 
following experiments were performed to address the objectives: 
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 Determination of the mutagenic potential of compound 60 via the Ames test using the 
histidine-requiring (His-) Salmonella TA100 strain. 
 Determination of the cellular transformation potential of compound 60 in HepG2 cells 
via the SAI assay. 
4.3  Methodology 
The methods for chemical syntheses and analyses are described in section 2.1. The methods 
for the biological assays conducted in this chapter are described in sections 2.6.3 and 2.9.  
4.4  Results and discussion 
4.4.1  Mutagenic determination of compound 60 
DNA damage induced by 2-(3-aminophenyl)oxazolopyridine 60 was shown to be repaired 
rapidly within 24 hours in HepG2 cells. However erroneous repair of the DNA may lead to 
gene mutations 375,376 resulting in cellular phenotypic transformation, the periodical 
transformation of normal into malignant cells 377-379 is the most prominent example. Moreover, 
cancers have been associated with impaired homologous recombination, nucleotide excision 
and mismatch repair mechanisms 376. The most important end-point measure of a carcinogenic 
compound is mutagenic activity since it is the onset of cellular transformation. Therefore, the 
Ames test was conducted in His- Salmonella TA100 using S9 liver extract to evaluate the 
mutagenic potential of compound 60 reflected by the mutability of bacterial cells. Prokaryotic 
cells such as Salmonella sp. are unable to produce metabolic enzymes similar to those of 
mammalian liver tissue, particularly those involved in phases I and II of chemical metabolism 
in humans 258,263. Therefore, the use of S9 liver extract in the Ames test was employed to detect 
pro-mutagens, which require enzymatic bio-activation to become mutagenic 380.  
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In the absence of S9 liver extract, there was no significant change in bacterial cells mutability 
when treated with compound 60 and PhIP 46 as compared to untreated cells (Figure 24). 
However, in the presence of S9 liver extract, the bacterial cells mutability significantly 
increased for both compound 60 and PhIP 46 when compared to untreated cells with 127 and 
133 revertant colonies/ plate respectively (Figure 24). The levels of bacterial cells mutability 
induced by compound 60 and PhIP 46 were also similar (Figure 24). An increase in bacterial 
cells mutability in the presence of S9 liver extract but the lack of bacterial cells mutability in 
the absence of S9 liver extract, indicated that compound 60 and PhIP 46 are not mutagenic on 
their own but are pro-mutagens, which require enzymatic bio-activation to be mutagenic. Liver 
microsomes consist mainly of cytochrome P450 (CYP) enzymes, which are involved in 
chemical metabolism, particularly those belonging to the CYP 1 (isoforms: 1A1, 1A2 and 
1B1), CYP 2 (2A6, 2B6, 2C8, 2C9, 2C19 and 2E1) and CYP 3 (3A4 and 3A5) families 381. 
The results for PhIP 46 in this experiment were not surprising as it is a known pro-mutagen, 
which requires activation by liver enzymes 382,383. More specifically, the bio-activation of PhIP 
46 involves N-hydroxylation catalysed by CYP 1A1, 1A2 and 1B1 108,384,385 to form a 
hydroxylamine. The hydroxylamine of PhIP 46 then undergoes phase II esterification by 
microsomes such as acetyltransferases and sulphotransferases to form the arylnitrenium ion, 
which is highly reactive with DNA to form mutagenic adducts 386,387.  
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Figure 24: Enzymatic bio-activation of compound 60. Mutagenicity was assessed using the 
Ames test in His- S. thyphi TA100. Bacterial cells were treated with compound 60 (10 µM) with 
(white bars) or without (black bars) S9 liver extract as indicated and grown for three days. The 
known mutagen, PhIP 46 (10 µM) was used as positive control. Mutagenicity data represent 
the mean of three independent experiments with three replicates each and is expressed as 
number of His+ revertant colonies/plate. Error bars represent SD; ** and ns denote P<0.01 
and P≥ 0.05 respectively. # denotes compound number. 
 
The similar levels of bacterial cells mutability were detected for compound 60 and PhIP 46 in 
the presence of S9 liver extract (Figure 24) which supports the functional similarity of both 
compounds. The known enzymatic bio-activation of PhIP 46 revolves around the amino group 
leading to the formation of the mutagenic arylnitrenium ion 384. Compound 60 also contains an 
amino group which could be involved in the mutagenic activity of the compound. However, 
the specific reaction mechanism is so far unknown and beyond the scope of the Ames test. 
Therefore, compound 60 appears to be a pro-mutagen, which requires enzymatic bio-
activation to be mutagenic and the current study is the first to report this for an 
oxazolopyridine compound.  
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4.4.2  Oxidation dependency in the activation of compound 60 
In phase I chemical liver metabolism, oxidation is the most common reaction to take place 
388,389. For the carcinogen, PhIP 46, the compound’s amino group is oxidised which results in 
the reactive N-hydroxylamine 93. As shown by the Ames test, 2-(3-aminophenyl) 
oxazolopyridine 60 depends on enzymatic bio-activation to be mutagenic. Based on the PhIP 
46 model, it was therefore proposed that compound 60 may have been oxidised during 
enzymatic bio-activation. To determine the role of oxidation of compound 60 during enzymatic 
bio-activation, the anti-oxidant, Trolox was used in the following experiment. It is also 
important to note that HepG2 cells were used in this experiment so that cellular production of 
microsomes needed for enzymatic bio-activation were present in the test system. 
Consistent with previous experiments, the amount of genotoxicity detected for compound 60 
(10 µM) was significantly higher than in untreated cells (Figure 25). However, in the presence 
of compound 60 (10 µM) + Trolox (10 µM), the amount of genotoxicity detected decreased as 
compared to the amount detected for 10 µM compound 60 (Figure 25). In fact, the amount of 
genotoxicity detected for compound 60 (10 µM) + Trolox (10 µM) was similar to untreated 
cells (Figure 25). Trolox (10 µM) itself did not significantly affect genotoxicity with levels 
similar to untreated cells (Figure 25). The positive control, hydrogen peroxide (200 µM) was 
genotoxic compared to untreated cells. 
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Figure 25: Oxidation dependency of compound 60 in genotoxicity. Genotoxicity in HepG2 
cells was assessed by manual scoring of ɣH2AX foci via immunofluorescence. Cells were 
treated with compound 60 (10 µM) and/or Trolox (10 µM) as indicated for 30 minutes. 
Hydrogen peroxide (200 µM) was used as positive control. Genotoxicity data represent the 
mean number foci per cell from 80 nuclei scored per condition from one independent 
experiment. Error bars represent SD; ** and ns denote P<0.01 and P≥ 0.05 respectively. # 
denotes compound number. 
 
The treatment with Trolox in cells likely prevented the oxidation of compound 60. This was 
reflected by a decrease in the amount of genotoxicity detected for compound 60 + Trolox as 
compared to treatment with the genotoxic compound 60 alone (Figure 25). The presumed 
inhibition of oxidation of compound 60 by Trolox even reduced the amount of cellular 
genotoxicity to baseline levels similar to those detected in untreated cells (Figure 25). These 
results suggest the importance of oxidation in the bio-activation of compound 60, which 
supports the proposed mode of activation based on the PhIP 46 model. If the mode of activation 
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of compound 60 is similar to PhIP 46, then the amino group in compound 60 could be oxidised 
into the genotoxic and mutagenic N-hydroxylamine. Although this was a promising finding, it 
needed further investigation to accurately determine the mode of action for compound 60. 
Based on what is known so far, the pro-mutagenic compound 60 depends on oxidative bio-
activation for its genotoxic activity. However, the most important outcome of mutagenicity, 
which is cellular transformation should be tested. This can be performed using a suitable in 
vitro model consisting of mammalian cells, which is more representative of mammalian tissues 
and complements the Ames test. 
4.4.3  Cell transformation effect of compound 60  
The Ames test provided a rapid method in the detection of mutagenicity. The main limitation 
of this method is that it is conducted in prokaryotic cells and may not be representative of the 
situation in humans. Given that 2-(3-aminophenyl)oxazolopyridine 60 was genotoxic but not 
cytotoxic at 10 µM in HepG2 cells, the SAI assay was used to determine the cell transformation 
potential of compound 60 in the same cell type. The SAI assay is a suitable cell transformation 
model as it measures the phenotypic transformation of adherent cells. The anchorage-
dependent growth of HepG2 cells prevent its growth in an agar matrix, which can be reversed 
to allow normal cellular growth as a result of mutation events 300,301. Three-dimensional cell 
growth in agar is detected through colony formation. The use of HepG2 cells ensured the 
cellular production of microsomes required for bio-activation, which a mutagenic pre-requisite 
for compound 60. 
Although detection of mutagenicity is more important than genotoxicity since gene mutations 
can lead to cancer, the cell transformation detection is even more important as it is the end-
point measure of cancer. Although DNA mutations are very detrimental, not all mutations will 
lead to the development of cancer 390. Mutations affecting oncogenes and tumour suppressing 
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genes are more likely to cause cancer compared to other genes 390,391. Moreover, induced 
mutations can still be removed by cells via post-replicative DNA repair 182. Therefore, the 
severity of a carcinogen is best measured through its ability to cause cellular transformation. 
Generally, there was a significant increase in cellular transformation detected for compound 
60 and PhIP 46 as compared to untreated cells (Figure 26A). Looking at the distribution of 
colony volumes, larger colony populations were detected for compound 60 and PhIP 46 
compared to untreated cells (Figure 26A). This was shown by the images of colonies captured 
under the microscope (Figure 26B). Comparing the data obtained for compound 60 and PhIP 
46, the levels of cellular transformation induced were similar (Figure 26A). Cells were 
embedded in agar to prevent surface attachment to allow cell growth, resulting in anoikis cell 
death 300. Larger cell colonies as a result to treatment with compound 60 or PhIP 46, indicate 
phenotypic transformation as adherent cells do not normally grow in an anchorage independent 
manner. This was supported by the lower frequency and size of colonies detected in untreated 
cells (Figure 26A), where these cells lack the ability to proliferate as mentioned.  
Small colonies detected in untreated cells however could be caused by spontaneous mutations, 
which occur naturally at a low frequency 392, could be a result of heterogeneity of the cell 
population and simply represent a basal ability of some cells to grow in this matrix. The 
unstable nature of purine and pyrimidine DNA bases commonly cause the onset of spontaneous 
mutations 393. For example, point mutations can arise due to spontaneous deamination of 
cytosine into uracil in the DNA double helix 393,394. As a result, the resulting daughter cells 
contain a T-A base pair in place of a C-G base pair in the wild type 393. Furthermore, induced 
errors can be amplified during DNA replication, resulting in more DNA damage 395.  
Extrinsic factors such as cellular stressors caused by cellular injury in trypsinisation during cell 
maintenance and the exposure to small amounts of DMSO, such as in this experiment, may 
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induce the production of reactive oxygen species (ROS) 396,397, which is mutagenic in vitro 398 
and in vivo 399. In fact, spontaneous mutations are common in many eukaryotic cell lines 393,400-
402. However, spontaneous mutations occurring on non-oncogenes are unlikely to cause cancer 
and are typically repaired fast by the DNA repair machinery 403. The oxazolopyridine 
compound 60 was found to phenotypically transform cells into a more invasive phenotype 
and given the results obtained so far, strongly indicate that it is a mutagen. As shown in 
this experiment, the cellular transformation potential of compound 60 and the reference 
compound, PhIP 46 are again very similar. 
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Figure 26: Cell transformation effect of compound 60. Magnitude of phenotypic 
transformation arise from mutation was assessed using the soft agar invasion assay in HepG2 
cells. Cells were treated with compound 60 (10 µM) for 30 minutes and grown for 22 days. 
The known mutagen, PhIP 46 (10 µM) was used as positive control. Phenotypic 
transformation data represent the mean of three independent experiments with three 
replicates each and is expressed as colony volume. Individual values for each individual 
experiment was plotted (represented by purple, green and blue plots). Error bars represent 
SD; ** and ns denote P<0.01 and P≥ 0.05 respectively. Panel B shows exemplary images of 
colonies analysed in one of three independent experiments with appropriate scales. # 
denotes compound number. 
A  
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4.5  Chapter summary 
In this chapter, the oxazolopyridine 2-(3-aminophenyl)oxazolopyridine 60 was found to be 
mutagenic in the Ames test in the presence of S9 liver extract by increasing mutability of the 
bacterial cells. The genotoxicity of compound 60 was also dependent on oxidation, 
emphasizing the importance of cellular oxidative bio-activation. The severity of the mutations 
induced by compound 60 through the formation of invasive cells was shown in the SAI assay. 
In summary, the oxazolopyridine compound 60 is a pro-mutagen and phenotypically 
transforms cells into a more invasive phenotype upon chronic exposure. Although the 
mutagenic mode of action of compound 60 is still unknown, the cellular responses to compound 
60 reported so far are similar to the carcinogen, PhIP 46. These results seem to support the 
hypothesis where the amino group of compound 60 is putatively transformed into the reactive 
N-hydroxylamine, later into N-arylnitrenium ion based on the PhIP 46 model, which requires 
thorough examination. Therefore, determination of key functional groups which cause 
carcinogenicity and the mode of action of oxazolopyridine compounds will be discussed in 
chapter 5. 
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Chapter 5  Mutagenic mode of action of oxazolopyridine compounds 
5.1  Overview and rationale 
As shown in the previous chapters, 2-(3-aminophenyl)oxazolopyridine 60 was strongly 
indicated to be mutagenic and to phenotypically transform cells. Due to the similar cellular 
responses of compound 60 and PhIP 46, it was hypothesised that the amino group is the key to 
mutagenicity based on PhIP 46 as a model. However, the role of the amino group in compound 
60 is unknown and needed to be further investigated. A QSAR study was performed using 
analogues of compound 60 with deletion of key functional groups to determine the role of the 
amino group in cellular genotoxicity. The rationale of performing these experiments was to 
determine the factors that affect the mutagenicity of compound 60 including the amino group 
itself, other functional groups of the oxazolopyridine core and the electron density of the 
heterocyclic system. In contrast to the initial hypothesis, the amino group of compound 60 was 
not responsible for reactivity but due to the electron density of the heterocyclic system. This 
result and other factors related to the activation of the oxazolopyridine compounds in 
genotoxicity and mutagenicity will be discussed in this chapter.  
5.2  Aims 
In the current study, it was established that 2-(3-aminophenyl)oxazolopyridine 60 is genotoxic 
and mutagenic. However, the mode of action of action of compound 60 in causing these effects 
was unknown. Therefore, the general aim of this section was to determine the mutagenic mode 
of action of the oxazolopyridine compounds. The following experiments were performed to 
address the objectives: 
 QSAR determination of the role of the amino group in compound 60 in causing 
genotoxicity. 
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 QSAR determination of the role of molecular electron density in causing genotoxicity. 
 Understanding the oxidation of oxazolopyridine compounds through the isolation and 
characterisation of oxidative products. 
 Evaluating the genotoxicity and mutagenicity of these oxidative products. 
 QSAR determination on oxazolopyridine analogues to identify the reactive site on the 
molecule. 
 Monitoring the oxidative bio-activation of the oxazolopyridine molecule by S9 liver 
extract using UPLC-MS, in an attempt to identify the active species. Further 
investigation on this using computational chemistry was also performed. 
5.3  Methodology 
The methods for chemical syntheses and analyses are described in section 2.1. The methods 
for the biological assays conducted in this chapter are described in sections 2.6.3, 2.6.5 and 2.9. 
The methods for the UPLC-MS detection of the oxazolopyridine metabolites are described in 
section 2.10. The methods for computational chemistry are described in section 2.11. 
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5.4  Results and discussion 
5.4.1  Structural-activity relationship of compound 60 
As previously mentioned, the amino group was hypothesised to be the key to the genotoxic and 
mutagenic mode of action of 2-(3-aminophenyl)oxazolopyridine 60 given its structural 
similarity to the known carcinogen, PhIP 46.  In PhIP 46, the amino group is converted into the 
highly electrophilic arylnitrenium ions, which preferentially bind to guanine forming the dG-
C8 PhIP-DNA adduct 56 107-112. Consequently, the amino group of compound 60 was suspected 
to undergo the same fate, which contributed to its genotoxicity and mutagenicity.  
Analogues with deletions or substitution of key functional groups compared to compound 60 
were synthesised and tested in cells to not only determine the role of the amino group but also 
other groups present in the molecule. In these compounds, the amino group was removed to 
give the 2-phenyloxazolopyridine 61 to evaluate the role of the amino group. The 2-phenyl 
group was then substituted for a 2-cyclohexyl group to give the 2-cyclohexyloxazolopyridine 
62 to test if the planar structure of the aryl group was required for activity. Furthermore, the 
corresponding benzoxazole analogues of compounds 61 and 62 were synthesised to give 2-
phenylbenzoxazole 63 and 2-cyclohexylbenzoxazole 64 respectively. In the benzoxazoles, the 
nitrogen at the pyridine ring of the oxazolopyridine core was substituted with a carbon to 
evaluate the role of the pyridine nitrogen on activity. 
 
 
               60                                                             61                                                           62 
 
                                             63                                                               64 
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Figure 27: Structural-activity relationship of compound 60 and analogues in genotoxicity. 
Genotoxicity in HepG2 cells was assessed by manual scoring of γH2AX foci via 
immunofluorescence. Cells were treated with analogues of 60 (compounds 61, 62, 63 or 64) 
(10 µM) for 30 minutes. Genotoxicity data represent the mean number foci per cell from 80 
nuclei scored per condition from one independent experiment. Error bars represent SD. # 
denotes compound number. 
 
Compound 60 (10 µM) and the positive control hydrogen peroxide (200 µM) were genotoxic 
consistent with previous experiments (Figure 27). Subjecting these compounds (10 µM) to the 
γH2AX assay, different genotoxic responses were observed (Figure 27). The lack of 
genotoxicity detected for the 2-phenyloxazolopyridine 61 (Figure 27), indicates that the amino 
group was required for activity. In fact, when the amino group was removed from 2-(3-
aminophenyl)oxazolopyridine 60 to give the 2-phenyloxazolopyridine 61, the amount of 
genotoxicity detected was close to baseline levels detected in untreated cells (Figure 27). Aside 
from the role of the amino group, it was suspected that the planar nature of the aryl group of 
compound 60 may contribute to its genotoxic effect. Many aromatic and planar molecules are 
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DNA intercalating agents that can insert between DNA base pairs, which inhibit the activity of 
DNA polymerase and result in DNA damage 404-406. DNA intercalation is made possible as 
these drug molecules mimic DNA bases, which also happen to be aromatic and planar 404,407. 
Therefore, the substitution of the 2-phenyl with the non-planar 2-cycloheyxl group to give 2-
cyclohexyloxazolopyridine 62 reduced the molecular planarity. The level of genotoxicity 
detected for 2-cyclohexyloxazolopyridine 62, was only marginally higher than the 2-phenyl 
derivative 61 and the levels of genotoxicity for both compounds were not significantly different 
(Figure 27). This indicates that molecular planarity does not influence the genotoxicity of the 
oxazolopyridine compound. 
In contrast, 2-phenylbenzoxazole 63 and 2-cyclohexylbenzoxazole 64 were genotoxic, 
although both compounds lacked the amino group. This was an interesting turning point of this 
study as it indicates that the amino group is not necessarily required for activity. In fact, the 
removal of the amino group and the substitution of the pyridine nitrogen of the oxazolopyridine 
core increased the genotoxicity in 2-phenylbenzoxazole 63 compared to the non-genotoxic 2-
phenyloxazolopyridine 61 (Figure 27). This was also consistent for the 2-cyclohexyl 
derivatives, where an increase in genotoxicity was detected for 2-cyclohexylbenzoxazole 64, 
compared to the non-genotoxic 2-cyclohexyloxazolopyridine 62. These results indicate that 
the molecular core influences genotoxicity and the nitrogen atom on the oxazole ring of 
the molecular core may be the key reactive site. This is consistent with reports of cellular 
genotoxicity of benzoxazole compounds 302-304. Furthermore, the oxidation of the nitrogen 
atom on heterocyclic molecules was recently reported to be genotoxic and mutagenic 408.  
This experiment indicates that the amino group may not be required for the genotoxicity 
reported for compound 60. If the amino group of compound 60 is not oxidized directly into the 
proposed N-hydroxylamine as potentially indicated by the genotoxicity of the benzoxazoles, 
the amino group may play a role in activating the molecular scaffold by acting as an electron 
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donor. The increase in molecular electron density may be linked to its activity. Subsequently, 
it was hypothesised that the electron withdrawing ability of the pyridine ring of the 
oxazolopyridine is related to the reduced genotoxicity of 2-phenyloxazolopyridine 61 
compared to the 2-phenylbenzoxazole 63. The role of the amino group in donating electron 
to the oxazole ring of the oxazolopyridine core can be investigated. This can be performed by 
synthesizing a range of oxazolopyridine compounds with different electron donor groups and 
testing them for genotoxic activities. If the genotoxicity is directly related to the electron 
density of the heterocyclic system, then a Hammett plot of genotoxicity versus electron density 
should show a correlation. 
5.4.2  Hammett plot for oxazolopyridine compounds 
The Hammett equation developed by Louis Hammett in 1937 409 described the linear-free 
energy relationship between chemical reactivity and the equilibrium constants of reactions, 
which involved benzoic acid derivatives of different substituents 410. Substituents with differing 
electron donating and withdrawing abilities on the molecule (either ortho, para or meta) have 
different constant values calculated using the Hammett equation 409,411. Hammett constant 
values are represented by the rho symbol, σ, where the more negative the constant value, the 
higher the electron donating ability 411. The linear relationship between the electron donating 
ability and molecular reactivity obeys the Hammett plot 410. In principle, the higher the electron 
donating ability of the substituent, the higher the electron density of the molecule, which is 
reflected in its increased reactivity 412. 
Following this principle, a range of 2-aryloxazolopyridine 40 analogues with substituents 
consisting of various electron donating groups at the phenyl ring were synthesised and tested 
for genotoxic activity in cells via the γH2AX assay (Table 10). The linearity of the relationship 
between the electron donating ability of the substituent at the phenyl ring and cellular 
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genotoxicity was tested in this experiment to prove or refute the hypothesis that the increased 
electron density into the oxazole ring of the oxazolopyridine molecule results in increased 
genotoxicity. 
 
Table 10: The Hammett constant, σ values of substituents, R as previously described 411 for 
the 2-aryloxazolopyridine 40 analogues tested in this experiment. 
 
 
 
40 
Analogue ID  Hammett constant, σ R 
40e 
65 
61 
66 
60 
40a 
40b 
+0.12 
+0.07 
0 
-0.15 
-0.16 
-0.27 
-0.66 
3-OCH3 
3-NHCOCH3 
H 
3-N(CH3)2 
3-NH2 
4-OCH3 
4-NH2 
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Figure 28: Hammett plot of 2-aryloxazolopyridine analogues in genotoxicity. Genotoxicity in 
HepG2 cells was assessed by manual scoring of γH2AX foci via immunofluorescence. Cells 
were treated with 2-aryloxazolopyridine 40 analogues with different R groups (in brackets) of 
different Hammett constant values, σ for 30 minutes. Genotoxicity data represent the mean 
number foci per cell from 80 nuclei scored per condition from one independent experiment. 
Error bars represent SD. 
 
A linear correlation (with R2 = 0.7428) between the level of cellular genotoxicity and Hammett 
constant was observed (Figure 28). The baseline level of genotoxicity was represented by the 
3-H derivative of the 2-aryloxazolopyridine 61 with the σ value of 0 with 10 foci/cell (Figure 
28).  A high electron donating ability of substituents such as in the 3-N(CH3)2 (66), 3-NH2 (60), 
4-OCH3 (40a) and 4-NH2 (40b) derivatives of 2-aryloxazolopyridine 40 (σ values of -0.15, -
0.16, -0.27 and -0.66 respectively), resulted in genotoxicity levels above the baseline value 
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(Figure 28). Moreover, the regression line shows that a more negative the σ value of the 
substituent resulted in increased genotoxicity of the 2-aryloxazolopyridine analogues 40 
(Figure 28). This indicates that increasing electron donating ability of the 2-
aryloxaozlopyridine 40 substituents increased electron density of the oxazolopyridine 
heterocyclic core, which resulted in higher genotoxicity. The error bars for this assay are large 
due to the different amounts of DNA in the nucleus at different developmental stages of the 
cell cycle during cell growth 413,414, which is one of the main limitations of the γH2AX assay. 
Therefore, the amount of DNA exposed to the test compounds in the cells differs depending 
on the developmental stages of the cells when the experiment was conducted. The data for 
compound 60 however, is consistent with previous experiments and indicates the reliability of 
the results obtained from this experiment (refer to chapter 3). 
Given the results obtained from the structural activity relationship and the current Hammett 
plot experiments, it was proposed that the attached substituent contributes to the electron 
density of the oxazolopyridine core to modulate its reactivity. Consequently, the 
oxazolopyridine core itself must be undergoing oxidation, with the nitrogen atom of the 
oxazole ring of the molecular core the likely key reactive site for the genotoxic and mutagenic 
activities. The 2-aryloxazolopyridine analogues 40 could be oxidised either by S9 liver extract 
or molecular oxidants to isolate and characterise the resulting oxidation products. This will 
allow the determination of the reactive site on the oxazolopyridine core as proposed. 
5.4.3  Oxidation of 2-aryloxazolopyridine analogues  
The 4-OCH3 (40a), H (61) and 3-NHCOCH3 (65) derivatives of 2-aryloxazolopyridine 40 were 
selected and reacted with a molecular oxidant. This was in an attempt to isolate the species 
responsible for the genotoxic and mutagenic activities of oxazolopyridines. The 4-OCH3 (40a), 
H (61) and 3-NHCOCH3 (65) derivatives of 2-aryloxazolopyridine 40 with σ values of -0.66, 
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0 and +0.07 respectively were chosen based on their different electron donating abilities. 
Therefore, the electron donating ability of the substituent to the oxazolopyridine core during 
oxidation was taken into account. Oxidation reactions of the 2-aryloxazolopyridine analogues 
40a, 61 and 65 were carried out using the oxidising agent, meta-chloroperbenzoic (mCPBA) 
and monitored via TLC every 30 minutes. The reactions were stopped when a new spot 
appeared on the TLC indicative of a new product formed. The product of the reaction was 
purified by flash chromatography and analysed.  
It was proposed that the oxazole nitrogen of the oxazolopyridine core was the reactive site 
based on the genotoxicity of both oxazolopyridines and benzoxazoles as previously shown 
(Figure 27, section 5.4.1). Mass spectral analyses of the new product showed an addition of an 
oxygen atom (increase in molecular mass of 16 m/z). However, 1H NMR of the new product 
showed the same number of CH resonances indicating that no oxidation of a CH bond occurred 
but potentially one of the nitrogen atoms had formed an N-oxide. Similarly, the oxidation of 
the 2-aryloxazolopyridine analogues 61 and 65 that showed limited genotoxic activities earlier 
(Figure 28, section 5.4.2) also resulted in the formation of N-oxides (Figure 29). Thankfully, 
the oxidation product, 68 was crystallised and the formation of an N-oxide was supported using 
single crystal X-ray crystallography (Figure 30). Surprisingly, the N-oxide was on the pyridine 
ring instead of the oxazole ring of the oxazolopyridine core as hypothesised (Figure 30).  
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Figure 29: Oxidation of 2-aryloxazolopyridine analogues 40. The oxidation of 2-
aryloxazolopyridine analogues 40a, 61 and 65 using mCPBA resulting in the formation of 2-
aryloxazolopyridine N-oxides 67, 68 and 69 respectively.  
 
 
 
 
 
 
 
Figure 30: The crystal structure of the 2-aryloxazolopyridine N-oxide 68 through single crystal 
X-ray crystallography. The N-oxide was found to be formed on the pyridine ring of the 
oxazolopyridine core as indicated (Atoms: C (grey), H (white), N (purple) and O (red)). 
Ellipsoids are shown at 50% probability. 
 
The oxidation of oxazolopyridine compounds produced N-oxides, which can potentially 
be genotoxic and mutagenic. This was based on the oxidative bio-activation requirement of 
                                    I                                                                                           II 
[O] 
mCPBA 
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oxazolopyridine compounds to exert these effects. Since the oxazolopyridine N-oxides were 
successfully isolated, their genotoxic and mutagenic activities could therefore be evaluated. 
5.4.4  Genotoxic and mutagenic determinations of oxazolopyridine N-oxides 
N-Oxides of heterocycles have been reported to be highly mutagenic in the Ames test 408. 
Therefore, the following experiment was performed to evaluate the genotoxicity of the 
oxazolopyridine-N-oxide. In this experiment, the 2-phenyloxazolopyridine 61 and the 
corresponding 2-phenyloxazolopyridine-N-oxide 68 were tested. Compound 61 was not 
genotoxic with 10 foci/cell, which was also the baseline value for genotoxicity in the Hammett 
plot previously shown (Figure 28, section 5.4.2). Therefore, the effect of N-oxidation of the 
non-genotoxic 2-phenyloxazolopyridine 61 was determined by comparing the amount of 
genotoxicity induced with its corresponding N-oxide 68 in the γH2AX assay. 
There was a significant increase in the amount of genotoxicity detected for the 2-
phenyloxazolopyridine-N-oxide 68 (10 µM) when compared to untreated cells but even more 
importantly, when compared to 2-phenyloxazolopyridine 61 (10 µM) (Figure 31).  The 2-(3-
aminophenyl)oxazolopyridine 60 (10 µM) and the positive control, hydrogen peroxide (200 
µM) were genotoxic consistent with previous experiments (Figure 31). The increased 
genotoxicity of 2-phenyloxazolopyridine-N-oxide 68 compared to 2-phenyloxazolopyridine 61 
supports the hypothesis that the oxidation of the oxazolopyridine core is required for 
genotoxicity. Furthermore, this is in agreement with the hypothesis that it is the 
oxazolopyridine core itself, which is responsible for genotoxicity.  
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Figure 31: The role of oxazolopyridine N-oxidation in genotoxicity. Genotoxicity in HepG2 
cells was assessed by manual scoring of γH2AX foci via immunofluorescence. Cells were 
treated with compounds 60, 61 or 68 (10 µM) for 30 minutes. Hydrogen peroxide (200 µM) 
was used as positive control. Genotoxicity data represent the mean number foci per cell from 
80 nuclei scored per condition from one independent experiment. Error bars represent SD; 
** and ns denote P<0.01 and P≥ 0.05 respectively. # denotes compound number. 
 
Based on the results obtained from the γH2AX assay, the 2-aryloxazolopyridine analogues 40a, 
61, 65 and corresponding 2-aryloxazolopyridine-N-oxides 67, 68, 69 were subsequently tested 
in the Ames test. In this experiment, the combined roles of electron density, enzymatic bio-
activation and N-oxidation of the oxazolopyridine molecule in mutagenicity were evaluated. 
Based on the genotoxicity of the oxazolopyridine-N-oxide 68 (Figure 31), it was proposed that 
the oxazolopyridine-N-oxide is the active form of the molecule, which could potentially react 
with DNA causing mutations. In theory, if the oxazolopyridine-N-oxide is the final activated 
form of the pro-mutagen, mutagenic activity of the N-oxides will be detected in the absence of 
S9 liver extract. 
Generally, in the absence of S9 liver extract, no significant changes in the bacterial cells 
mutability detected for any of  the 2-aryloxazolopyridine analogues 65, 61 or 40a (in ascending 
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σ values of the R groups) and their corresponding 2-aryloxazolopyridine-N-oxides 69, 68 or 67 
compared to untreated cells (Figure 32). In the presence of S9 liver extract, there was a 
significant increase in the level of bacterial cells mutability when treated with 2-(4-
methoxyphenyl)oxazolopyridine 40a, 2-(4-methoxyphenyl)oxazolopyridine-N-oxide 67 and 
2-phenyloxazolopyridine-N-oxide 68 compared to untreated cells (Figure 32). The presence of 
S9 liver extract led to a significant increase in bacterial cells mutability detected for 2-(4-
methoxyphenyl)oxazolopyridine-N-oxide 67 when compared to 2-(4-methoxyphenyl) 
oxazolopyridine 40a (Figure 32). 
The 2-aryloxazolopyridine analogues 65, 61 and 40a did not induce mutability in bacterial cells 
in the absence of  S9 liver extract, consistent with the lack of mutagenicity detected for 2-(3-
aminophenyl)oxazolopyridine 60 under similar conditions (refer to section 4.4.1). This 
strongly indicates that the oxazolopyridine compounds are pro-mutagens, which require 
enzymatic bio-activation for activity. In agreement to this, the 2-aryloxazolopyridine analogue 
40a was mutagenic in the presence of S9 liver extract. The lack of mutagenic activities for the 
other 2-aryloxazolopyridine analogues 65 and 61 under similar conditions could be due to the 
lower electron donating ability of the substituents in these analogues as compared to 40a.  
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Figure 32: Mutagenicity of oxazolopyridine-N-oxides. Mutagenicity was assessed using the 
Ames test in His- S. thyphi TA100. Bacterial cells were treated with 2-aryloxazolopyridines 
analogues (65, 61 or 40a) and corresponding N-oxides (69, 68 or 67) (10 µM) with (white bars) 
or without (black bars) S9 liver extract as indicated and grown for three days. Mutagenicity 
data represent the mean of three independent experiments with three replicates each and is 
expressed as number of His+ revertant colonies/plate. Error bars represent SD; *, ** and ns 
denote P<0.05, P<0.01 and P≥ 0.05 respectively. # denotes compound number. 
 
Surprisingly, the 2-aryloxazolopyridine-N-oxides 69, 68 and 67 were not mutagenic in the 
absence of S9 liver extract. Furthermore, only the 2-aryloxazolopyridine-N-oxides 68 and 67 
were mutagenic in the presence of S9 liver extract. Similarly, the lack of mutagenic activity for 
the 2-aryloxazolopyridine-N-oxide 69 could be attributed by the lower reactivity as a result of 
lower electron density as previously described. In contrast to the hypothesis, the 
oxazolopyridine-N-oxides are not mutagenic on their own and need to be further bio-activated. 
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The oxazolopyridine-N-oxide could potentially be an intermediate during the enzymatic bio-
activation of oxazolopyridines. This was evident based on the further increase in mutagenicity 
transitioning from the 2-aryloxazolopyridine analogue 40a to its corresponding N-oxide, 67. 
This also highlights that other sites than the N-oxide on the pyridine ring of the 
oxazolopyridine core may be involved in its mutagenicity and genotoxicity. For instance, 
the oxazole nitrogen of the oxazolopyridine core could be oxidised and become the reactive 
site for mutagenicity.  
5.4.5  Mechanism of oxidative bio-activation in oxazolopyridines 
The reactive role of the oxazole nitrogen of the oxazolopyridine core would be consistent with 
the mutagenic activity of benzoxazoles 302-304. It was therefore hypothesised that the first 
oxidation of the pyridine nitrogen at the core of the 2-aryloxazolopyridine molecule 40 
increases the electron density of the pyridine ring, which then donates electron density to the 
oxazole ring (Figure 33). This is a well-known method to increase the electron density of 
pyridines to increase reactivity for chemical transformations 415. The pyridine-N-oxide is 
isoelectronic with a phenyl ring. Therefore, the oxazolopyridine-N-oxide 73 is isoelectronic to 
the benzoxazole molecule 74 (Figure 33). A second oxidation event may occur at the oxazole 
nitrogen of the oxazolopyridine-N-oxide 73 to give compound 75, similar to the formation of 
mutagenic heterocyclic N-oxides 408.  
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Figure 33: Proposed oxidative bio-activation of oxazolopyridine core. The oxidation of the 
oxazolopyridine molecule 40 results in the formation of an oxazolopyridine-N-oxide 73. The 
pyridine ring of the oxazolopyridine-N-oxide 73 is rich in electrons (blue box) and is 
isoelectronic with a benzoxazole molecule 74. The electron rich pyridine ring of the 
oxazolopyridine-N-oxide 73 then donates electrons to the oxazole nitrogen, increasing the 
electron density of the oxazole ring of compound 75 (red box) and its reactivity. 
 
In the current experiment, the 2-(4-methoxyphenyl)oxazolopyridine 40a was chosen as the 
reference point since it was shown to be mutagenic along with its corresponding N-oxide 67 
(Figure 32, section 5.4.4). The pyridine nitrogen of 40a was substituted with carbon to give 
the 2-(4-methoxyphenyl)benzoxazole 70. To support the hypothesis, the benzoxazole 70 
should show similar activity to the oxazolopyridine-N-oxide 67.  
 
 
 
 
electrons electrons 
                                   40a                                                                                70   
[O] [O] 
Isoelectronic 
            40                                                                      73                                                                75 
        74  
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The role of the oxazole nitrogen on the benzoxazole can be tested by preventing its N-oxidation. 
This was performed by substituting the oxygen in compound 70 with sulphur to give 2-(4-
methoxyphenyl)benzothiazole 71. The presence of sulphur in place of oxygen shunts the 
oxidation of the oxazole nitrogen in the electron rich oxazole, where the sulphur atom 
undergoes oxidation instead. 
 
 
 
Upon the oxidation of the oxazole nitrogen, it was proposed that the oxazolopyridine molecule 
may undergo further oxidative cleavage to give the 2-oxooxazolopyridine 72 or hydrolysis to 
give the hydroxylamine 76 (Figure 34). For these reasons, the syntheses of 72 and 76 were 
attempted as a proof of concept. Out of the two, the 2-oxooxazolopyridine, 72 was successfully 
synthesised and tested in the current experiment. The synthesis of the hydroxylamine 76 was 
not successful although hydroxylamines are known to be genotoxic and mutagenic 416-418. This 
latter transformation has not been proposed for any oxazolopyridine or benzoxazole within the 
literature. 
 
 
 
 
 
 
71 
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Figure 34: Proposed events following the N-oxidations of nitrogen atoms of the 
oxazolopyridine molecule.  Compound 75 may undergo oxidative cleavage to give the 2-
oxooxazolopyridine 72 or hydrolysis to give the hydroxylamine 76. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 35: Determining mode of action of oxazolopyridines through genotoxicity. 
Genotoxicity in HepG2 cells was assessed by manual scoring of γH2AX foci via 
immunofluorescence. Cells were treated with compounds 40a, 70, 71 or 72 (10 µM) for 30 
minutes. Hydrogen peroxide (200 µM) was used as positive control. Data represents the mean 
number foci per cell where 80 nuclei were scored per condition. Genotoxicity data represent 
the mean number foci per cell from 80 nuclei scored per condition from one independent 
experiment. Error bars represent SD; ** and ns denote P<0.01 and P≥ 0.05 respectively. # 
denotes compound number. 
 
[O] H2O 
             72                                                               75                                                                    76 
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Generally, a significant increase in genotoxicity was detected for 2-(4-methoxyphenyl) 
benzoxazole 70 (10 µM) and 2-oxooxazolopyridine 72 (10 µM) compared to untreated cells 
(Figure 35). The 2-(4-methoxyphenyl)benzothiazole 71 however lacked genotoxicity and was 
similar to the baseline value detected in untreated cells (Figure 35). The 2-(4-
methoxyphenyl)oxazolopyridine 40a (10 µM) and the positive control, hydrogen peroxide (200 
µM) were genotoxic consistent with previous experiments (Figure 35). The amount of 
genotoxicity detected for 2-(4-methoxyphenyl)benzoxazole 70 (10 µM) was higher than 2-(4-
methoxyphenyl)oxazolopyridine 40a (10 µM). Finally, the genotoxicity detected for 2-(4-
methoxyphenyl)benzothiazazole 71 (10 µM) was lower than 2-(4-methoxyphenyl) 
benzoxazole, 70 (10 µM). 
The 2-(4-methoxyphenyl)benzoxazole 70 was found to be genotoxic, consistent with the 
genotoxicity reported for benzoxazoles 302-304. Moreover, this supported the hypothesis that the 
oxazole nitrogen is the reactive site for genotoxicity. The higher genotoxicity detected for 2-
(4-methoxyphenyl)benzoxazole 70 compared to 2-(4-methoxyphenyl)oxazolopyridine 40a is 
likely due to compound 70 being “pre-activated” since the benzoxazole is isoelectronic to the 
oxazolopyridine-N-oxide. Therefore, during cellular bio-activation, the conversion of 2-(4-
methoxyphenyl)benzoxazole 70 into the active form will be quicker than 2-(4-methoxyphenyl) 
oxazolopyridine 40a, resulting in higher genotoxicity induced. 
The reactivity of the oxazole nitrogen of the oxazolopyridine core was further supported by the 
lack of genotoxicity detected for the 2-(4-methoxyphenyl)benzothiazole 71. Upon substitution 
of the oxygen in the oxazole ring in compound 70 to sulphur in compound 71, the amount of 
genotoxicity detected was reduced to baseline value reported for untreated cells (Figure 35). 
Therefore, N-oxidation of the oxazole nitrogen was needed for activity and the substitution of 
the oxygen with sulphur prevented this. This was also consistent with the lack of genotoxicity 
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419 and mutagenicity 420,421, even in the presence of S9 liver extract 421 reported for 
benzothiazoles.  
The 2-oxooxazolopyridine 72 was found to be genotoxic but the amount of genotoxicity 
induced was similar to 2-(4-methoxyphenyl)oxazolopyridine 40a, where no further increase in 
genotoxicity was observed. This indicates that 2-(4-methoxyphenyl)oxazolopyridine 40a is not 
converted to 2-oxooxazolopyridine 72 as genotoxicity would be expected to be much higher. 
Although the hydroxylamine 76 cannot be tested, information about its genotoxicity would 
have added value to this study. These compounds were also tested in the Ames test (Figure 36) 
to determine if the mutagenic and genotoxic activities of these compounds were consistent. 
 
 
 
 
 
 
 
 
 
Figure 36: Determining mode of action of oxazolopyridines through mutagenicity. 
Mutagenicity was assessed using the Ames test in His- S. thyphi TA100. Bacterial cells were 
treated with compounds 40a, 70, 71 or 72 (10 µM) with (white bars) or without (black bars) 
S9 liver extract as indicated and grown for three days. Mutagenicity data represent the mean 
of three independent experiments with three replicates each and is expressed as number of 
His+ revertant colonies/plate. Error bars represent SD; *, ** and ns denote P<0.05, P<0.01 and 
P≥ 0.05 respectively. # denotes compound number. 
 139 
 
In the presence of S9 liver extract, the level of bacterial cells mutability detected for 2-(4-
methoxyphenyl)benzoxazole 70 (10 µM) and 2-oxooxazolopyridine 72 (10 µM) were higher 
than in untreated cells (Figure 36). The 2-(4-methoxyphenyl)benzothiazole 71 did not induce 
mutability in bacterial cells, similar to untreated cells (Figure 36). The 2-(4-
methoxyphenyl)oxazolopyridine 40a (10 µM) was consistently mutagenic in the presence of 
the liver S9 extract as reported previously (Figure 36). In the absence of S9 liver extract, none 
of the tested compounds showed mutagenic activity reflected by the lack of bacterial cells 
mutability (Figure 36).  
The results obtained from the Ames test (Figure 36) were consistent with the γH2AX assay 
(Figure 35) especially for compounds 71 and 72. Surprisingly, the level of mutagenicity 
detected for 2-(4-methoxyphenyl)benzoxazole 70 was not the highest in the Ames test (Figure 
35) given that it was most genotoxic among all the tested compounds in the γH2AX assay 
(Figure 35). The highly genotoxic nature of the compound 70 may have led to toxicity issues. 
Moreover, the anti-microbial activity of compound 70 was not determined in the current study. 
In addition, the test concentration for all the compounds was standardised at 10 µM, which can 
be too high for the test organism in the Ames test. This limitation can be addressed by 
establishing a dose-response curve in the test organism, which was not conducted in the current 
study due to time constraints. More importantly, the high mutagenic activity detected for 2-
oxooxazolopyridine 72 only in the presence of the S9 extract (Figure 34) further supported that 
it is not the active form of the oxazolopyridine molecule, as further enzymatic bio-activation 
was still required for activity. 
Despite the proposed events following N-oxidation of the oxazolopyridine (Figures 33 and 34), 
other active species can also be formed, which require further investigation. The active species 
are often unstable and difficult to chemically synthesise and isolate 422. During cellular bio-
activation, the formation of these metabolites is difficult to monitor due to low yields and the 
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complex cellular matrices makes the isolation of these metabolites extremely challenging 
423,424. The enzymatic bio-activation of the oxazolopyridine compound however can be 
monitored using a highly sensitive method such as LC-MS. 
5.4.6  Monitoring the oxidative bio-activation of oxazolopyridines 
In summary, the pyridine nitrogen of the oxazolopyridine molecule can be oxidised forming 
an N-oxide. The oxazolopyridine-N-oxide is then converted into the active species where the 
oxazole nitrogen was proposed to be the reactive site. The experiments so far correlated well 
with this hypothesis but more direct evidence was needed. To achieve this, the characterisation 
of metabolites produced during enzymatic bio-activation of the oxazolopyridine compound 
using S9 liver extract was monitored via UPLC-MS. The method is considered robust and 
reproducible as it is conducted under readily controlled conditions 425. Moreover, the risk of 
material loss was minimised as the reaction mixture was analysed directly using UPLC-MS.  
The mutagenic and genotoxic 2-(4-methoxyphenyl)oxazolopyridine 40a was selected for the 
current experiment. After incubating the 2-(4-methoxyphenyl)oxazolopyridine 40a in S9 liver 
extract for 3 hours, the 2-(4-methoxyphenyl)oxazolopyridine-N-oxide 67 (RT= 4.41 minutes) 
(Figure 37A) and the starting material 40a (RT= 5.82 minutes) (Figure 37B) were detected 
using UPLC-MS by multiple reaction monitoring (MRM). The retention time corresponding 
to the monitored compounds were compared against the standards (Figure 37C,D). This 
provided evidence that the oxazolopyridine compound is converted into an N-oxide under 
enzymatic conditions and supported the proposed oxidative bio-activation mechanism of the 
oxazolopyridine compound. However, as no standard for the proposed hydroxylamine 76 from 
the oxazole ring opening of the oxazolopyridine molecule (Figure 34, section 5.4.5) was 
available, MRM for this compound could not be performed. 
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Figure 37: Monitoring the enzymatic bio-activation of the oxazolopyridine compound using 
UPLC-MS (MRM mode). The 2-(4-methoxyphenyl)oxazolopyridine 40a (1 µM) was incubated 
with S9 liver extract for 3 hours and the sample was analysed. (A) Detection of 2-(4-
methoxyphenyl)oxazolopyridine-N-oxide 67 in the incubated sample; (B) detection of 2-(4-
methoxyphenyl)oxazolopyridine 40a in the incubated sample; (C) compound 67 standard; and 
(D) compound 40a standard. MRM transitions for compounds 67 and 40a were 243.3226.2 
m/z and 227.2 184.1 m/z respectively. # denotes compound number. 
 
Instead of monitoring the presence of known analytes, the elution profile of the reaction sample 
after incubation was compared to time zero via UPLC-MS using total ion count (TIC) mode in 
the following experiment. After 3 hours of reacting the 2-(4-methoxyphenyl)oxazolopyridine 
40a with S9 liver extract, a new peak (RT= 4.80 minutes) was detected (Figure 38). This was 
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compared to the chromatogram at time zero where only the peak corresponding to compound 
40a (RT= 5.88 minutes) was present (Figure 38). Surprisingly, the peak corresponding to the 
2-(4-methoxyphenyl)oxazolopyridine-N-oxide 67 was not detected in the chromatogram using 
this mode due to low concentration. Although the TIC mode is  good for the monitoring of new 
metabolites formed, it is not sensitive to detect very low concentrations of analytes compared 
to MRM 426. Analysis of the new metabolite (RT= 4.80 minutes) (Figure 38) using mass 
spectrometry revealed that the molecule had a [M+H]+ of 213 m/z, indicating a molecular mass 
of 212 g/mol (Figure 39). Compared to compound 40a (molecular mass of 226 g/mol), there 
was a loss of mass of 14 g/mol, which corresponds to loss of CH2. 
 
 
 
 
 
   
 
 
Figure 38: Monitoring the formation of new metabolite upon the enzymatic bio-activation 
of the oxazolopyridine compound using UPLC-MS (TIC mode). The 2-(4-
methoxyphenyl)oxazolopyridine 40a (1 µM) was incubated with S9 liver extract for 3 hours 
and the sample was analysed. The peak at RT= 5.88 minutes correspond to compound 40a. A 
new peak corresponding to a new metabolite at RT= 4.80 minutes was detected after 3 hours. 
# denotes compound number. Full scan in TIC mode was conducted within the range of 100-
300 m/z. 
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Therefore the metabolite detected at RT= 4.80 minutes was proposed to be 2-(4-
hydroxyphenyl)oxazolopyridine 77, which can be formed by oxidative cleavage of the methyl 
group. However, this is likely to be unrelated to the mode of genotoxicity since the 2-
aryloxazolopyridine 40 analogues which have been reported to be genotoxic (Figure 28, 
section 5.4.2) do not necessarily contain a methoxy group at the phenyl ring like compound 
40a, which could be metabolised into a hydroxyl group. 
 
 
 
As proposed (Figure 34, section 5.4.5), a second oxidation event occurring on the oxazole 
nitrogen of the oxazolopyridine-N-oxide 73 to give compound 75, further drives the bio-
activation reaction to form the active species. However, in the current study, the metabolite of 
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2-(4-methoxyphenyl)oxazolopyridine 40a with both nitrogen atoms oxidised was not detected 
via UPLC-MS (Figure 38). Therefore, the oxidation of 2-(4-methoxyphenyl)oxazolopyridine-
N-oxide 67 was attempted using a strong oxidising agent such as peroxytrifluoroacetic acid and 
monitored via NMR. Isolation of a product was not conclusive as the starting material, 
compound 67 remained as the dominant species after the reaction. Therefore, the feasibility of 
the conversion of 2-(4-methoxyphenyl)oxazolopyridine-N-oxide 67 into compound 78 via the 
oxidation with peroxytrifluoroacetic acid was investigated by density function theory (DFT) 
calculations (Figure 40). The second oxidation event happening on the oxazole nitrogen was 
thermodynamically plausible indicated by the calculated Gibbs energy (ΔG) of the product 78 
at -29.7 kcal/mol (Figure 40).  
 
 
 
 
Figure 40: Oxidation reaction of 2-(4-methoxyphenyl)oxazolopyridine-N-oxide 67 into 
compound 78 using peroxytrifluoroacetic acid.  
 
Although a metabolite of higher oxidation state was not identified via UPLC-MS, the 
hydroxylamine 79 was suspected to be the active form of the metabolite. Therefore, the 
feasibility of the reaction from compound 78 to form the hydroxylamine 79 was investigated 
by DFT (Figure 41). This transformation has not been reported previously but the calculations 
suggest that the conversion of compound 78 to the hydroxylamine 79 is thermodynamically 
plausible indicated by the ΔG of the product 79 at -11.5 kcal/mol (Figure 41). The hydrolysis 
                                       67                                                                                         78 
ΔG = -29.7 kcal/mol 
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of compound 78 requires two transition structures (TSA-B and TD-E) with an overall activation 
energy of 27.6 kcal/mol before forming the hydroxylamine 79 (Figure 41). 
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Figure 41: Free energy diagram in the determination of reaction kinetics of the proposed 
mechanism of the conversion of compound 78 to the hydroxylamine 79. Values in normal 
script are corrected Gibbs energies and those in brackets are electronic energies calculated 
at M06_2X/BS2//B3LYP/BS1. All values in kcal/mol. 
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5.5  Chapter summary 
The initial hypothesis stated that the amino group in compound 60 is responsible for the 
genotoxicity and mutagenicity (based on the PhIP 46 model), which was supported by the 
results outlined in chapters 3 and 4. Moreover, this hypothesis formed the foundation for the 
current study. However, upon deeper investigations on the genotoxicity and mutagenicity of 
the oxazolopyridine molecule revealed that this hypothesis was incorrect. In fact, the initial 
QSAR experiment indicated that the oxazole nitrogen of the oxazolopyridine core to be the 
reactive site for the genotoxic and mutagenic activities. The amino group in compound 60 did 
not contribute directly to genotoxicity but indirectly contributed by its electron donating ability 
into the phenyl ring. This was supported by the linear relationship between genotoxicity and 
electron donating ability of substituents on the aryl ring of the 2-aryloxazolopyridines 40, 
which indicates that the high electron density of the oxazolopyridine core was the driving force 
for genotoxicity.  
In addition, the oxidation products of 2-aryloxazolopyridines 40 were identified to be 2-
aryloxazolopyridine-N-oxides 73. The N-oxidation reverted the non-genotoxicity of 2-
phenyloxazolopyridine 61, indicating that the oxazolopyridine-N-oxide could potentially be 
the active species, which reacts with DNA. Further to this, the oxazolopyridine-N-oxides were 
also mutagenic in the Ames test. Even more surprising, the results in this experiment indicate 
that the oxazolopyridine-N-oxide is not the active species and needed to undergo further bio-
activation by S9 liver extract. This suggests that the oxazolopyridine-N-oxide is an intermediate 
during the enzymatic bio-activation of the oxazolopyridine molecule. It was therefore 
hypothesised that a second oxidation occurs at the oxazole nitrogen. Further QSAR studies 
revolving around the nitrogen atoms on the oxazolopyridine core supported that the oxazole 
nitrogen is the reactive site for genotoxicity and mutagenicity. In an attempt to monitor the 
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enzymatic bio-activation of 2-(4-methoxyphenyl)-oxazolopyridine 40a using S9 liver extract, 
the 2-(4-methoxyphenyl)oxazolopyridine-N-oxide 67 was detected after three hours. Also, a 
new metabolite, 2-(4-hydroxyphenyl)oxazolopyridine 77 was detected, which had lost a methyl 
group when compared to the starting material, 2-(4-methoxyphenyl)-oxazolopyridine 40a. 
While the results of this chapter are intriguing, the definitive species responsible for 
genotoxicity and mutagenicity was not conclusively determined. However, the formation of 
the hydroxylamine 79 suspected to be the active metabolite was calculated to be energetically 
feasible. Further work is therefore required to monitor the bio-activation of the 2-
aryloxazolopyridine compounds 40 and to identify the active metabolite. 
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Chapter 6 Conclusions, limitations and future work 
This thesis has addressed research questions related to the genotoxic and mutagenic activities 
of the oxazolopyridine scaffold. Due to the structural similarities of 2-(3-
aminophenyl)oxazolopyridine 60 and the known carcinogen, PhIP 46, it was hypothesised that 
compound 60 may be genotoxic and mutagenic. The amino group of PhIP 46 has been widely 
reported to be the mutagenic reactive site where it is converted into an arylnitrenium ion, which 
binds covalently to DNA 107-112. Therefore, it was hypothesised that the amino group of 
compound 60 may be the reactive site for genotoxic and mutagenic activities, using PhIP 46 as 
a model.  
In Chapter 3, compound 60 was non-cytotoxic up to concentrations of 100 µM consistent with 
previous reports for oxazolopyridine compounds, while PhIP 46 was only mildly cytotoxic. In 
contrast, compound 60 showed genotoxicity at concentrations as low as 0.001 µM. Although 
potently genotoxic, compound 60 appeared less genotoxic than PhIP 46 which was seen in two 
different assays. The potent genotoxicity of compound 60 coupled with its lack of cytotoxicity 
was rather surprising since genotoxic agents are commonly associated with cytotoxicity. 
Further investigations revealed that the cellular DNA damage induced by compound 60 was 
effectively repaired within 24 hours. This indicates that the DNA damage caused by compound 
60 was easily dealt with by the cellular DNA repair machinery, which repair kinetics 
comparable to damage induced by oxidative stress. Further investigations suggested that the 
cellular DNA repair pathways employed in response to compound 60 were likely dependent 
on the DNA repair enzymes, PARP1 and ATM. 
In chapter 4, compound 60 was found to be a pro-mutagen requiring enzymatic bio-activation 
by S9 liver extract to show activity in the Ames test. Similarly, PhIP 46 is not mutagenic itself 
but is converted into N-hydroxylamine 52 by liver cytochrome P450s (CYP) 92-98, which is then 
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converted into the mutagenic PhIP arylnitrenium ion 54 52,104. The enzymatic bio-activation of 
compound 60 was also oxidation dependent consistent with the role of CYP enzymes in the 
oxidation of xenobiotics in the liver. The oxidation-dependent metabolism was shown by 
reduced genotoxicity of compound 60 in the presence of the anti-oxidant, Trolox. Consistent 
with a pro-mutagenic activity, compound 60 phenotypically transformed cells to a more 
invasive phenotype, using the soft agar invasion (SAI) assay as an in vitro cell transformation 
model. 
The results in chapters 3 and 4 showed that the similar cellular responses to both compounds 
supported the hypothesis that the amino group of compound 60 is involved in its genotoxic and 
mutagenic activities similar to PhIP 46. However, deeper investigations on the genotoxicity 
and mutagenicity of the oxazolopyridine molecule in chapter 5 led to the conclusion that this 
hypothesis was incorrect. The amino group of compound 60 did not contribute directly to 
genotoxicity but instead, increased the electron density of the oxazolopyridine core which was 
ultimately identified as key to genotoxic activity. This was supported by the Hammett plot 
generated using 2-aryloxazolopyridines 40 analogues with substituents of different electron 
donating abilities. The oxidation of 2-aryloxazolopyridines 40 resulted in the formation of 2-
aryloxazolopyridine-N-oxides 73. These N-oxides were tested and found to be even more 
genotoxic and mutagenic than the pre-cursors and was thought to be the active species. 
However, further bio-activation by S9 liver extract was required for the oxazolopyridine-N-
oxides to be mutagenic. It was therefore hypothesised that a second oxidation event was 
occurring, which may lead to the ring opening of the oxazolopyridine-N-oxide into a 
hydroxylamine, suspected to be the active species. This was supported by QSAR determination 
revolving around the nitrogen atoms of the oxazolopyridine core. Enzymatic bio-activation of 
2-(4-methoxyphenyl)-oxazolopyridine 40a using S9 liver extract was monitored where the 2-
(4-methoxyphenyl)oxazolopyridine-N-oxide 67 was formed, consistent with the results so far. 
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However, the definitive species responsible for genotoxicity and mutagenicity was not 
conclusively determined due to time constraints. The formation of the hydroxylamine 79 
suspected to be the active metabolite was investigated by density function theory (DFT) to be 
energetically feasible.  
Further work is therefore required to address some of the limitations associated with the current 
study. In the determination of DNA repair kinetics in cells exposed to compound 60, only 
hydrogen peroxide was used as the positive control in this experiment. However, this is limited 
by the different types of DNA damage caused by hydrogen peroxide, which mainly induces 
DNA strand breaks 342,343 compared to PhIP 46 which causes base modifications 107-109. 
Therefore, repair kinetics for PhIP 46-induced DNA damage should also be assessed to provide 
a more appropriate comparison of the genotoxic modes of action of compound 60 and PhIP 46. 
In addition, the experiment involving DNA repair inhibitors only provided some indication of 
the role of regulatory proteins involved in the repair of the DNA damage induced by compound 
60. However, the exact pathway(s) involved in DNA repair of the damage induced by 
compound 60 could not be established due to the multi-faceted nature of DNA repair enzymes 
as discussed. Therefore, a screen using a yeast gene knock-out library of DNA repair genes 
could be conducted as it would be faster and more accurate to determine the type of DNA repair 
mechanism involved 427,428. 
As shown in the current study, the role of oxidative bio-activation is important for the genotoxic 
and mutagenic activity of the oxazolopyridine compounds. While the data presented in the 
current study have been consistent, determining the exact roles of specific oxidative 
cytochrome P450 (CYP) enzymes would have provided more information on the mutagenic 
mode of action and the specific risk to different tissues arising from the oxazolopyridine 
compounds. Therefore, CYP1A1 (-/-) and CYP 1A2 (-/-) knockout mice as previously 
conducted with PhIP 46 429,430 could be used to extend the findings of the current study. This 
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approach would determine the roles of these CYP enzymes 431 in the bio-activation of the 
oxazolopyridine compounds or expanded to investigate on other CYP enzymes as well. 
Although the soft agar invasion (SAI) assay is a rapid method in determining cellular 
transformation potential of a mutagen, in vivo cancer models are more representative to the 
tumour development in humans and should be used to further the findings of the current study. 
In particular, the use of immune-deficient mice such as nude mice, which are susceptible to 
cancer was reported previously to monitor the development of tissue-specific drug-induced 
tumours 432,433. Further work can also be conducted to monitor the bio-activation of other 2-
aryloxazolopyridine 40 compounds and to identify the active metabolite. The synthesis of the 
proposed hydroxylamine 76 to test for genotoxic and mutagenic activities could further 
substantiate the findings of the current study. The hydroxylamine 76 could also be synthesised 
and used as a standard for monitoring the bio-activation of the 2-aryloxazolopyridine 40 
compounds by UPLC-MS. The reaction of the synthesised hydroxylamine 76 or detected bio-
activated metabolite in future experiments, with nucleotides or DNA can be monitored via 
UPLC-MS. This could potentially be used to determine the type of DNA lesion caused by the 
oxazolopyridine compounds to explain its lack of cytotoxicity, which was not fully 
characterised in the current study. In addition, the current study should also be extended to 
other popular and biologically active drug scaffolds such as benzoxazoles, benzimidazoles and 
imidazopyridines due to the similar activities and close relationships with the oxazolopyridines.  
The results of this thesis indicate that the oxazolopyridine core should be treated with extreme 
caution due to its potential genotoxic and mutagenic activities. There is now significant 
evidence to suggest that the oxazolopyridine system as a scaffold for drug discovery could be 
associated with severe long term liabilities. In fact, the development of benzoxazole-related 
compounds as drug candidates should also be reconsidered and more in-depth biological testing 
should be performed to evaluate their mutagenic potentials. 
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Appendix 1: Determination of 
concentrations of DNA repair 
inhibitors. Viability of cells 
was assessed by colony 
formation assay using HepG2 
cells. Cells were treated with: 
(A) DPQ, (B) Ku55933 or (C) 
MxHCl as indicated for 12 
days. Hydrogen peroxide (200 
µM) was used as positive 
control. Viability data 
represents the mean of three 
independent experiments 
with three replicates per 
experiment and is expressed 
as % of untreated control. 
Error bars represent SD, 
dotted lines is used to indicate 
the concentration of the DNA 
inhibitors at 95% viability on 
the curve of best fit. 
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